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Abstract
Silicate glasses function effectively as bone grafts by stimulating bone regeneration
through gene activation. However these materials offer little therapeutic potential for the
regeneration of healthy bone in those suffering from metabolic bone diseases such as
osteoporosis. Examining the composition-structure-property relationships arising from
the incorporation of therapeutic ions such as strontium (Sr) and zinc (Zn) into such
glasses in order to allow for healthy bone regeneration and antibacterial efficacy, as well
as sodium (Na) to allow for controlled ion release was the objective of this work. Eight
calcium-strontium-sodium-zinc-silicate glass compositions were produced, based on
incremental additions of Sr and Na. Glasses were characterised using x-ray diffraction
(XRD), differential scanning calorimetry (DSC), network connectivity calculations, and
magic angle spinning nuclear magnetic resonance spectroscopy (MAS-NMR). Glasses
were subsequently sterilised (30kGy y-irradiation) and re-characterised. Comparison of
characterisation data pre-and post-irradiation confirmed that sterilisation by this method
did not structurally effect the examined glass compositions.

Based on the

characterisation data, Sr"^ and Zn^^ release was quantified over 1, 7 and 30 days, under
normal and extreme physiological conditions for six glass compositions, BTllO-BTl 15.
The Zn^^ release results at pH 7.4 ranged from 3ppm-19ppm and indicated that under
normal physiological conditions, all examined Zn-containing glass compositions may
have potential as therapeutic bone grafts, but under extremely acidic physiological
conditions, the high Zn^^ levels (124ppm-750ppm) may produce cytotoxic effects. Srcontaining glasses demonstrated Sr^^ release in the range 7.5ppm-3500ppm at pH 7.4 and
88ppm-1280ppm at pH 3, and indicated that all examined glass compositions may have
therapeutic potential under both physiological conditions. Based on this therapeutic ion
release data, extracts of the three most promising glass compositions, BT110-BT112,
incubated over 1, 7 and 30 days were examined using cell culture testing (L929
fibroblasts and MTT assay) and compared to the state-of-the-art glass bone graft
Novabone. In general, the results from the viability assay indicated that the experimental
groups showed either no difference or significantly increased cell viabilities when
compared to the commercial control Novabone, demonstrating the equivalent or even
enhanced in vitro compatibility of these glass compositions in relation to a current state

II
of the art material.

The antibacterial activity of zinc-containing BTIIO, BTlll and

Novabone was then assessed using five bacterial strains commonly associated with
orthopaedic implant infections - Methicillin-sensitive Staphylococcus aureus (MSSA),
methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis.
Pseudomonas aeruginosa and Enterococcus faecalis.

The results indicated that both

experimental compositions demonstrated antibacterial properties, with the best effects
noted against S. epidermidis and P.aeruginosa, and that overall both BTl 10 and BTl 11
demonstrated better antibacterial efficacy than Novabone. The results of this research
have established the excellent potential of the examined glass compositions to function as
therapeutic, antibacterial bone grafts.
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Introduction
Research into materials to aid in skeletal tissue regeneration has increased, due to
the need to address the shortcomings of traditional bone grafts. Bioactive glasses have
become a key focus due to the ability of their ionic dissolution products to promote bone
cell proliferation, cell differentiation and activate gene expression. However, many of
these materials offer little therapeutic potential for specific pathological situations, and
their value has also been limited by a lack of inherent antibacterial efficacy.
A critical factor to consider in formulating a bioactive glass composition capable
of addressing these needs is the specific target tissue - in this case bone tissue. Chapter 1
of this thesis reviews the structure and properties of bone in order to gain an
understanding of its physiology and repair mechanisms. Chapter 2 introduces the basic
concepts of bone grafting, the circumstances in which bone grafting is required and tlie
charactenstics a material needs to exhibit in order to function effectively in a bone graft
capacity. Biologically and synthetically derived bone graft materials are discussed, their
effectiveness in meeting the needs of a bone graft material and the disadvantages
associated with their use. The use of bioactive glass as a bone grafting material is the
focus of Chapter 3. The structure and formation of glass is reviewed, along with the
effect that glass stmcture and composition has on subsequent glass properties.
Traditional and commercially available bioactive glass compositions are discussed
including their assocated disadvantages. Chapter 4 reviews the role of the therapeutic
ions zinc and strontium in bone regeneration, along with their role in infection prevention
and in the treatment of osteoporosis. Commonly used methods to assess compatibility
and the antibacterial efficacy of materials are outlined in Chapter 5 followed by the
rationale for the work programme and the methods section, in chapters 6 and 7
respectively.
The objective of this thesis was to develop and evaluate bioactive glass
compositions incorporating the therapeutic components zinc and strontium. Chapter 8
presents the results of this research in detail, with conclusions presented thereafter in
chapter 9. Directions for the further development and evaluation of strontium and zinc
containing bioactive glass compositions are discussed in chapter 10.
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BONE - ANATOMY, PHYSIOLOG Y & REPAIR

Bone is a dynamic, highly organised and specialised connective tissue.

Along with

cartilage, bone comprises the tissues which form the skeletal stmctures of most
vertebrates [1].

This unique tissue plays a multi-facetted and essential role in our

biology. Bone primarily has a supportive and mechanical function, providing the basic
structural foundation for the body and allowing movement by attachment to various
muscle groups [2]. In addition, in many parts of the body, bone provides a protective
function to vital organs - the rib cage providing protection for the organs in the thoracic
region being a good example of this. Secondarily, osseous tissue has homeostatic
functions.

Red bone marrow is one of the major sites of haematopoiesis or blood

formation, also producing many cells of the immune system [1]. The skeleton is the
body’s main mineral reservoir, storing and releasing calcium and phosphate according to
the body’s physiological needs [2], Bone tissue also buffers the blood against excessive
pH changes by absorbing or releasing alkaline salts, performing a vital acid-base
function. The following chapter will first outline and explain the composition of bone,
and how this relates to its structural anatomy, histology and formation. Secondly, this
chapter will outline the bone remodelling process and the important role of the vascular
system.

Finally, this chapter will cover the mechanical properties of bone and

mechanisms of failure and repair.

1.1 Bone composition
The composition of bone is dependant on a large variety of factors including, but not
limited to, age, sex, anatomical location, health and nutritional status. In general, osseous
tissue consists of an extracellular matrix and cells. The extracellular matrix provides the
structural component of bone and can be sub-divided into organic and inorganic matter.

1.1.1

Organic matter

The organic matter is composed primarily of type 1 collagen. Type 1 collagen is a fibril
forming collagen composed of three polypeptide chains - two identical alpha-1 chains
and one distinct alpha-2 chain [3,4]. These chains are characterised by a repeating amino

2
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acid motif, with glycine present in every third position (Gly-X-Y)n. This repeat structure
allows the chains to form a right-handed triple helix, with glycine residues positioned in
the centre and residues X and Y exposed on the surface [5], The X and Y positions are
commonly occupied by proline and hydroxyproline [4],

The polypeptide helices are

stabilized by many hydrogen bonds and held together by covalent bonds at the ends of the
collagen molecule, where there is a short region of nonhelical polypeptide called a
telopeptide [6], as illustrated in Figure 1.1.

These telopeptide regions also function in

linking the structure to other molecular structures of the surrounding matrix [4],
triple helix
telopeptide
(non-helicat)

telopeptide

(noD'h^ical]

Figure 1.1: Molecular structure of type 1 collagen [4]

Type 1 collagen derives its key attributes from its ability to form fibrils.

Collagen

molecules assemble into fibrils in a quarter staggered array, leaving regular 40nm gaps
within each periodic unit [7] (Figure 1.2). These gaps are thought to act as nuclei for
calcium apatite crystal formation [7]. This staggered arrangement allows for interfibrillar
cross-linking through the formation of very stable trivalent bonds with neighbouring
molecules, providing the structural integrity to bone [6].

Collagen molecules are

synthesized and secreted by osteoblast bone cells, assembled into these fibrils, grouped
into fibres and, once mineralized, are organised into concentric layers known as lamellae,
as illustrated in Figure 1.2. Collagen appears primarily responsible for the toughness of
bone and its contribution to the mechanical properties of bone shall be discussed in more
detail in section 1.6. The ground substance in which collagen is embedded is comprised
of glycoproteins and proteoglycans including osteocalcin, fibronectin and osteopontin [8].
These proteins are produced by osteoblasts or are derived and concentrated from the
serum [8].

Fibronectin is involved in stimulating osteoblast differentiation and

3-
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proliferation by binding to integrin receptors located at the cell surface [9], Fibronectin is
also thought to be involved in the regulation of the mineralization of bone by binding to
other matrix proteins, modifying their activity [9].

Osteopontin belongs to the Small

Integrin-Binding Ligand N-linked Glycoprotein (SIBLING) family of proteins and is
known to stimulate osteoclast induced bone resorption [8, 10], Osteocalcin is produced
by osteoblasts and is known to play a role in bone mineral maturation and regulation of
remodelling [11].

Lamellae

Collagen Fiber

collagen
fibril

Haversian
Canal

1.23 nm
collagen
molecules

300 nm

40 nm
27 nm

protein
triple
helix

bone mineral
crystal
50 X 25 X 3 nm

Figure 1.2: A schematic diagram illustrating the assembly of collagen fibrils, fibers and bone mineral
crystals [12].

1.1.2

Inorganic matter

The inorganic matter constitutes about 75% of bone tissue by weight, with the majority in
the form

of a crystallized calcium phosphate

salt known

as

Hydroxyapatite

[Caio(P04)6(OH)2]. Hydroxyapatite (HA) in bone consists of small crystals, ranging in
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length from 30-50nm, width 15-30nm and thickness 2-3nm [7, 12], The mature crystals
are plate-shaped, occur between the discrete spaces within collagen fibrils (Figure 1.2)
and grow with their c axes roughly parallel to the long axes of the collagen fibrils [12].
The HA crystals in bone can be described as poorly crystalline, giving rise to a broad Xray diffraction peak relative to synthetic HAl, a characteristic attributed to the inclusion of
many impurities, including carbonate, magnesium, sodium, potassium, fluoride and
sulphate ions into the HA lattice [7],
The initial stages of bone mineralisation are thought to involve matrix vesicles (MV).
MV are formed by polarized budding and pinching-off from specific regions of the outer
plasma membranes of chondrocytes and osteoblasts [13], and are selectively located at
sites of initial calcification in bone [13]. MVs are thought to have two main roles in
initiating calcification - (1) involving MV enzymes which regulate the ratio of inorganic
phosphate (Pi) to the calcification inhibitor pyrophosphate (PPi) in the extracellular fluid
and (2) MV proteins and lipids which are thought to serve as nucleation sites for apatite
deposition [14], MV initially function by increasing the intravesicular concentration of
calcium ions (Ca^^) and Pi, leading to the formation of apatite crystals within the vesicle
[11].

Subsequently, MV migrate to the collagen fibril hole zones (Figure 1.2), the

crystals are exposed to the extracellular environment because of protrusion through the
MV membrane [15], and the crystals are inserted into the interfibrillar spaces [14],
Crystal growth and propagation are thought to proceed by heterogenous nucleation with
both the MVs and the collagens fibrils suggested as the initial nucleation site [11, 14].
Bone mineralisation is slower than bone matrix deposition, leading to unmineralised bone
matrix called osteoid close to the site of active bone formation [8], The main function of
the mineral component of bone is to impart stiffness and rigidity, and will be discussed
further in Section 1.6 -The mechanical properties of bone.
1.1.3

Cellular component

The cellular components of bone play a vital role in its formation, resorption, and
maintenance.

Four functionally distinct cells are involved; osteoblasts, osteocytes,

osteoclasts, and bone lining cells.

5-
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The main function of osteoblast cells is in creating and maintaining skeletal architecture
[16], Osteoblasts are responsible for the production and deposition of the extracellular
matrix, and play a role in its subsequent mineralisation and are involved in osteoclast
maturation and activation (Figure 1.3) [8, 11]. As osteoblasts differentiate from their
precursors they begin to secrete collagen (type 1) and non-collagenous proteins including
proteoglycans [16], Osteoblasts are involved in matrix mineralisation via the liberation
of matrix vesicles and the production of numerous proteins [11]. They also influence the
differentiation of osteoclast cells through the binding of the surface protein receptor
activator of NF-kB ligand (RANKL) to its receptor (RANK) on osteoclasts [16],
Similarly, RANKL also binds to RANK on mature osteoclasts stimulating bone
resorption

(Figure

1.3)

[16].

Osteoblasts

are

derived

from

spindle-shaped

osteoprogenitor cells located in the periosteum, haversian and volksmans canals [11], and
are cuboidal or columnar in shape [11], Two main transcription factors are known to be
required for osteoblast differentiation and maturation - Runx2 (Runt-related transcription
factor 2) and Osterix [17]. Runx2 acts as a master regulator as it mediates the temporal
and/or repression of phenotypic genes (e g. osteoclacm) as osteoblasts mature and
differentiate [17], Its essential role is highlighted in null-mutation mice which show a
cartilaginous skeleton with a complete absence of osteoblasts [18].

Osterix is a zinc

finger protein known to be important for the commitment of pre-osteoblasts to the
osteoblastic phenotype [8]. Osterix null mice develop a skeleton entirely composed of
cartilage, lacking in osteoblasts and mineralised bone matrix [18]. Functionally mature
osteoblasts are characterised by well-developed Golgi apparatus, a large nucleus,
extensive granular endoplasmic reticulum, numerous mitochondna and express high
levels of alkaline phosphatase (ALP) [17], Osteoblasts also display multiple cytoplasmic
processes that connect cells with adjacent osteoblasts and osteocytes via gap junctions,
mediating cell signalling between these cells [8].

6
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Bone formationinducing factors (e g.
TGF-3, PTH)

-

-

Bone resorptioninducing factors
(e-9- PTH)

Osteoclast precursors

T ^
Osteoblasts—t
Osteoclast

Osteoid

Mineralised
bone matrix

RANK

A

RANKL

Figure 1.3: Schematic overview of osteoblast function! 16],

Osteocytes are the most abundant resident cells in bone tissue, accounting for 95% of the
bone cell population [8], They are non-proliferative, terminally differentiated cells of the
osteoblast lineage and are formed when osteoblasts become buried and trapped during
bone formation [8], They are distributed throughout the mineralized bone matrix residing
in spaces called lacunae [17], They consist of numerous, long cytoplasmic processes that
transverse the bone matrix through small tunnels called canaliculi [17],

Matrix

metalloproteinases have been implicated in the regulation of osteocyte production and
generation of the appropriate canalicular system [19],

Osteocytes are capable of

communication with neighbouring osteocytes and other bone cells through the formation
of gap junctions between cytoplasmic processes [8]. These junctions primarily consist of
the gap junction channel protein connexin 43 and connexin 43-mediated communication
is essential for osteocyte phenotypic maturation, activity and survival [17], The primary
function of osteocytes is mechanosensory [19], Osteocytes and their extended cellular
network are stimulated by mechanical stimuli and
osteoprogenitor cells, osteoblasts and osteoclasts.

influence the activity of

These cells, in turn, respond by

remodelling bone mass according to environmental mechanical demands - referred to as

-7

Bone - Anatomy, Physiology & Repair

WolfTs law [8, 19],

Another function attributed to this cell is the maintenance of

mineral homeostasis. The osteocyte responds to changes in ion concentrations and can
stimulate the exchange of ions between the bone matrix and the extracellular fluid
through the canalicular system [20],
Osteoclast cells are multinucleated cells that mediate the resorption of bone matrix [8].
Osteoclasts originate from the fusion of preosteoclasts which are derived from
hematopoietic stem cells, which progress through the colony-forming unit for
granulocytes and macrophages (CFU-GM) to become a CFU-macrophage (CFU-M)
before entering the osteoclast lineage [21],

The transcription factor PU-1 and the

cytokine macrophage colony-stimulating factor (MCSF) have both been implicated in
macrophage differentiation from progenitor cells [8], PU-1 null mice lack osteoclasts and
m.acrophages, indicating the importance of this transcription factor in macrophage
differentiation [22], MCSF is produced by osteoblasts and bone marrow stromal cells
and binds to its receptor, the tyrosine kinase c-Fms, on osteoclast precursors and
stimulates their survival and proliferation [17, 22], It has also been demonstrated that
RANKL and its receptor RANK are essential for osteoclastogenesis.

As previously

mentioned, RANKL is a glycoprotein which is produced by osteoblasts and stromal cells
[17], Binding of RANKL to its receptor stimulates the differentiation of monocytic cells
into the mature osteoclast phenotype [23] (Figure 1.4).

Factors known to increase

osteoclastogenesis, such as PTH, function through increasing RANKL expression by the
accessory cell [11]. OPG is a soluble decoy receptor, which serves to prevent RANKL
binding to its target on osteoclast precursors and thus cause osteoclast differentiation to
be suppressed [23].

-8
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p] Macrophage colony-stimulating factor
(M-CSF) receptor
9

M-CSF ligand
RANK ligand

Monocyte
RANK

•

PTH

Functional osteoclast

Figure 1.4: Schematic representation of the regulation of osteoclast differentiation [11

Osteoclasts reside in shallow depressions on the bone surface called resorption bays or
Howship’s lacunae [24],
osteoclast.

Figure 1.5 illustrates the typical morphology of an active

Active osteoclasts typically have between 4-20 nuclei and demonstrate

polarization with the nuclei and Golgi apparatus situated away from the resorbing bone
surface [8], Similarly they demonstrate at least 4 specialized membrane domains - the
ruffled border, the sealing zone, a functional secretory domain and a basolateral
membrane [25]. The ruffled border is the cell surface in direct apposition to bone and is
comprised of extensive infolds of the plasma membrane. It serves as the exit site for
protons and lysosomal proteases such as cathepsin K which are involved in the
degradation of the bone matrix [11, 26].

A 3 dimensional ring-like area around the

perimeter of the ruffled border contains abundant actin microfilaments and constitutes the
sealing zone.

The primary function of the sealing zone is in the attachment of the

osteoclast to the bone matrix [11]. The secretory domain of the membrane is thought to
function as the site for exocytosis of resorbed and transcytosed matrix-degradation
products [25].

-9
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Svcrctory
Oom*in

OsteoctMt

Ba»olateral

Saaling

Mambran*

Zona

_____
*
fj rj-'r*//

•

Ruffled
Border

Oataoponbn

ReeorpbvePif
TRAP
Cathapeei K

Figure 1^ Schematic representation of the structure of an osteoclast cell [27]

Bone lining cells are found on the surfaces of bone that are inactive or not undergoing
formation or resorption. They appear to belong to the same lineage as osteoblasts, but do
show important morphological and functional differences [8], The cells appear broad and
planate and accommodate a very flat nucleus, sparse numbers of secretory granules and
few other cytoplasmic organelles [28], The cells are capable of proliferation and appear
to play a role in bone re-modelling and regulation of plasma calcium levels.

1.2 Bone Anatomy and Histology
With knowledge of the composition of bone, the next step to understanding osseous
tissue is an appreciation of how all its components are structurally and architecturally
arranged, both from a macroscopic and microscopic perspective.

1.2.1

Classification

Bones can be classified into five different groups according to their shape and
corresponding functions - long, short, flat, irregular and sesamoid bones [29].

Long

bones serve as levers that are acted upon by the skeletal muscles to produce movement,
an example of such being the humerus and the femur. Short bones are nearly equal in

10
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length and width, for example the carpal and tarsal bones, and they are found where
strength but limited motion is required.

Flat bones usually enclose and protect soft

organs and provide broad surfaces for muscle attachment for example the ribs and
cranium. Irregular bones vary in size and shape, for example the vertebra. Sesamoid
bones are nodules of bone which ossify within a tendon at a point of friction and protect
muscle tendons from wear [29, 30].

1.2.2

Macroscopic Anatomy

The stmcture of a typical long bone can be seen in Figure 1.6. It can be divided into 3
main regions, namely the epiphysis, the metaphysis and the diaphysis. The epiphysis is
the rounded head at each end of the bone, occupying the portion from the growth plate to
the joint surface and is enlarged to strengthen the joint and provide added surface area for
tendon and ligament attachment [11]. The metaphysis is the segment of bone on the
opposite side of the growth plate, is highly vascularised and rich in cancellous or spongy
bone [3, 31]

Long Bone
Epiphysis

Metaphysis

Diaphysis

Epiphysis

Figure 1.6: Physical structure and general features of a long bone

The diaphysis is the cylindrical shaft of the bone, which surrounds the medullary cavity
where the haematopoietic bone marrow is housed. The diaphysis provides leverage and
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is composed mostly of cortical bone [11]. The ends of the bones that form joints are
covered with hyaline cartilage, the ‘articular cartilage’.

The surface of the bone consists

of an outer sheath, the periosteum, and an inner sheath, the endosteum. The periosteum is
a thin vascular membrane-like layer composed of a peripheral fibrous coat of collagen
and an internal cambium layer of osteoprogenitor cells [3].

The endosteum lines the

internal surface of bone and consists of a thin film of reticular connective tissue and
osteoprogenitor cells with the capacity to divide and differentiate into osteoblasts and
osteoclasts [31, 32],

1.2.3

Microscopic Anatomy

Structurally, bone can be classified into 2 categories: cortical or compact bone, found
largely in the diaphysis and spongy or cancellous bone, found primarily at the epiphysis
[31], Compact bone, which constitutes approximately 80-85% of total bone mass in the
adult human, is so named due to its minimal gaps and spaces which give bones their
smooth, white and solid appearance. The osteon is the basic stmctural unit of cortical
bone (Figure 1.7). It is composed of a cylinder of tissue running parallel to the long axis
of the diaphysis and encompasses a central canal known as the haversian canal which is
lined by endosteum containing blood vessels and nerves [30].

Smaller canals called

Volkmanns canals run at right angles to the long axis of the central canal, connecting it to
the blood and nerve supply of the periosteum and to adjacent osteon units [2]. Each
haversian canal is enveloped in concentric onion-like layers of matrix known as lamellae.
The collagen fibres of a particular lamella are arranged in a single direction, while fibres
in adjacent lamellae run opposite. This allows lamellae to reinforce one another and to
resist twisting or torsion stress [11]. Osteocytes and their cytoplasmic processes which
are housed in lacunae and canaliculi are arranged circumferentially around the central
canal lateral to the lamellae [20]. Situated in the space between haversian systems are
interstitial lamellae.

These are the remnants of previous osteons which have been

remodelled. Just deep to the periosteum and superficial to the endosteum there are no
haversian systems and the lamellae, known as circumferential lamellae, are arranged
parallel to the periostal and endosteal surfaces [31].
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Lacunae containing osteocytes

Osteon of compact bone

Lamellae-

Trabeculae of spongy
bone

Canaliculi -

Osteon

-

Haversian
canal

Periosteum
Volkmann's canal

Figure 1.7: Graphical rqjresentation of the components of Compact and Spongy bone [33],

Cancellous or spongy bone is an open-cell porous network and is so called due to its
spongy appearance. It consists of a lattice of slender rods, plates and spines referred to as
trabeculae, and is covered by a stratum of flattened cells, the resting osteoblasts [3], It is
permeated by spaces filled with bone marrow and is arranged in parallel lamellae. The
strongest trabeculae are established along lines of stress, according to Wolffs law, thus
cancellous bone can be considered anisotropic due to this microstructural directionality
[34],

Its structural design imparts strength while adding a minimum of weight and

provides a surface area almost ten times that of compact bone for metabolic activities.
Histologically, bone tissue is characterised by 2 main types, woven or non-lamellar bone
and lamellar bone [2]. Woven bone is formed during periods of rapid osteogenesis such
as fracture repair and shows a lack of organisation and consequently consists of randomly
orientated coarse collagen fibres.

This random network is reflected in this bones

response to external mechanical stress which is identical regardless of the orientation of
the stress and demonstrates more flexibility than lamellar bone [8]. All bones are woven
at the time of birth. Lamellar or mature bone eventually replaces woven bone and is
characterised by the presence of collagen fibres arranged in parallel layers and is present
in both stmctural bone types, cortical and cancellous. Lamellar bone is stronger and
more rigid than woven bone but demonstrates less elasticity [31].
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1.3 Bone Physiology and Formation
Central to understanding the roles and functions of the components of bone is an
awareness of its origin and development. There are two types of bone histogenesis, intramembranous ossification and endochondral ossification.

13.1

Intra-membranous ossification

Intramembranous ossification is a mechanism of bone formation characterised by the
absences of a cartilaginous model of the developing bone [35]. It is responsible for the
formation of flat bones such as the skull and the clavicle. The process involves bone
developing from a condensed sheet of embryonic connective tissue known as
mesenchyme [36]. Cells within this stratum aggregate and differentiate into osteoblasts
which actively synthesize new bone matrix called osteoid, which radiates from the
ossification centre forming trabeculae [37].

Trabeculae eventually join together to form

spongy bone which undergoes calcification [8]. Some of the now-calcified trabeculae
form permanent spongy bone due to the early appearance of osteoclasts and the resultant
bone resorption and re-modelling. Trabeculae closer to the surface continue to calcify
until all spaces between them are filled, giving rise to compact bone [36]. Mesenchyme
at the surface remains uncalcified, becomes increasingly fibrous and ultimately forms the
periosteum [2],

1.3.2

Endochondral ossiflcation

Most bones develop

through a process

known as endochondral

ossification.

Endochondral ossification is characterised by an initial stage involving the formation of a
cartilage model of the bone which, during foetal and post-natal development, is gradually
replaced by bone and accompanies longitudinal growth [38].
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Figure 1^: A schematic diagram showing the development of endoehondral bones.

The primary ossification centre (Figure 1.8) appears in the centre of the cartilage model,
and produces chondrocytes (cartilage cells) which proliferate and increase in size and
produce ECM [39], This maturation and expansion of chondrocytes is subject to the
influence of numerous systemic factors and transcription factors including Growth
Hormone, insulm-like growth factors and Sox9 [40]

The chondrocytes undergo

hypertrophy, which stimulates angiogenesis, resulting in the appearance of mesenchymal
cells that gives rise to the bone-forming osteoblasts, bone-resorbing osteoclasts and blood
forming cells of the bone marrow [41],

These cells activate the degradation of the

cartilage matrix, chondrocytes undergo apoptosis and the osteoblasts replace the cartilage
with bone [42], As ossification progresses and expansion towards the epiphyses occurs, a
growth plate known as the epiphyseal plate forms between the newly generated bone of
the diaphyses and the cartilaginous bone ends. Secondary ossification centres form in
these epiphyses and are separated from their primary counterpart by this growth plate.
This longitudinal bone growth continues until puberty when chondrocyte proliferation
ceases, the primary and secondary ossification centres fuse and the epiphyseal plate
gradually disappears. The only remaining cartilage is the articular cartilage situated at the
ends of the bone [39].

1.4 Bone remodelling
Bone is a highly dynamic and metabolically active tissue, continually being broken down
and reformed by the co-ordinated actions of osteoclasts and osteoblasts [3]. A delicate
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balance is maintained between this bone resorption and bone formation in a complex
process known as bone remodelling. Bone remodelling involves a cyclical sequence of
events whose combined actions lead to the ultimate goal of the replacement of older or
damaged bone tissue by new bone [3], It is essential both to maintain structural integrity
of the skeleton and to subserve its metabolic functions as a storehouse of calcium and
phosphorus.

This cycle can be divided into the following stages - osteoclastic bone

resorption, a reversal phase and osteoblastic bone formation.

The cycle of bone

remodelling is accomplished by a discrete temporary anatomical structure known as a
BMU or Basic Multicellular Unit.

A BMU is comprised of teams of bone resorbmg

osteoclasts, bone forming osteoblasts and some form of blood supply and associated
connective tissue [43].

1.4.1

Bone resorption

The bone resorption cascade, accomplished by the activity of osteoclasts, involves a
series of steps that culminate in the removal of the mineral and organic components of the
bone matrix. The first step begins with the attraction and recruitment of mononuclear
osteoclast precursors from haemopoietic tissues via the circulating bloodstream [44]. The
exact mechanism which initiates this is currently unclear, but chemotactic factors
released from areas of skeletal microdamage, along with stimulatory signals produced by
local cells in the microenvironment such as immune cells are thought to play a role [45].
These precursors subsequently proliferate and differentiate into multi-nucleated
osteoclasts [45]. To &cilitate passage of these osteoclasts to the mineralised bone, lining
osteoblast cells release collagenase, which removes the unmineralised osteoid layer [46].
The osteoclast now attaches to the bone matrix via the interaction of integrins with
arginine-glycine-aspastic acid sequences in matrix protein [47], forming a tight sealing
zone (Figure 1.5). Osteoclast polarization allows acidification of the sealed resorptive
cavity and release of lysosomal enzymes leading to degradation of the matrix [47], It is
important to note that in humans this process of bone resorption can take up to 1 month
[45].
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1.4.2

Reversal Phase

When bone resorption is complete, the osteoclast moves away from the bone surface,
signifying the beginning of the reversal phase, and undergo apoptosis or programmed cell
death.

Cement formation on the resorbed surface also commences [45],

The exact

mechanisms responsible for this arrest in osteoclastic activity and initiation of the
reversal phase are poorly understood, but several local factors are speculated to play a
role [47],

Amassing of calcium ions in the resorptive pit appears to greatly affect

osteoclastic activity, causing rapid cell retraction [47],

It is postulated that the

macrophage-like cells seen on the bone surface during this phase may release agents
which inhibit osteoclasts and encourage osteoblast activity [44], These cells have also
been shown to be involved in cleaning the resorptive pit through the action of serine
proteases [47],
Bone remodelling cycle

Bone lining cell*>

r

Mineralization

Quiescence

Osteoblast
Osteoid -

Reversal

Figure 1.9: The bone remodelling cycle [46]

1.4.3

Bone formation

Bone formation is triggered by the chemotactic attraction of osteoblast precursors to the
site that has undergone resorption. This attraction is mediated by locally derived factors
released during the resorptive process [44], Additional agents, including members of the
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TGF-P superfamily, are sequestered in the bone matrix [44], and the transcription factor
Cbfal, which binds to several osteoblast-specific genes encourage proliferation and
differentiation of osteoblast precursors. Once differentiated, the mature osteoblasts lay
down uncalcified bone matrix, and after approximately 10 days calcification occurs,
forming mature mineralized bone.

Mineralisation of the bone is promoted by

osteoblastic-involved degradation of pyrophosphate - a naturally occurring inhibitor of
mineralisation present in the extracellular fluid [46], The final phase of the formation
process is cessation of osteoblast activity. This may occur due to a negative feedback
loop in which factors produced during osteoblast differentiation decrease osteoblast
activity [48] or due to TNF-induced osteoblast apoptosis [44]. Finally, after resorption,
reversal and formation are completed a phase of quiescence resides.

The overall

formation phase takes approximately 4 months, leading to a total remodelling period of
over 150 days [46].

1.4.4

Remodelling regulation

One of the most distinctive features of bone remodelling is the precise temporal and
spatial coupling of bone resorption and formation. This balance is of critical importance
to long term bone health as a breakdown in this regulation has been implicated in many
bone pathologies, including osteoporosis [49] The process is governed by a number of
differing systemic and local mechanisms involving endocrine, immune, and cytokine
mediators some of which are illustrated in Table 1.1. Systemically, 2 major calcium
regulating hormones play a part. Parathyroid hormone (PTH) and 1,25-dihydroxy vitamin
D. PTH regulates bone integrity through changes in calcium homeostasis, partly due to
its effects on mineral handling in the intestine and kidney [50], PTH is also a potent
stimulator of bone resorption, stimulating differentiation of osteoclast progenitors to fuse
and form mature multinucleated osteoclasts [48]. However, PTH has also been shown to
have antagonistic effects.

Continuous PTH exposure shows the mentioned catabolic

effect, whereas intermittent release conversely produces anabolic effects [51], 1,25Dihydroxy vitamin D is a potent activator of bone resorption, encouraging osteoclastic
progenitors to differentiate and merge. The most important systemic hormone effecting
bone remodelling is estrogen.
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Table 1.1: Systemic regulation of bone remodeling.

Factor

Bone resorption

Bone formation

T
i

m?

PTH
l,25(OH)2 Vitamin D
Calcitonin
Estrogen
Glucorticoids

i
T

9

i
i

^ t=increase -l^decrease ?=not known. , ^ PTH and vitamin D decrease collagen synthesis in high doses

Estrogen deficiency leads to an increase in bone remodelling and a subsequent decrease
in bone mass caused by an imbalance between bone resorption and formation [52].
Several mechanisms of action producing this decline in bone mass have been proposed.
One such process is the suppression of IL-6 production by estrogens, as this cytokine has
shown importance in osteoclastgenesis.

Estrogens also influence other important

osteoclast-stimulating cytokines, such as lL-1 and TNF-a [53]. Locally derived agents
including cytokines and growth factors also play a vital role in remodelling regulation.
For example. Transforming Growth Factor-p (TGF-P) is a multifunctional polypeptide
that is released from the bone matrix during resorption and commonly inhibits osteoclast
formation by down-regulating the proliferation and differentiation of its precursors [48].

1.5

Bone vascularisadon

Bone is a highly vascular structure. The need for numerous nutrients, factors and cells in
the composition, growth and normal physiology of bone serves to reinforce the
significance a working circulatory system plays. The cytokines and growth factors that
regulate bone remodelling also regulate intraosseous angiogenesis and close functional
relationships exist between the blood supply to bone and bone formation, resorption and
fracture repair.

1.5.1

Blood afferent system

The blood supply in bone consists of interdependent components and can be divided into
afferent vessels, efferent vessels and a microvascular network [33]. The afferent system.
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for instance, in the lone bong bone schematic of Figure 1.10, comprises the principal
nutrient artery, epiphyseal, metaphyseal and periosteal arteries which form a network of
rings circling the diaphysis and metaphysis and are connected by long anastomoses [32,
54], Periosteal arteries enter the diaphysis through many perforating canals and supply
the periosteum [32],

For the cortex, the main blood supply is achieved through the

diaphyseal or nutrient artery, which passes through a hole in the compact bone called the
nutrient foramen [32], This artery branches within the medullary cavity, separates into
the ascending and descending arteries and supplies the whole length of the medullary
bone [55],

The metaphyseal arteries enter through the medullary cavity at each

metaphyseal region of the long bone. They anastomose with branches of the nutrient
artery at each end of the medulla and supply the red bone marrow and bone tissue of the
metaphysic [55]. The tissue of the epiphysis is supplied by the epiphyseal artery, which
remains a separate circulation (divided by the growth plate) until maturity [54]

Figure 1.10; Diagram of the arterial vascularisation of a long bone [54]
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Blood efferent system

The efferent system consists of a network of veins and venules whose function is to carry
waste products away from the bone. As can be seen from Figure 1.11, it is comprised of
a perforating vein, epiphyseal veins, metaphyseal veins, a nutrient vein and periosteal
veins [32]. A large central venous sinus runs along the middle of the diaphysis and drains
into veins that mn parallel to the corresponding arteries, namely the nutrient vein, the
metaphyseal vein and the epiphyseal vein [54]. The venous blood can also drain into a
perforating vein that empties into the large venous trunks of the limb [55],
penosteal veins also exit with their respective arteries in the periosteum [32].

Figure 1.11; Diagram of the venous vascularisation of a long bone [54]

Small
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1.5.3
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Microvascular network

The microvascular channels in the cortex travel m the rigid and bony Haversian and
Volkmann canals [54, 55], Each vessel ultimately conveys nutrients to the osteocytes
through the canalicular network [54],

1.6

The Mechanical properties of Bone
The mechanical properties of bone are a result of a compromise between the need

for a certain stiffness (to reduce strain), and the need for enough ductility to absorb
impacts (to reduce the risk of fracture and minimize skeletal weight).

These

biomechanical properties are dependant on 2 factors - the properties of the bone material
itself and the geometric spatial architecture in which this material is arranged [34], From
a materials perspective, bone is essentially a non-homogenous composite consisting of a
hard mineral phase (mainly hydroxyapatite crystals), a more compliant collagenous phase
and water [56],

It is a combination of the characteristics of these individual bone

components and component interactions that define bone’s material properties.

Table 1.2 - Some Biomechanical Properties of bone [57]

Properties
Youngs Modulus (GPa)
Tensile Strength (MPa)
Compressive Strength (MPa)
Stain to failure

Measurements
Cortical Bone
14-20
50-150
170-193
1-3

Trabecular Bone
0.05-0.5
10-20
7-10
5-7

The mineral phase of bone imparts strength and stiffness to the tissue [58], Bone
mneral density has long been associated with bone strength and stiffiiess [59], but as
mneralisation increases, the tissue becomes more brittle and requires less energy to
fncture [59], Thus, hypermineralisation can introduce fragility through a decrease in
b(ne toughness [59], Bone strength is not only dependant on degree of mineralization;
cr/stal number, crystal size and degree of crystallinity have all been shown to effect
bine’s mechanical behaviour [59], Bone crystals are plate or needle-like in shape and are

h
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quite small having a length, width and thickness of approx. 50nm, 25nm and 1.5-4 nm,
respectively [60]. The longer c-axes of the crystals are aligned along the longer axis of
collagen fibers [58].

Carbonated apatite crystals become elongated as they grow and

mature, many fusing with adjacent crystallites [58]. Consequently, bone becomes stiffer
along the direction of the longer axis of the crystal and adds tensile strength and stability
to the collagen structure [58].
The collagen phase of bone affects the overall toughness of the tissue and has a
profound effect on bone’s post-yield properties [61]. In contrast to the mineral phase,
collagen appears to play a negligible role in bone stiffness as is evident from the elastic
moduli of collagen (approx. 1.5 GPa) and hydroxyapatite (114 GPa), respectively [62].
Collagen’s central function may be related to the amount of collagen and the fiber
orientation [62]. Lamellar bone, with lamellae of parallel collagen fibers, is stronger than
woven bone with randomly orientated fibers [34]. It has also been found that longitudinal
collagen fiber orientation correlates with the modulus and strength of bone [34]. The
biomechanical effects of collagen also depend largely on cross-linking between fibrils.
Cross-linking is a salient feature of bone because it not only organizes fibrillation but also
contributes to the mineralization process [60].

It can either be enzymatic or non-

enzymatic in nature. Lysyl oxidase mediates enzymatic cross-linking, results in trivalent
collagen cross-links and has been linked to improved bone mechanical properties [6].
Non-enzymatic cross-linking occurs via spontaneous condensation of arginine, lysine and
free sugars. Collagen can accumulate substantial non-enzymatic cross-links with age and
this has been inversely correlated with bone toughness and strain to failure [6].
While it becomes obvious that mineral and collagen contribute to bones
mechanical competency, their interaction with water is equally important to the
mechanical behaviour of bone. Water is distributed in bone in a mobile form in lacunae
and canaliculi, but also exists within and interacts with the collagen matrix and mineral
apatite [63]. As water is a polar molecule, it naturally associates itself with collagen and
mineral [60].

Hydrogen bonding with hydrophilic residues occurs on and between

collagen molecules and helps stabilize collagen [60], and provides post-yield toughness
to bone [63]. Removing this water thus increases strength and stiffiiess but decreases
bone toughness. Water interacts with the mineral phase either by inserting itself into the
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lattice structure or binding to the surface of crystals [63], Loss of water within the apatite
likely decreases strength and bone toughness [60],

1.7

Bone Fracture and Repair
It is important to understand the different causes and mechanisms of fracture, the

different stages of healing and the factors that influence these processes in order to
appreciate and ultimately manipulate fracture repair.
1.7.1

Mechanisms of fracture
A fracture describes a loss of continuity in the substance of a bone [64], The

nature of a fracture depends on the direction, magnitude, loading rate and duration of the
mechanical load sustained, as well as the health and maturity of the bone at the time of
injury [64],

There are 2 main types of bone fracture - traumatic fracture and stress

fracture [64]. Traumatic fracture occurs when bone is subjected to an accidental overload
which substantially exceeds the normal range of loading to which it has become
accustomed [65]. This overload can be in the form of an external impact, for example, a
fall or can occur spontaneously by a muscular contraction without trauma [66], This kind
of fracture can also be produced by normal physiological loading of a bone weakened by
disease - referred to as a pathologic fracture [65]. Osteoporosis and bone tumours are
examples of such diseases that can alter the mechanical properties of bone and lead to
such fractures [67]. Stress fracture is caused by creep or fatigue. Cyclic loading of bone
can lead to the accumulation of microdamage which surpasses the repair rate of
remodeling [68]. Microcracks, which can manifest themselves in varying ways including
(debonding of the collagen-hydroxyapatite composite and cracking along cement lines or
lacunae), can subsequently multiply, propagate and ultimately lead to complete fracture
[66, 68].
1.7.2

Fracture healing
The primary goal of fracture healing is to re-establish the stmctural integrity of

the injured bone and thus restore function.

The processes involved are complex,

involving the coordination of many cells and are affected by the biomechanical stability
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and biological environment of the fracture.

In essence, fracture healing involves the

recapitulation of the physiologic pathways involved in the histogenesis of bone as
previously described. Primary fracture healing occurs in cases of extreme stability and
negligible gap size, involving a direct attempt by the bone to form itself directly, with no
intermittent cartilaginous phase [66, 69].

Secondary healing is far more common. It

occurs when there is relative stabilization, for example fractures treated in a plaster cast,
and gap size is moderate [64, 66]. It involves healing processes within the bone marrow,
periosteum and the surrounding soft tissue [69],
Secondaiy fracture healing (Figure 1.12) can be divided into overlapping
biological phases: haematoma formation, the inflammatory phase, and the reparative and
remodeling phase [65, 70], The first stage begins immediately after bone fracture. Blood
vessels crossing the fracture line are broken and blood leaks from the medullary cavity,
the periosteum and damaged neighbouring vessels [64, 70].

This heamorrhage causes a

blood clot which forms approximately 6-8 hours after injury and fills the fracture gap
space [64]. This is known as the fracture haematoma. The circulation to the osteons in
and around the fracture site is disrupted leading to an ischaemic environment. Death of
the osteocytes occurs and the necrotic fractured bone ends begin to be resorbed by
osteoclasts [71]
The healing process now enters the inflammatory phase. The vascular framework
provides the cellular inflammatory response in the form of various migrating immune
cells including neutorphils, monocytes and macrophages [64, 72]. These cells remove
debris from the fracture site and granulation tissue begins to replace the haematoma.
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Figure 1.12: Secondary fracture healing - bridging of fracture by external callus [64]

This inflammatory stage lasts between 3 and 4 days and promotes immobilization
of the bone by causing substantial pain and swelling [65], thus optimizing the local
mechanical environment for fracture healing [69, 72], Over the next few weeks, due to
the action of fibroblasts, chondroblasts and osteoblasts from the periosteum, the
granulation tissue matures, becoming more fibrous and collagenous [72],

The result is

the formation of a callus which serves to stabilize and bind together the bone fragments
temporarily for healing [71 ].
Fracture healing now enters the reparative stage.

Osteoclasts degrade the

calcified cartilage and allow the invasion of blood vessels. In the well-vascularised areas,
osteogenic cells develop into osteoblasts. The fibrocartilage matrix begins to be replaced
by spongy bone in a process similar to endochondral ossification [72], Re-establishing
the vascular supply is essential for fracture healing. Vascular endothelial growth factor
(VEGF) has been shown to be a key player in the coupling mechanism between
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vascularisation of the callus and osteogenesis, showing a role in the recruitment and
activity of osteoclasts, endothelial cells and osteoblasts [71], Remodeling of the fracture
site now begins and compact lamellar bone gradually replaces the spongy bone,
eventually restoring the bone to its original shape and strength, a process which can take
up to a year [66],
Fracture healing is not only regulated by a cascade of biological events.
Mechanical perturbations have been shown to modulate the repair process [73]
Mechanical loading of a fracture callus can occur as a result of weight-bearing and
application of cyclic compressive displacements has been shown to enhance healing
through increased callus formation and more rapid ossification [73], Chondrocytes have
also been shown to upregulate type-11 collagen in unstabilized fractures in comparison to
stabilized fractures [73],
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2.

Bone Grafts and Bone Graft Substitutes
As discussed in chapter 1, bone is capable of self repair when the skeleton

sustains damage. It involves a series of events which culminate in the healing of the bone
and in most cases proceeds unimpeded.

However, there are scenarios such as an

underlying metabolic bone disease, bone loss and comminution (division into small
parts), when bone fracture repair is delayed or even arrested, and the bone struggles to
regenerate completely [74], For these cases, bone grafting is frequently employed, as it
can provide mechanical or structural support, fill defective gaps and enhance bone tissue
formation [57]. The use of bone grafting is also not limited to that of fracture repair, and
is often employed in scenarios where an increase in bone quality or quantity is required.
In dentistry, sinus augmentation procedures involving the addition of bone to the upper
jaw are frequently required in order to support the base of a dental implant. Similarly,
bone grafting is often used in the treatment of osseous defects caused by inflammatory
periodontal disease [75], However, regardless of application, the various characteristics
which render bone grafts effective remain the same.

2.1

Bone Graft Physiology and Characteristics
The physiology and incorporation of a bone graft involves a multistep cascade

that is similar to that of fracture healing. Firstly, implantation of the graft provokes an
inflammatory response, and allows for the accumulation of inflammatory cells. Various
growth factors, including TGF-p, act to chemotactically attract host mesenchymal stem
cells, which subsequently undergo proliferation and differentiation into cartilageproducing chrondroblasts.

Osteoblast phenotypic cells transform this cartilage and

produce bone on the 3D framework of the graft followed by bone remodeling [76]. Bone
graft incorporation differs from fracture healing in that it can involve the processes of
necrotic graft resorption and graft revascularization - both which occur concurrently with
the above bone induction cascade [76]. An ideal bone graft must essentially be capable
of assisting and aiding the various stages involved in graft incorporation, and so must
exhibit the following- osteoconduction, osteoinduction, osteogenesis, osteointegration,
biocompatibility and structural support [74].

Bone Grafts and Bone Graft Substitutes

2.1.1
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Osteoconduction
Osteocx)nduction is the process by which a material or graft allows bone growth

on its surface [77],

The bone graft acts like a scaffold, allowing vascular invasion,

cellular infiltration, deposition and calcification of bone matrix and ultimately new bone
formation. Ideally an osteoconductive graft should eventually be partially or entirely
resorbed at a rate commensurate with bone replacement- a process known as creeping
substitution [78], Porous structures similar to that of cancellous bone are ideal, enabling
for a more complete incorporation [19].

Osteoconductive materials are not viable in

nature but act as more as a passive structure onto which grows the osteoprogenitor tissue
[79],

2.1.2

Osteoinduction
Osteomduction is the process of stimulating bone formation by activating and

differentiating the host osteoprogenitor stem cells from the surrounding tissue into bone
forming osteoblasts [80], An osteoinductive material allows repair in a location that
would normally not heal if left untreated [81 ]. The process is regulated by a cascade of
signals, with stimulation achieved by blood-borne proteins, growth factors and cytokines.
A cytokine is a regulatory protein which is released by cells of the immune system and
functions as an inter-cellular mediator in the generation of an immune response [27].
Growth factors, subsets of cytokines, are proteins capable of stimulating cell
differentiation and proliferation [74], an example being Bone Morphogenetic Proteins
(BMP) [82].

2.1.3 Osteogenesis
The osteogenic potential of a bone graft refers to its cellular content, which is
capable of or has the potential upon differentiation to directly form bone [78].
Osteogenesis may originate from living cells within the bone graft itself or from the host
bed [82].
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2.1.4

Osteointegi’ation and Biocompatibility
Osteomtegration refers to the ability of a graft material to from a bond with bone

[80], and biocompatibility to the ability of a graft to be accepted by living tissue [27] or
more recently defined as the ability of a graft or material to perform with an appropriate
host response in a specific application [83], Both characteristics are important as to avoid
any toxic or immunological reaction caused by the graft which can lead to graft failure,
tissue necrosis and fibrous encapsulation [84],

2.1.5

Structural Support
When a bone fracture involves bone loss or when a bone graft will be subject to

compressive loads, its ability to provide mechanical stability and structural support is
paramount [78],

Bone healing is known to be sensitive to mechanical stimuli [85] -

initial instability of a fracture can lead to delayed healing [86], Maintenance of
mechanical stability is largely achieved with internal and external fixation techniques
[74], while many bone grafts augment this role by helping prevent displacement and
providing a supportive function [87],

A good example of this is the LT-cage®

(Medtronics, US), a titanium device used in conjunction with a bone graft, which
stabilizes the spine while it is fusing [88],
The success of a bone graft is largely dependant on its inherent ability to fulfill
the above criteria, but bone graft healing is also affected by other biological and systemic
factors - as can be seen in Table 2.1. Age is a determinant as the osteogenic potential of
a graft may be diminished due to the reduction of mesenchymal stem cells in bone tissue
with age [82]. Metabolic bone diseases such as Osteoporosis have been shown to reduce
bone fracture healing and subsequently the success of a bone graft [82, 89].
Table 2.1: Some Factors effecting bone graft healing [89]

Biological factors

Mechanical factors

Systemic factors

Preparation of recipient site

Biomechanical stability

Nutrition

Vascular supply of soft tissue

Biomechanical loading

Age

Bone graft material (quantity, type)

Osteoporosis

Local bone disease (eg tumour)

Smoking
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Types of Biological Bone Grafts and Substitutes
Bone grafting has evolved to provide surgeons with numerous graft options.

These grafts can be categorized using numerous factors. For the purposes of this thesis
they have been divided into those of biological origin and synthetic origin.

2.2.1

Autologous Bone
Autologous bone grafts are those taken from the patients own body and remain

the traditional standard for treating any condition requiring a bone graft [90]. Autologous
bone grafts have osteoinductive, osteoconductive and osteogenic abilities, show inherent
immunologic- and histo-compatibility and often provide stmctural support - satisfying
the criterion for an ideal bone graft [80]. Autologous bone is traditionally harvested from
the iliac crest, but can also be harvested from other bones such as the proximal tibia,
distal radius and fibula [87, 91].

The structure of these grafts can be cortical or

cancellous in nature, a combination of the two or consist of vascularized bone [91]
Cancellous bone shows good osteogenic potential and is more rapidly revascularized and
incorporated into the host site, but provides little mechanical stability [87],

Cortical

grafts provide more structural strength but incorporation is achieved more slowly as bone
resorption and remodeling takes significantly longer [84, 90], Vascularized grafts are
harvested on their own blood supply, which can be preserved at the recipient site by
micro vascular anastomoses to recipient vessels [92], Consequently, such grafts do not
become necrotic and tissue repair is analgous to fracture healing as previously described
(section 1.7.2). Vascularized grafts have also shown greater mechanical strength during
the first six months after transplantation [87].
Despite their obvious benefits, autologous bone grafts do have significant
disadvantages. Many post-operative complications can occur at the site of the harvest.
Major complications include donor site morbidity, bleeding, neurological injury, deep
infection, and pelvic instability with impaired gait [93, 94]. In iliac bone graft harvesting,
proximity of the site to injury prone nerves such as the lateral femoral cutaneous nerve
can account for the majority of the major complications [93]. Acute and chronic pain is a
frequently reported complaint among patients that undergo such harvesting [93] and can
be accounted for by neurological injury. Autologous bone can also be of limited supply
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for example among older osteoporotic individuals and also adds increased expense for
patients due to increased operative time and hospitalization [93],

2.2.2

Allogous Bone
Allogous bone refers to bone harvested from a donor [91]. Allografts provide an

ideal scaffold for bone growth and are considered highly osteoconductive [89], They are
weakly osteoinductive through the release of osteogenic bone-inducing proteins and are
not osteogenic as the graft itself does not provide any viable cells [87, 89], Allografts
have the added benefit of being site-specific (when available) - the graft could originally
be harvested from the same site as to which it is to be used allowing for structural and
mechanical similarity.

Allografts also eliminate the need for a second surgery,

decreasing possible complications, including pain and blood loss.
However, allografts present an immunological problem - an immune response
may be elicited by the recipient and lead to graft rejection [84], The response of the host
to the allograft is predominately a cell-mediated response to cell surface antigens carried
by cells in the graft. These class-1 and class-11 antigens are encoded for by genes of the
major histocompatibility complex (MHC) [95]. Rejection or activation of an immune
response by the allograft can occur when the allograft is different from the recipient at the
MHC gene locus, and it appears that the greater the genetic disparity between donor and
recipient the more substantial an impact on the incorporation and success of the graft
[96], Allogous bone also poses the threat of transfer of infection, systemic orders or
potentially transmissible diseases of viral or unknown aetiology [97]. For these reasons
Allogous bone is traditionally sterilized before being implanted, often combined with
aseptic excision techniques to reduce disease transfer risk and antigenicity.

Primary

sterilization involves aseptic procurement of the bone in a sterile operating room - and is
usually preformed on cadavers wfrich have been washed in a separate preparation room
[98] ,

Secondary or terminal sterilization is used when the grafts are not aseptically

procured. Gamma irradiation and ethylene oxide are examples of sterilizing processes
[99] , but both have been shown to adversely affect the biological and mechanical
properties of the tissue [100]. The methods used to preserve the tissue can also play a
large role. Cryopreservation in deep freezers (-40 to -80°C) or liquid nitrogen (-196°C) is
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Whilst this storage reduces immunogenicity, it has little effect on

bacterial and viral contamination [101], Finally, due to the general increase in life span,
the eligible donor population is decreasing. This is due to that fact that more people
suffer from conditions like osteoporosis which effects bones mechanical properties and
renders them unsuitable for donation [102].

2.2.3

Demineralised Bone Matrix
Demineralized Bone Matrix (DBM) is a less immunogenic and processed form of

allograft bone [78], It is formed by the mild acid extraction of the mineral phase of bone
[103], leaving a mixture of type 1 collagen (approx. 93% of DBM) and non-collagenous
proteins (approx. 5% of DBM), with the remaining 2% being comprised of residual
mineralized m.atrix [104, 105].

Ulrist et al, in the 1960’s, showed DBM to have

osteoinductive capacity - a property discovered while preparing soluble extracts from
demineralized bone [104].

It has since been identified that the principal component

responsible for this osteomduction is a group of low-molecular-weight glycoproteins,
found within the organic matrix, and belonging to the Transforming growth factor (TGFP) superfamily [105]. The most important of these proteins are known as Bone
Morphogenetic Proteins (BMP’s). They appear to be “inhibited” by bone mineral and are
“unmasked” upon demineralization of the bone, allowing the proteins increased contact
with the surrounding mesenchymal cells and ultimately stimulating bone formation at the
implantation site [106, 107]. DBM appears to differ in its mode of osteoinduction,
depending on the site of implantation and the tissue-type it is exposed to.

In

subcutaneous, intramuscular and long bone tissues, DBM firstly induces mesenchymal
stem cells to differentiate into chondroblast cells which produce cartilage. This cartilage
is subsequently resorbed and replaced with bone in a process similar to endochondral
bone formation [108]. Whereas in cranial defects DBM has been shown to induce stem
cells to differentiate into osteoblasts which synthesise bone directly, a process which
more closely resembles intramembranous bone formation [109, 110], Although DBM is
primarily an osteoinductive agent, it also shows weak osteoconductive properties mainly
through the bone collagen matrix, but provides little or no structural support.
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Similar to Allogous bone, DBM before implantation needs to undergo processing
- involving washing, demineralization with organic solvents, drying and sterilization
[111]. Procedures used can vary greatly with differing factors such as temperature and
solvent concentration during demineralization, ethylene oxide or gamma irradiation
sterilization, and frozen storage or lyophilization and room temperature storage [111].
Processing

significantly decreases

the

risk of transmitting

infection

but can

simultaneously decrease the graft’s osteoinductive capacity [107]. Once extracted from
bone, DBM exists as a particulate powder. For ease of handling and use, DBM is often
combined with various carriers to from a putty or paste- glycerol, poloxamer, gelatin,
calcium sulfate, lecithin and hyaluronic acid all being examples [111].
Many different commercially available DBM formulations exist. Grafton DBM,
produced by Osteotech, has several formulations in a glycerol water soluble carrier and is
available in a gel, putty and semisolid form [74, 111]

Clinical data from studies

comparing Grafton DBM and Autograft performance in ununited diaphyseal humeral
fractures have shown healing at similar rates [112]. But the use of a glycerol carrier is
questionable, as toxic reactions have been shown at high doses in rats [74].
Dynagraft/Orthoblast (GenSci Regeneration Sciences Inc.) is in a poloxamer carrier, a
polymer gel containing water which becomes rigid with an increase in temperature.
Clinical studies comparing the efficacy of Grafton and Orthoblast in periarticular
fractures have shown a success rate of 100% and 69%, respectively [111]. Table 2.2
below summarizes other commercially available DBM formulations.

Table 2.2: Summary of some commercially available DBM Preparations [74, 113-116]

Product

Company

Type

Allogro/
Allofuse Putty & Gel
DBX
Osteofil gefputty and
paste
Regen afil/
Regenaform Paste

Allosource

Particulate DBM, reconstitute with saline
DBM in reverse phase medium
DBM in hyaluronic acid and collagen carrier
DBM in gelatin and water medium

Synthes USA
Regeneration Technologies
Inc.
Exatech Inc.

DBM in biological carrier thermoplastic
moldable
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2.2.4

Bone Morphogenetic Proteins (BMP)
As mentioned, BMP are proteins which belong to the TGF-p superfamily. They

are dimeric molecules composed of 2 polypeptide chains held together by a single
disulphide bond [117], Currently, 16 human BMP have been identified [118] and they
can be divided up into at least 4 subgroups depending on their primary amino acid
sequence - Group one consists of BMP-2 and BMP-4, Group two BMP-5, -6 and -7,
Group three BMP-14, BMP-13 and BMP-12 and Group four BMP-3 (otherwise known as
osteogenin) and BMP-3b [119], BMP are considered osteoinductive as they have been
shown to govern and regulate the three key steps m the bone-induction cascade chemotaxis or attraction of mesenchymal cells and subsequent proliferation of these cells,
differentiation of the cells into cartilage and finally replacement of the cartilage by bone
[117], BMP also appear to stimulate bone formation by stimulating the synthesis and
secretion of angiogenic growth factors [119],

BMP are thus considered pleiotropic

morphogens - pleiotropy being the property of a single gene or gene product such as a
protein to have a multiplicity of biological actions [117, 119], The cellular and molecular
mechanisms by which BMP aid bone formation are complex and are illustrated in Figure
2.1. They involve the binding of BMP to specific mesenchymal cell surface receptors
which are of two types, I and 11 and are serine/threonine protein kinases. These kinases
are enzymes which then phosphorylate and activate intercellular proteins called Smads.
These Smads then translocate to the nucleus where they influence the regulation of the
expression of genes involved in bone and cartilage formation [117, 120, 121].
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Figure 2.1: BMP mode of action via Smad activation [120].

BMP were originally extracted from DBM, but only small quantities were able to
be obtained.

To allow for sufficient research and clinical use, genetic engineering

involving the cloning and sequencing of BMP-specific genes can be applied to produce
much larger amounts of recombinant BMP [122], The two most commonly studied are
rhBMP-2 and rhBMP-7 [123], Both are commercially available for clinical applications
- rhBMP-2 marketed under the name InFUSE (Medtronic Sofamor Danek), and rhBMP7 as OP-1 (Osteogenic Protein-1) (Stryker Biotech) [118],

InFUSE is soaked onto a

collagen sponge which is designed to be resorbed over time [124], OP-1 is available in a
putty form with a purified type I collagen carrier [125], Studies comparing OP-1 (in
conjunction with an intramedullary rod) to fresh Autograft in the treatment of tibial non
unions have shown similar success [126].
Though BMP are highly osteoinductive, a disadvantage associated with their use
is their price, often costing from $3500 to $5000 each [102, 127, 128], Although BMP
are human proteins, there is still a possibility of developing an immune response to the
products, a risk which increases if rhBMP are administered several times [129], Also,
another limitation to the success of BMP is the fact that they are very water soluble
proteins, leading to rapid diffusion in body fluids.

This leads to the problem of
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containment of the protein at the graft site to enable it to induce its clinical effect and also
to prevent bony overgrowth [130], This problem is being addressed with the inclusion of
assorted carriers with varying success [129, 131],

2.3

Types of Synthetic Bone Graft Substitutes

23.1

Ceramic-based substitutes

23.1.1 Calcium Sulphate
Calcium sulphate (CS) has been associated with bone healing for over a century
[74],

CS, or gypsum, is a mineral consisting of calcium sulphate dihydrate

(CaSO4.2H20)

When heated to above 110°C, this material loses water resulting in

calcium sulphate hemihydrate, also known as Plaster of Paris [132].

Setting of CS

hemihydrate can be inhibited by proteins and other biological marcomolecules thus preset
CS forms are often preferable [132], Its mechanism of action as a bone graft appears to
be largely by osteoconduction [132], though much evidence indicates that the material
resorbs rapidly at a rate which often exceeds the capacity of the surrounding bone to
regenerate [122], Strochi et al, suggested that CS may display angiogenic properties,
demonstrating CS filled defects in rabbits to have a higher micorvascular density versus
autogenous filled [133], Use of CS in pellet form has shown clinical success in treating
various orthopedic bone defects [134], However, Hing et al., in a rabbit calvarial model,
demonstrated that dense CS elicited a mild inflammatory response and was rapidly
resorbed by dissolution before significant quantities of new bone growth were formed
[135], This rapid dissolution has rendered CS effective in the delivery of therapeutic
agents such as antibiotics, in particular in the treatment of osteomyelitis [136], Evidence
has also indicated that the resorption of CS may be accelerated in osteoporosis and that
this may affect the osteoconductivity of the material [137], Osteoset® (Wright Medical,
US) was one of the first commercially available CS based bone grafts. It is available in
pellets of two different sizes, 30mm and 48mm, and has been shown to typically dissolve
in vivo in 30-60 days [138],

Other marketed CS products include Boneplast®

(InterporeCross) which is available in pellet, block, and injectable forms [74],
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2^. 1.2 Hydroxyapatite
Synthetic Hydroxyapatite, tricalcium phosphate and combinations of the two are
the prevailing calcium-phosphate based bone graft substitutes. Hydroxyapatite (HA) is
frequently used as a bone graft substitute owing to its chemical and structural similarity
with natural bone mineral [57],

Stoichiometric HA has a chemical composition of

Caio(P04)6(OH)2 with a Ca:P ratio of 1.67 [57],

It can be derived from synthetic or

natural sources. Synthetic HA powder can be prepared by numerous methods including
wet chemical procedures, solid-state diffusion and hydrothermal processes [139].
Synthetic HA can similarly be produced in dense, sintered or porous forms. Sintered HA
allows for better mechanical properties, demonstrating tensile strength ranging 120-150
MPa and fracture toughness 38-300MPa.; however, such materials demonstrate decreased
remodeling and resorption in vivo. Porous HA, which can be formed by burning out an
organic pore former such as a polyurethane sponge, allows for increased bone ingrowth
and osteointegration but demonstrates reduced strength. Natural HA can be derived from
the calcium carbonate of sea coral. Coralline HA can be manufactured by the conversion
of natural coralline calcium carbonate to HA by substitution of carbonate components
with phosphates. HA demonstrates good biocompatibility and osteointegration due to its
ability to form a strong bond with bone. HA acts solely in an osteoconductive capacity,
not demonstrating any osteoinductive properties. Many different commercially available
forms of HA exist. Endobon® is a bovine derived HA (Merck, Germany). It is available
in blocks and cylinders with interconnecting pores ranging from 100-1,500 pm.
Endobons® primary indication is for reconstruction of metaphyseal and cancellous bone
defects.

Cinical trials involving metaphyseal bone defects of the distal radius have

demonstrated good osteointegration and fibrovascular ingrowth [140]. However, implant
site infections have been noted when Endobon® was used as a bone defect filler in
aricular fractures [141].
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Figure 2.2: ProOsteon® in particulate and block form

ProOsteon® (Biomet, US - Figure 2.2), a coralline derived HA, demonstrates an
average 200pm interconnected porosity.

Studies have demonstrated that proOsteon®

allows for good bone ingrowth but exhibits poor resorption capacity [142],

Other

researchers determined proOsteon to be equivalent to an iliac crest autograft in anterior
cervical fusions [143], Table 2.3 demonstrates other commercially available HA bone
grafts.
Table 23: Summary of some commercially available HA products [57, 144, 145]

Product

Company

Type

Calcitite
Ceros 80
O^rovit
OrthoMatrix HA

Calcitek USA
Straumann Ltd UK
Cerasiv, Germany
Exatech Inc.

Dense crystalline HA, granules 400-8C)0pm
Dense polycrystalline HA particles
Porous HA, pore size:200-600pm
Particulate, includes HA-500, HA-1000 and
HA-2000 with particle diameter 240-2000pm

2.3.1.3 Calcium phosphate
Tricalcium phosphate (TCP - Ca3(P04)2), a physiological mineral salt that
exchanges readily with HA molecules [74], is one of the earliest calcium phosphate
compounds used as a bone graft substitute [136]. Alpha and beta forms exist, which have
the same chemical composition but differ in their crystal structure [146], and thus vary in
their rate of degradation and resorption. Overall, TCP possess higher biodegradability in
vivo than HA [147], with a-TCP dissolving more easily than P-TCP [147].

p-TCP

undergoes reabsorption via dissolution and fragmentation over a 6-18 month period
[136], a-TCP undergoes a similar dissolution process at a faster rate, and otsteoclasts are
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thought to play only a minor role in the degradation of both forms [148], TCP primarily
acts in an osteoconductive capacity, and both forms have been found to be biocompatibile
[147, 148], Ehara et al. demonstrated that a-TCP did not influence the proliferation rate
of the pre-osteoblastic cells MC3T3-E1, but did stimulate extra-cellular matrix formation
and mineralization and promoted a shift to a more differentiated state [149]

Other

researchers similarly demonstrated that a-TCP is capable of supporting the in vitro
growth and differentiation of human-osteoblast like cells [150], In vivo studies have
indicated that a-TCP supports new bone growth in tibial head defects in minipigs,
however a concurrent mild inflammatory reaction was noted [151],
demonstrated positive in vivo results.

p-TCP has also

Walsh et al, using a bilateral tibial defect in

rabbits, demonstrated P-TCP to be osteoconductive and support new bone formation
[152],

Similarly, researchers have demonstrated p-TCP granules effective in the

treatment of defects in the femoral medial condyles of sheep, the material exhibiting good
biocompatibility and osteodonductive properties [153],

p-TCP has also demonstrated

clinical efficacy allowing for vascular invasion, osteoblast cell attachment and bone
formation in excised bone tumour cavities [154, 155],

However, comparison of TCP

against other bone graft substitutes for antibacterial efficacy has demonstrated that TCP
alone exhibits little antibacterial potential [156],
Numerous commercially available TCP-based products exist in different forms.
Vitoss® (Orthovita, US) is a P-TCP product available in foam form demonstrating
polyporosity with pores ranging from 1-1000pm [157],

Clinical efficacy has been

established for Vitoss® as a spinal graft extender, as well as for periodontal, dental and
orthopedic tumour defects [158], ChronOS® (Synthes, US), a pure p-TCP product, is
available in particulate, cylinder, block and wedge forms and is also available as an
injectable cement [114].

ChronOS® has been successfully used in fusion of thoracic

spine defects [159]. Table 2.4 provides a summary of other commercially available TCP
based bone grafts.
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Table 2 A: Summary of some commercially available TCP bone grafts [160-163]

Product

Company

Type

Cerasorb
Ceros 82
Calciresorb
Synthograft
Osferion
Biobase

Curasan (Europe)
Mathys medical (Europe)
Ceraver (France)
Miter (US)
01ympus(Tokyo)
Biovision (Germany)

P-TCP, granules and block form
Pure P-TCP, porous granules and putty
Porous pure [3-TCP
Small size dense particulate (3-TCP
Porous P-TCP, granules and block form
Particulate a-TCP

23.2

Polymer-based substitutes
Polymers used as bone graft substitutes can be broadly divided into those of

natural or synthetic origin [164], Those of natural origin are largely based on collagen
and chitosan, and synthetic polymers include poly(lactic acid) (PLA), poly(glycolic acid)
(PGA), poly(lactic-co-glycolic acid) (PLGA) copolymers and poly(caprolactone) [164].

2.3.2.1 Collagen
Type I collagen, as discussed in section 1.1.1, is the most abundant protein in the
extra-cellular matrix of bone. It has a structure which is conducive to promoting mineral
deposition, contributes to vascular ingrowth and growth factor binding, providing a
favourable environment for bone regeneration [80].

Collagen may carry potential

immunogenicity [165] and provides minimal structural support, however purified forms
demonstrate

good

biocompatibility,

osteoconductive properties [57].

biodegradability,

non-antigenecity

and

The functionality of collagen is enhanced by

incorporating other bone graft materials such as HA and BMP. Collagraft® (Zimmer,
US) is a composite of suspended fibrillar bovine derived collagen and a porous calcium
phosphate ceramic, in a ratio of 1:1 [138]. In a rabbit femoral defect model, Collagraft®
demonstrated significantly enhanced bony ingrowth, compared to other bone graft
substitutes [166]. Similarly, clinical trials have indicated that when Collagraft® is mixed
with autogenous bone marrow it functions effectively in the treatment of acute long bone
fractures [167]. Healos® (Orquest, US - figure 2.3) is a HA mineralized Type I collagen
sponge [138] and is mainly used as an osteoconductive matrix.

Tay efa/., in a rabbit

bilateral intertransverse fusion spine model, demonstrated that when Healos® was
combined with bone marrow it produced fusion rates that were comparable with those of
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autologous bone grafts [168],

Other researchers have demonstrated in a rat calvaria

defect model, that Healos® enhanced bone formation in young rats, but not in aged rats
[169], It was also noted that the material produced an inflammatory response in aged rats
[169],

Figure 23: Healos® in sponge form

23.2.2 Chitosan
Chitosan is a biodegradable cationic aminopolysaccharide derived from the
acetylated naturally occurring polysaccharide chitin [164], Chitosan has a hydrophilic
surface promoting cell adhesion, proliferation and differentiation [164],
biocompatibile,

which

is

primarily

attributed

to

its

structural

Chitosan is
similarity

to

glycosaminoglycan in the ECM, and can be molded into various forms including porous
structures [170], It demonstrates osteoconductive properties, enhancing bone formation
both in vitro and in vivo [171], and also stimulates wound healing [172],

However,

similar to collagen, chitosan is mechanically weak. Chitosan has been combined with a
variety of materials such as calcium phosphate and HA in order to enhance its potential in
orthopaedic applications.

By incorporating calcium phosphate into chitosan scaffolds

both the compressive modulus and yield strength were greatly improved and a reinforced
microstructure was achieved [173].

Also such composites demonstrated apatite

formation when immersed in simulated body fluid indicating their bioactivity [174].
Chitosan/HA composites have significantly stimulated bone forming ability in vitro as
demonstrated by induced proliferation of human fetal osteoblast cells and mineral
deposition [175].
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23.2.3 PLA, PGA & PLGA
These polymers are collectively known as poly(a-hydroxyacids). They are easily
p'ocessed and their degradation rate and physical properties are adjustable over a wide
range by changing the molecular weight or copolymer ratio. However, these polymers
degrade by hydrolysis, leading to the release of acidic degradation products which can
cause a strong inflammatory response [176], PLA exists in three forms: L-PLA, D-PLA
aid a mixture, D,L-PLA [164], A porous 3D L-PLA/D-PLA (80%/20%) scaffold has
been demonstrated to support attachment and proliferation of sheep osteoblasts in vitro
[177]. In vitro and in \ivo studies have also indicated that when PLA is combined with
human bone marrow stromal cells, the composite demonstrates a mechanical advantage
over PLA alone, and exhibits osteoinductive and osteogenetic properties [178],
High-molecular weight PGA is a hard, tough, crystalline polymer. The strength
properties of PGA can be increased by spinning into fibre form, and similarly by a selfreinforcing technique comprising of oriented fibres and a binding matrix [179]. PGA is
generally considered biocompatibile, however local foreign-body tissue reactions have
been noted [179]. A self-reinforcing PGA (SR-PGA) membrane has been successfully
used to repair orbital floor fractures, the stability of the healing defect showing no
adverse effects from absorption of the membrane and subsequent loss of mechanical
strength [180].

Ashammakhi et al. demonstrated that SR-PGA membranes have a

positive inductive effect on new bone growth in a metaphyseal bone defect in rats [181].
PLA and PGA can be copolymerized to create poly(lactic-co-glycolic) acid
(PLGA).

PLGA forms amorphous polymers and the LA/GA ratio determines the

degradation rate of the copolymer [182]. Ishaug et al., demonstrated PLGA foams in
vitro support the proliferation and differentiation of osteoblasts, as indicated by high
alkaline phosphatase activity and deposition of a mineralized matrix by the cells [183].
PLGA has also been combined with other materials in order to enhance its functionality.
Kang et al. demonstrated better bone regeneration with injecable apatite-coated PLGA
microspheres than PLGA microspheres alone in a rat model [184]. Other researchers,
using rat skull defects, imparted osteoinductive properties on PLGA by combining it with
BMP [185]. Yao et al., produced 3D porous PLGA/bioactive glass composites which
supported cell growth and promoted differentiation of marrow stromal cells to osteoblast
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cells in vitro. However, PLGA alone has not demonstrated efficacy in the regeneration of
healthy bone in osteopenic states, only with the incorporation of drugs such as ipriflavone
has PLGA demonstrated limited therapeutic efficacy [186],

Commercially available

PLGA products include a foam matrix produced by BoneTec. Inc. (Toronto, Canada) and
a particulate product, Immix extender (Figure 2.4), used as a graft extender produced by
Osteobiologics Inc, US.

^
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Figure 2.4: Immix extenders particulate PLGA

23.2.4 Poly(caprolactone)
PCL is a hydrophobic, semi-crystalline polymer and its crystallinity tends to
decrease with increasing molecular weight [187], PCL demonstrates good solubility,
though it does degrade at a slower rate than PGA and PLA, and it possesses superior
rheological and viscoelastic properties [187]. PCL cylindrical scaffolds with gradually
increasing pore size along the longitudinal direction (88-405pm) have been found to be
effective in promoting new bone growth in vitro and in vivo [188]. Kweon et al, also
demonstrated that 3D PCL gel networks encouraged attachment and proliferation of
osteoblast cells in vitro [189]. Similar to other polymers, PCL is often combined with
other materials in order to enhance its functionality in a bone graft capacity.

PCL/HA

composites have been shown to promote in vitro deposition of apatite, leading to good in
vitro mineralization and inclusion of HA has also been shown to improve
osteoconductivity [164]. Other researchers demonstrated that L-PLA fibers embedded in
a porous PCL matrix promoted the in vitro proliferation of human marrow stromal cells
and osteoblasts [190]. PCL/TCP composites have been successfully used in combination
with platelet rich plasma in the treatment of critical-size defects of the mandible in dogs
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[191], Commercially available PCL based products include Osteomesh™ (Osteopore,
Singapore), a medical grade PCL mesh, which can be cut to shape and used primarly in
craniofacial surgery such as repair of orbital floor fractures [192],
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3.

Bioactive Glass
Up until the late 1960’s it had become generally accepted that any implanted

synthetic material would elicit a foreign body response. But in 1969 Hench discovered
that certain compositional ranges of soda lime phosphosilicate glasses appeared readily
accepted within the body, and even formed a chemical bond with bone. These glasses
have been subsequently termed bioactive glasses - the term bioactive referring to their
ability to elicit a biological response at the material interface, resulting in a bond with the
host tissue [193].

The key to its bioactivity lies in its behaviour upon immersion in

aqueous solution, ultimately leading to the formation of a HCA layer. The formation of
this layer is critically dependent upon the structure and composition of the glass, so an
understanding of how the various elements of a glass affect its structure and properties is
warranted.

3.1

Glass Formation and Structure
A glass can be defined as “an amorphous solid completely lacking in long range,

periodic

atomic

structure,

and

exhibiting

a

region

of glass

transformation

behaviour”[194]. Many theories have been formulated in order to explain the formation
of glass and these theories can be broadly divided into two main approaches - stnictural
and kinetic.

3.1.1

Structural theories of glass formation
Structural theories of glass formation attempt to address the question of why

certain materials will form glass, based on considerations such as co-ordination number,
bond type, bond strength and field strength.

The glass formation concepts of

Zachariasen, termed the random network theory, serve as a good basis to understanding
glass stmctures, and the effects of various elemental species on glass formation and
properties.

Zachariasen formulated several rules for glass formation largely based on

observations made from silicate glass systems, and subsequently classified the structural
roles for various component oxides [195].

Firstly, the co-ordination number of the

network-forming cation/s must be small, 4 or less.

Si, which if termed the network
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former, fulfills this criterion. The basic building block for the silicate glass network is
characterized by a central silicon atom surrounded by 4 oxygen atoms in a tetrahedral
formation [196], Secondly, the anion (oxygen atom in this case) must be linked to no
more than 2 glass forming cations and the oxygen polyhedra must share only comers and
not edges or faces [194], The 2-dimensional representation in Figure 3.1 illustrates these
concepts for Si02, in its crystalline and glass form. Thirdly, at least 3 comers of each
oxygen polyhedron must be shared in order to form a 3-dimensional network [194, 196].
However, it can be seen that these mles can describe network stmctures both crystalline
and amorphous.

So as to explain glass formation and stmcture, the network must be

distorted to destroy any long range periodicity. The siloxane (Si-O-Si) bond or bridge in
the S1O2 network can achieve this by variation in its angle (between 100-170 degrees) and
rotation of the bond about its axis [197].

(3) Cry^^Mii^^Si02

(b) Amo^hous Si02

TT

Figure 3.1: 2-dimensional schematic of Si02 in its (a) Crystalline form and (b) Amorphous form

Due to this flexibility when the crystalline form is melted the stmcture is
completely dismpted and rapid cooling to solidification maintains this disordered state
and allows the formation of an amorphous glass [198].

Many oxides do not meet

Zachariasen’s criteria and are incapable of forming networks in isolation. If a non-glass
forming oxide, such as Na20, is added to Si02, it acts to dismpt the network by breaking
the oxygen link between 2 adjacent Si04 tetrahedra [199].

This oxide is termed a

netw’ork modifier. This Si-O-Si bridge mpture leads to a loosened network stmcture with
2 types of oxygens - an oxygen bonded to two Si, called a bridging oxygen, and an
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oxygen bonded to one Si called a non-bridging oxygen, as illustrated in Figure 3.2 [195].
The network connectivity (NC) of a glass addresses the number of bridging and non
bridging bonds in the network, and is related to the representation of a glass network as
an inorganic polymer as suggested by Ray. The network connectivity of a glass can be
calculated using molar composition by equation 1 [200],
NC =

No. BOs

-

No. NBOs

Equation 1

Total No. Bridging species

Where;
BO=Bridging Oxygens
NBO=Non-Bridgmg Oxygens
The consequence of the addition of network modifiers is a decrease in network
connectivity, which affects various properties of the glass.

The melting temperature,

viscosity and glass transition temperature are all reduced [194, 199]. In addition the glass
becomes more reactive and degradable - a key feature in the functionality of bioactive
glasses.
Jon-bridging oxygens

Bridging oxygens

Si

Q

O

On.. O

Figure 3.2; 2-D Illustration of the structure of soda-lime-silicate glass; a 4* oxygen would be located
above each silicon in the 3-D structure [194]
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The extent of these effects is also dependent on the nature of the modifier species.
Alkali oxides such as Na20 have a more profound effect than alkaline earth oxides such
as CaO. The ionic bonding of the monovalent Na^ cation is weaker, requiring only 1
neighbouring NBO to maintain local charge neutrality [194], Whereas the divalent Ca^^
cation must have 2 neighbouring NBO, providing stronger network linkages [194, 201],
Figure 3.2 illustrates these concepts for soda-lime-silicate glass. Other oxides such as
AI2O3 are termed network intermediates. They are unable to form a glass by themselves
but can isomorphically substitute for silicon in the vitreous network [194, 201]. In doing
so, they acquire an excess negative charge of -1, so an associated cation must be present
in the vicinity of each such tetrahedron to maintain local charge neutrality.
Since Zachahasen, others have applied additional crystal chemistry principles in
order to define glass stmcture and formation. Dietzel suggested the measurement of the
strength of a cation-oxygen bond as a parameter to classify oxides and determine their
effect on the behaviour of glass [202], He categorized ions using field strength, z/a^,
where z is the valence of the cation and a is the distance between the cation and the
oxygen [202],

Field strength can be considered indicative of the magnitude of the

electrostatic attractive force between the cation and oxygen. Using such classification,
cations with high field strength (>1.3) such as silicon and phosphorus tend to play the
role of network formers. Those with much lower field strengths (<0.4), such as sodium
and strontium, encompass the network modifier group and those ranging between 0.4-1.3,
such as zinc, appear to play the role of network intermediates [194, 203]. Sun suggested
that the process of forming a glass had to involve an inability to rearrange the bonds in
the liquid state during crystallization, and hence suggested the higher the bond strength
the better the glass former [197],

He defined bond strength in terms of the energy

required to dissociate an oxide into its component atoms in the gaseous state and
demonstrated that high single bond strength oxides were glass formers and low single
bond strength oxides glass modifiers [203]. Stanworth correlated the tendency of glassformation with the degree of ionicity of the bond and classified oxides again into glass
formers, modifiers or intermediates, on the basis of the electronegativity of the cation
[194, 204].
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3.1.2

Kinetic theories of glass formation
As mentioned, structural theories of glass formation attempt to answer the

question of why certain materials form glass. It is now well recognized that virtually any
material will form a glass if the cooling rate is sufficiently rapid, relative to the kinetics
of crystallization [205], Accordingly, kinetic theories of glass formation have focused on
addressing the question of how fast a material must be cooled in order to avoid detectable
crystallization. Crystallisation refers to a combination of two processes, nucleation and
crystal growth. A nucleus, which is a precursor to a crystal, is required so that a crystal
will subsequently grow to a detectable size [194]. In order to understand the kinetics of
glass formation, the energetics and kinetics of these two processes must be addressed as
they establish a time scale for the cooling process.
Nucleation is the process by which constituent particles order spontaneously into
tiny units or embryos by virtue of thermal fluctuations [204]. Nucleation can either be
homogenous, spontaneous formation from the melt; or heterogenous, formation at a pre
existing surface such as a cmcible wall [194]. If no nuclei are present, crystal growth can
not occur and the material will form a glass. There are two barriers to the formation of
nuclei - thermodynamic and kinetic. The thermodynamic barrier (W*) involves the free
energy change in the system associated with nucleus formation. The kinetic barrier (AGd
- where D refers to diffusion) is associated with moving or rearranging the material to
create or grow a nucleus [197].

The overall process can be described in terms of

nucleation rate (I) by the following equation -

I = Aexp[-(W*+AGD)/kT]

Equation 2

Where A is the pre-exponential factor, k is the Boltzmanns constant and T the absolute
temperature (K) [194].
From a thermodynamic perspective, the formation of a nucleus involves two
changes in the energy of the system - the volume free energy and the surface energy as
illustrated in Figure 3.3. The volume free energy (AGv) decreases due to the crystalline
state having lower free energy than the melt, and if a nucleus is taken to be spherical the
free energy reduction for a volume of material to transform a glass to the
thermodynamically favoured crystalline nuclei can be expressed by -
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(4/3)7ir'AGv

Equation 3

Where (4/3)7ir^ corresponds to the volume of a sphere [194, 197],
The surface energy (y) increases upon nucleation, due to the formation of a new interface
between regions of different stmctures and can be expressed by -

Equation 4

4;rr"y

Where 47cr" corresponds to the surface area of a sphere [197],

>CD
C
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Figure 33: Representation of the energy changes needed in a system in order for nucleation [206]

Nucleation is dependent on the balance between surface and volume energies and the net
change in energy, W, for a sphere of radius r, is thus given by the sum of these terms -

W= (4/3)7tr’AGv + 4311^7

Equation 5

The terms have opposite signs as AGv is negative for temperatures below the
melting point (Tm) [194],

Thermodynamically stable nuclei can be formed when r
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reaches a critical size, r*, known as a critical radius thus forming critical size nuclei. R*
is given by -

r*= -2y/AGv

Equation 6

If r* is substituted into equation 5, the free energy change in the system W* can be
defined for the critical nucleus -

W*= Ibrry'VSAGv^

Equation 7

A number of approximations can be made for AGv and its expression per volume basis
can be written as -

AGv^-AHv(T„,-T)A^„,T„

Equation 8

Where AHv is the heat of fusion and Vm is the molar volume of the crystal phase.

It

becomes apparent from the above equations that the further below Tm the greater the
driving force for nucleation [204], However, it is known that all melts do not crystallize
upon cooling, and the reason for this is that for nucleation to occur there is also a kinetic
barrier to overcome.
The kinetic barrier for nucleation, AGd, is related to how fast the material moves to the
surface of a growing nucleus and is expressed as a diffusion coefficient -

D = (kTX.^/h)exp(-AGD/kT)

Equation 9

Where X is the atomic jump distance, h is plancks constant, and k is the Boltzmann
constant.

The diffusion coefficient is related to the viscosity of the melt (q) by the

following relation -

D = kT/3?iq

Equation 10

Using the relations given by equations 8 and 9, and substituting into the original equation
for nucleation rate (equation 2), the following expression can be obtained -
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I = (Ah/3jrX,^ti)exp(-W*/kT)

Equation 11

It can be noted from equation 11 that increasing the viscosity (q) will decrease the
nucleation rate. A graphical representation of equation 11 is given in Figure 3.4 It can
be seen that there is a metastable zone of undercooling in which no stable nuclei will
form.

This is due to the value of AGv being very small at temperatures close to Tm.

Thus, the critical radius needed to form a stable nucleus will be very large and the
probability of the nucleus reaching such a size is very low [194].

T
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Figure 3.4: Graphical rqjresenlation of the thermodynamic and kinetic contributions to nucleation rate as a
function of temperature [206]

Nucleation describes only one part of the process of crystallization - crystal
growth being the second. A kinetic barrier for crystal growth exists (AE) and similarly to
the kinetic barrier for nucleation is diffusion related. The thermodynamic contribution
consists of a crystallization energy driving force (AG) due to the free energy of a particle
in the melt side being slightly higher cx)mpared to the free energy of the growing crystal
|204]. Figure 3.5 illustrates the energy changes in the system for crystal growth.
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Crystal Crowth

Figure 3^: Representation of the energy ehanges needed in a system in order for crystal growth [206]

The rate of crystal growth (U) can be given by the following expression -

U = aoV exp(-AE/kT)[l -exp(AG/kT)]

Equation 12

Where ao is the interatomic separation distance and v is the vibrational frequency.
Using the same theory as nucleation rate, and thus introducing equations 9 and 10 to
describe diffusion we obtain the following expression -

U = (kT/37iao^Ti)[l-exp(AG/kT)]

Equation 13

Thus crystallization of a melt (which should be avoided for glass formation) is
governed by two functions expressed in equations 2 and 13, corresponding to nucleation
and crystal growth, respectively.

The temperature dependence of both can be shown

schematically as demonstrated in Figure 3.6.

The extent of the overlap between

nucleation and growth rate is an indication of glass forming tendency. For example, if a
melt exhibits a large overlap, it can be considered to be a poor glass forming melt as
nucleation and crystal growth will occur contemporaneously. Thus in order for a melt to
avoid crystallization and form a glass, the melt must be rapidly cooled faster than the
nucleation and crystallisation rates as to avoid this overlap region [194, 204].
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Rate

Figure 3.6: The relationship between growth and nucleation rate as a function of temperature [206]

By knowing the nucleation rate and crystallization rate at various temperatures the
volume fraction of crystals in a sample can be calculated in time/temperature space to
produce Time-temperature-transformation (TTT) curves, for example Figure 3.7.

Time of Heal Treatment

Figure 3.7: A sample TTT curve for a glass forming melt. [194] .

The least favourable conditions for glass formation occur at the temperature Tn,
corresponding to the nose of the curve. The minimum cooling rate to produce a glass i.e.
the critical cooling rate can be obtained from the slope of the tangent to the curve, where
the initial conditions are defined as Tm at time zero [194],
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3.2

Properties of bioactive glass

3.2.1

Glass surface reactivity
When a glass is immersed in an aqueous solution, a series of reactions can take

place at its surface.

These reactions can be generalized into three processes - ion

leaching or dealkalinization of the alkali and alkali-earth cations from the bulk of the
glass into solution, dissolution and rupture of the silica network and precipitation. The
surface of silicate glasses can be classified accordingly into five types, depending on
which of these reactions predominates (Figure 3.8). Type I glasses undergo a surface
hydration reaction leading to a very thin surfece layer analogous in composition to that of
the bulk glass. High purity vitreous silica exposed to a neutral solution is an example of a
Type I surface [207]. Type II surfaces undergo selective ion leaching with the exchange
of alkali and alkaline earth ions for

or/and H30^ from solution. A silica rich layer

develops, protecting the glass from further dissolution [207],

Type III glasses are

characterized by the formation of a dual protective film such as calcium-phosphate, on
top of the silica rich layer.

Type IV surfaces occur when the silica surface layer is

unstable due to, for example, an OH' rich solution which can break Si-O-Si bonds [208].
Type V glasses have a surface composition equivalent to the bulk glass composition as
the glass is undergoing total network attack or congruent dissolution [208]. Using this
classification, the type of surface formed when a bioactive glass is immersed in solution
is Type III.
In order to gain insight into glass dissolution, numerous researchers have
attempted to analyse the kinetics of these surface reactions. Two of the most commonly
used models to describe glass dissolution are referred to as the homogenous and
heterogeneous models.

The homogenous model is based on the assumption that the

liquid enters the particles completely and reacts throughout them at all times.

The

particles thus behave as if they were dissolved and the rate of the reaction is given in the
same form as for a homogenous reaction [209]. In the heterogeneous model, the reaction
is considered to take place at the outer surface of the particles, and as the reaction
progresses the unreacted “core” shrinks as the outer reaction layer thickens [209]. Two
stages are recognized in this model. The first stage is dominated by the exchange of
alkali ions with protons in solution, and alkali and silica release vary with the square root

Bioactive Glass
of time.
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The second stage is dominated by network dissolution and ion extraction is

linear with time [210, 211], However, neither model has been found to be completely
adequate.

The pH and the ionic strength of the solution have been shown to cause

deviation from predicted kinetics [212]. The formation of surface layers causing a drop
in dissolution rate is thought to account for some deviations seen [213].

Figure 3.8: The five types of silicate glass surface reactions. The y axis represents the relative
concentration of Si02 in the glass and the x axis the depth into the glass surface [207].
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3.2.2

HCA formation and bone bonding
The principles of the aqueous degradation mechanisms demonstrated by bioactive

glasses are directly linked to important properties of these materials. The dissolution and
precipitation phenomena are associated with their ability to bond directly with bone. The
reaction is characterized by several distinct stages as illustrated in Figure 3.9, and have
been elucidated using Fourier transform infrared (FTIR) spectroscopy of the reacted
surface as a function of time [193].

The reactions described herein are those for the

nominal Bioglass 45S5 composition containing weight % 45 Si02, 24.5 Na20, 24.5 CaO
and 6 P2O5.
I^eached
Si-rich

Original
Surface

Figure 3.9: Schematic illustration of the surface stage reactions on bioactive glass [214],

The first stage is characterized by rapid exchange of Na^ from the glass with

or H30^

from solution ;
Si-O-Na^ + IT + OH

Si-OH^ + Na

(solution)

OH'

This stage is usually controlled by diffusion and its rate is parabolic in character (t
The release of Na^ ions buffers the glass solution interface towards an alkaline pH,
neutralizing the effects of the acidic environment created by macrophages involved in
wound healing and bone repair [193, 215]. The second stage is characterized by the loss
of soluble silica in the form of Si(OH)4 to the solution, resulting from the breakage of Si0-Si bonds and formation of Si-OH (silanols) at the glass solution interface [193] ;
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2(Si-0-Si) + 2(OH)

Si-OH + OH-Si

This stage is usually controlled by the interfacial reaction and its rate is linear in
nature. The third stage involves the condensation and repolymerization of a Si02 rich
layer on the surface that is depleted in alkalis and alkaline earth cations;
2(Si-OH) + 2(OH-Si) ^ -Si-O-Si-O-Si-O-Si-0This stage is interface controlled and is also linear in nature [216], The fourth
stage is dominated by migration of Ca^^ and P04^’ groups to the surface through the
Si02-rich layer forming a Ca0-P205-rich film on top, followed by growth of an
amorphous Ca0-P205-rich film, by incorporation of soluble calcium and phosphate from
solution [193, 216],

The final stage of this reaction involves crystallization of the

amphorous Ca0-P205 film by incorporation of OH and COs^* anions from solution to
form a mixed hydroxyl, carbonate, apatite layer - the HCA layer [193, 208], This HCA
layer is similar in composition to that of the mineral phase of bone (section 1.1.2) and is
thus capable of bonding and incorporating with host bone tissue.

These five reaction

stages are entirely inorganic - not requiring cells or organic molecules. The reactions are
initiated within minutes of contact with aqueous solution or body fluids and are
completed within a few hours as indicated by Figure 3.10. However, the rate of these
reactions can be found to be sensitive to glass composition. Glasses with increased Si02
content, 52-58%, show the same sequence of reactions but the kinetics are much slower.
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Figure 3.10: Sequence of interfacial reactions involved in forming a bond between bone and a bioactive
glass [193]
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After and during this physicochemical reaction, a sequence of biological events
occur as illustrated in Figure 3.10. One of the first stages is thought to be the adsorption
of growth factors which are involved in stimulating the attachment, proliferation and
differentiation of stem cells into mature osteoblasts, leading to the proliferation and
growth of new bone.

3.2.3

Control of cell cycle and gene activation
Recent research has indicated that formation of the HCA layer, though useful,

appears to not be the critical stage of the reaction for bone regeneration. The inorganic
ions which are released during stages 1-5 of the physicochemical reaction appear to play
an important role in stimulating the differentiation and proliferation of stem cells towards
the osteoblastic phenotype.

In order to understand their effect on cell growth and

proliferation an understanding of the cell cycle is required. Figure 3.11 illustrates the cell
cycle for an osteoblast progenitor cell.

APOPTOSIS

TERMINAL

3.11: Schematic representation of the osteogenic progenitor cell cycle [217].
Resting cells are considered to be in phase GO of the cell cycle. Osteoprogenitor
cells must receive the correct chemical stimuli from the local environment in order to
enter the active phases [218]. During the first step, called the G1 (growth) phase, the cell
grows and carries out its normal metabolism. For a fully mature osteoblast this may
involve synthesis of phenotypic cell products such as ALP and tropocollagen
macro molecules (section 1.1) [218].

If the chemical environment is suitable, and
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following a critical period of cell growth, the cell will enter the S (synthesis) phase (step
2) where DNA replication and chromosome duplication occur [219], Completion of the
S phase requires synthesizing a complete genomic sequence of DNA and RNA [220],
Following successful DNA replication, the cell prepares to undergo mitosis during step 3,
termed the G2 phase [217]. The G2 phase is characterized by a critical increase in cell
mass and synthesis and activation of various growth factors which stimulate mitosis.
Also during this phase DNA replication accuracy is checked using DNA repair enzymes
[217]. Upon completion of the G2 phase, the cell undergoes nuclear division (mitosis)
followed by cell division (cytokinesis) [219].

Cells are known to possess numerous

feedback controls including regulatory proteins which monitor the status of the cell cycle
events such as DNA replication and integrity. If the local chemical environment is not
conducive to progression of the cell cycle, the cell can proceed to programmed cell death
called apoptosis [218], Apoptosis is critical in order to prevent the proliferation of cells
that have an incorrect phenotype for bone repair.
Xynos et al. reported the effect of 45 S5 bioglass versus a bio inert control on the
cell cycle of human osteoblasts [221], The authors demonstrated that the percentage of
osteoblasts in the S phase and G2-M phase of the cell cycle were significantly higher for
the bioactive glass group after 2 days of incubation [221].

However, they also

demonstrated that the control exhibited statistically higher cell densities and that
apoptosis was significantly higher for the bioactive glass group [221], They determined
that only cells capable of differentiating into mature osteoblasts were favoured to survive
in the bioactive glass group, resulting in a mature cell population capable of producing
bone [217]. Cells grown on the inert control were closer in phenotype to those of scar
tissue [217]. This shift in the osteoblast cell cycle has been linked to the release of
critical concentrations of ions, mainly 17-21 ppm Si'*^ and 60-88ppm Ca^^ from the
bioactive glass, and this effect has been shown to be under genetic control [220],

A

number of genes involved in bone growth and turnover are upregulated when exposed to
bioactive glass dissolution products [222]. Increased genetic expression of cell cycle
regulators such as cyclins has been noted which provide the vital stimulus needed for the
progression of the cell through the Gl/S checkpoint [217]. Genetic expression of growth
factors such as Insulin-like growth factor n (IGF-II) which induce osteoblast proliferation
has been shown to be upregulated by over 300% [223],

Increased expression of
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phenotypic osteoblast products such as ALP and collagen 1 have been induced in
response to exposure to bioactive glass dissolution products [222, 224], Expression of
BMP-2, a potent inducer of bone formation, has also been stimulated [225],

3.2.4

Commercially available bioactive glasses
One of the first bioactive glasses to become commercially available was

Perioglas® (Block dmg Corp., USA). The composition of Perioglas® is based on the
original bioglass composition (section 3.2.2), and it is primarily used in dental and
maxillofacial applications, including restoration of bone loss due to periodontal disease
and alveolar ridge augmentation [75]. Perioglas® is available in particulate form ranging
in size from 90-71 Opm, which is known to facilitate manageability and packing into
osseous defects [75].

In vivo studies indicate that Perioglas® produces significantly

greater bone repair in surgically created defects in non-human primates, in comparison to
other bone graft substitutes and unimplanted controls [226]. Similarly, clinical data has
indicated that periodontal flap surgery with Perioglas® yields significantly greater infill
of the intrabony defects [227]. Novabone® (American Biomaterials Corp.), a bioactive
glass again based on the original bioglass composition, was introduced into the European
market in 1999 [228] in particulate and putty forms. Its primary uses are in orthopedic
bone grafting and reconstructive procedures [228].

Clinical data has indicated

Novabones® effectiveness in accelerating fracture healing in tibial fractures with internal
fixation [229]. Biogran™ (Orthovita, US) is a resorbable bioactive glass consisting of
300-355 pm diameter granules and again has the same composition as Bioglass 45S5
[230]. Upon exposure to physiological fluids, due to the dimensions of the particles, a
dual reaction layer is formed consisting of an internal silica-rich gel surrounded by a
calcium-phosphorus (CaP) rich shell [231]. Phagocytosing cells can penetrate the CaP
rich shell and resorb the internal silica-rich gel [75],

This resorption leads to the

production of protective pouches where osteoprogenitor cells can adhere, differentiate,
proliferate and produce bone [75]. In vivo animal studies involving the implantation of
Biogran™ into the partial endentulous jaws of beagle dogs indicated the material to
stimulate bone repair [232]. Similarly, Scheper et al, have demonstrated that Biogran™
can be used successfully in the treatment of human oral osseous defects [233]. Consil®
(Nutramax labs, US) is another bioactive glass based on the original bioglass composition
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which is commercially available as a particulate for veterinary use [234],

Consil®

particles have been utilized as a treatment option for periodontal and maxillofacial
defects in monkeys, dogs and cats [235],
Though much success has been noted with the commercially available bioactive
glasses, they do demonstrate some disadvantages, especially in relation to the provision
of a therapeutic effect in vivo for patients suffering from metabolic bone diseases such as
osteoporosis. Limited research has been carried out on the effect of these bioactive glass
compositions on bone healing in ovariectomy models [236], however no current
commercial bioactive glass offers therapeutic release of active ingredients to promote the
regeneration of healthy bone in place of diseased bone tissue [237], Bioglass has also
been shown to exert an antibacterial effect on certain oral bacteria [238], but limited
research has been carried out with regard to its effect on clinically important bacteria
known to infect orthopaedic surgery sites [239, 240], Furthermore, all currently available
bioactive glass compostions used in a bone graft capacity are based on the inclusion of
phosphorus and largely adopt a compositional approach to controlling compatibility. In
light of the recent evidence, highlighting the critical role of bioactive glass ionic
dissolution products in bone regeneration, and in order to address the discussed
shortcomings of conventional glass compositions, a shift in focus is warranted. Seeking
to control fiinctionality by the synthesis of phosphate-free, highly disrupted glass
networks with compositional variants may allow for better therapeutic tailorability.

-63 -

The role of therapeutic ions in bone regeneration

4.

The role of therapeutic ions in bone regeneration

4.1

Zinc - Fracture repair and infection prevention

4.1.1

Biological role of zinc
Zinc (Zn) is one of the most important trace elements in the body, with a total

body content of 2-4gs [241], 85% of whole body Zn is sequestered in muscle and bone,
with 50% of this intracellular zinc residing in the cytoplasm and organelles, 40% in the
nucleus and the remainder in the cell membrane [242], Zn, acting in a structural and
activity modulating role, is required for the biological function of more than 300 enzymes
[243], Consequently, Zn impacts on a variety of cell processes including DNA synthesis,
cell proliferation and cell differentiation, influencing normal growth, brain development,
bone formation and wound healing [242], Many regulatory proteins in the nucleus and
cytoplasm of cells contain zinc-finger domains which are essential for binding to DNA
and thus important in gene expression and regulation [242, 243],

Zn deficiency is

postulated to be associated with an increase risk of DNA damage [243],
Zn has profound effects on immune function affecting both innate and acquired
immunity [244], The main functions of cells of the innate immune system, including
natural killer (NK) cell activity and phagocytosis of macrophages are impaired under zinc
deficiency [244, 245].

Zn, through its influence on the thymic hormone thymulin,

stimulates T-cell development [244, 245]; correspondingly its deficiency is associated
with impaired antibody responses [243], Zn is also a critical nutrient for development of
the Central Nervous System (CNS).

Many zinc-dependent enzymes and proteins are

involved in brain growth and function [246].

In neurons, decreased Zn availability

results in diminished neuronal proliferation and the triggering of neuronal apoptosis
[247], Zn is also known to affect wound healing. It is thought to promote tissue repair
and regeneration through its involvement in re-epithelialisation and the synthesis of
granulation and scar tissue [248]. More recently, Zn has been implicated in an anti
oxidant role. The DNA damage and carcinogenic effects of several heavy metals has
been linked to the displacement of Zn from zinc-finger transcription factors and the
release of damaging oxygen radicals on the DNA where they are bound [249]. Zn has
been shown to play a role in the physiological suppression of apoptosis through a direct
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effect on apoptotic regulators including the caspase family of enzymes [250], While the
biological roles of Zn are extensive, its physiological effects on bone tissue in health and
pathology are pertinent to this discussion.

4.1.2

Role of Zinc in bone
The feet that most of the body’s Zn content is located in bone, where it ranges

from 125-250ppm [251], highlights its importance in bone growth and development. Zn
has been shown to have an anabolic effect on bone in vitro and in vivo, influencing both
osteoblasts and osteoclasts [252]. Overall, Zn stimulates cell proliferation, differentiation
and mineralization in osteoblasts, thereby promoting bone formation.

Figure 4.1

illustrates the effects of Zn on osteoblast cells. Chen et al illustrated that physiological
concentrations of Zn (25-200pg/dl) have a direct stimulatory effect on bone DNA
synthesis - DNA synthesis being an indicator of cell division and proliferation [253].
Furthermore, Ma et al, suggested that this stimulatory effect in osteoblasts may be due to
activation of DNA polymerase, a zinc enzyme related to DNA synthesis [254]. Zn has
also been shown to enhance osteoblast protein gene expression and protein synthesis.

I

. Type f collagen
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Figure 4.1: Illustration of the effects of zinc on osteoblasts [252].
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Yamaguchi etal, demonstrated that Zn has a stimulatory effect on the mRNA expression
of Runx2 - a transcription factor involved in osteoblastic cell differentiation [255], This
effect was completely blocked by the presence of cycloheximide - an inhibitor of protein
synthesis at the transcriptional level [255, 256], suggesting that the zinc-induced gene
expression was as a result of newly synthesised proteins [257], Similarly, Zn is known to
enhance the expression and production of osteocalcin, a marker of osteoblastic
differentiation [252]; of type 1 collagen, a matrix protein in bone [252]; and of IGF-1, a
growth factor [256],

Cerovic et al, demonstrated that Zn up-regulated alkaline

phosphatase (ALP) activity in osteoblast-like cells, indicating bone formation [258], It is
thus evident that the effect of Zn on osteoblast cells is diverse and that such effects lead
to the up-regulation of osteoblastic activity and the promotion of bone formation,
indicating its potential to stimulate fracture healing.
In contrast, Zn has been shown to have an inhibitory effect on bone resorption
(Figure 4.2) [252]. Osteoclasts, the bone resorbing cells, are formed by differentiation of
bone marrow cells and Zn has been shown to inhibit this osteoclasto genes is in rat marrow
cultures in vitro [259]. Kishi etal, also established that osteoclast cell formation induced
by bone-resorbing factors such as PTH and PGE2 is suppressed by Zn [260]. It has been
suggested that this suppressive effect is mediated through the inhibition of RANKL
(Receptor activator of NF-kB ligand), which is required for osteoclastic differentiation
[255, 261].

Yamaguchi et al examined the effect of Zn on the gene expression of

molecules related to bone resorption - tartrate resistant acid phosphatase (TRAP) and
cathepsin K [262].

Their results showed significantly suppressed expression of these

enzymes which are involved in degradation of the bone matrix [262]. Zn has also been
shown to have indirect effects on osteoclast formation. Zn is known to stimulate the gene
expression and release of osteoprotegerin (OPG) in osteoblast cells which is a natural
antagonist of RANKL thus down regulating its activity in pre-osteoclastic cells [263].
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Figure 4.2: Illustration of the effects of zinc on osteclasts [252].

It has also been suggested that a possible mechanism by which Zn inhibits
osteoclast function is stimulation of an increase in intracellular calcium concentration
[264], Calcium, though not as potent as Zn, has been shown to inhibit resorption [264],
Zn has also shown the ability to block the proton channel in osteoclasts, which in turn
inhibits proton secretion [265], Similar to osteoblasts, Zn effects on osteoclasts appear
multi-facetted, culminating in the down regulation of the cells.
With an understanding of the bone metabolic effects of Zn, it is not surprising that
It has been linked in a pathophysiological role in bone metabolism diseases such as
osteoporosis. Depletion of Zn in bone cells has been shown in aged rats (30 weeks), in
comparison to weanling rats (3 weeks) [266], and this decrease has been associated with
the development of bone loss with increasing age [267]. Osteoporotic patients have been
shown to have decreased levels of skeletal Zn in comparison to healthy individuals [252,
262], and women with osteoporosis have been shown to excrete larger amounts of Zn in
their urine [268].

Yamaguchi et al, demonstrated that oral administration of the Zn

compound P-Alanyl-L-histidinato zinc (AHZ) to ovariectomized rats completely
prevented a reduction in bone mass [269].

Thus Zn may be an effective tool in the

treatment of osteoporosis, and due to its bone metabolic effects may also be useful in the
treatment of osteoporotic fractures.

4.1.3

Role of zinc in biomaterials
The potential biological role ofZn incorporation in biomaterials in an orthopaedic

setting is evident by the discussed anabolic effects of Zn on bone metabolism. Ito et al
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incorporated Zn into tricalcium phosphate (P-TCP)/hydroxyapatite (HA) composites
leading to enhanced osteoblastic cell proliferation and differentiation in vitro [270],
Storrie et al, integrated Zn with organoapatite (ZnOA) subsequently coating it on the
surface of titanium mesh substrates. This lead to the earlier onset of biomineralization
and increased ALP activity in pre-osteoblastic cells in vitro [271],

Zn has also been

incorporated into ionomeric bone cements, showing increased osteointegration and
osteoconduction in vivo in rats [272].
properties of certain biomaterials.

Zn is also known to affect the mechanical

Ramaswamy et al., incorporated Zn into a Ca-Si

system (Hardystonite Ca2ZnSi207), leading to increased bending strength and fracture
toughness [273], Furthermore, Zn inclusion decreased the dissolution rate of the material
leading to more beneficial effects on osteoblast cells [273]. The incorporation of Zn in
biomaterials has also exhibited anti-inflammatory effects.

HA particles are known to

induce inflammation and zinc-substituted HA has displayed anti-inflammatory effects on
human polymorphonuclear cells (PMNs) [274] and monocytes [275]. More recently, Zn
has been integrated into bioactive glass systems. Lusvardi et al., examined zinc-doped
phosphosilicate glasses in vitro and in vivo, showing good bioactivity and osteogenic
potential [276]. Aina et al, highlighted the reduction in the overall leaching activity of
zinc-containing glasses leading to a decrease in solution pH, suggesting this may have a
beneficial effect on cytocompatibility [277].

In a subsequent paper, Aina et al.

demonstrated that the levels of Zn released from their glass compositions induced
cytotoxicity in vitro [277], suggesting the cell damage was via oxidative stress. This
emphasizes the need to control Zn release from bioactive glasses in order to impart
beneficial and therapeutic effects in vitro and in vivo.
Another advantage pertaining to Zn containing orthopaedic materials is their
inherent antibacterial efficacy.

Bacterial infection at implant sites has a significant

impact in terms of morbidity, mortality and medical cost [278]; and implant infections are
frequently a cause of implant failure [279]. Figure 4.3 highlights the main pathogenic
species associated with implant infections.
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Figure 43: Frequency of the main pathogenic species among orthopaedic clinical isolates of implantassociated infections [278],

Zn has been shown to be toxic to a broad range of pathogenic bacteria, including
Staphylococci, the most commonly found genus in infected hip joints [280, 281], Boyd
et al, demonstrated good antibacterial efficacy in glass polyalkenoate cements by
incorporating Zn [282], Similarly, Chung et al. produced zinc-doped HA, resulting in
good antibacterial effects against Streptococcus strains [283], Thus, incorporating Zn
into an orthopaedic biomaterial at the appropriate concentration may not only aid in
stimulating bone regeneration and repair, but may have the added effect of imparting
antibacterial properties.
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4.2 Strontium - Anti-osteoporotic effects
4.2.1

Biological role of strontium
Contrary to the defined roles of zinc in human biology, the biological role of

strontium (Sr) has yet to be fully elucidated.

The average body content of Sr is

approximately 0.32g/70 kg body weight [284] and under normal physiological
conditions, 99.1% of this Sr is distributed in bone [285],

Basal levels of serum Sr range

from lOpg/1 - 217pg/L [285]. Absorption of dietary Sr in the gastrointestinal tract (GIT)
appears age dependent, decreasing with age [285]. Absorption of calcium and Sr by the
GIT occurs via a common carrier system. Discrimination in favour of calcium absorption
develops over time in rats and has been suggested as an explanation for the age-related
differences in Sr absorption [286]. Sr is largely eliminated from the body via urine and
shares common renal tubular transport paths with calcium [284]. However, Sr is excreted
by the kidney at a much higher rate and this is thought to be related to its larger atomic
size [284, 287], Toxic symptoms due to Sr overdose have not been reported in man
[284]. However, in rats with renal failure Schrooten et al, reported that high Sr levels
lead to bone mineralization defects [288], Similarly, Morohashi et al., demonstrated that
high Sr doses of 875pmol/day disturbed calcium metabolism leading to hypocalcemia
[289]. In endocrinological systems, Sr tends to mimic the actions of calcium, but to a
weaker extent [284]. An example of such is, similar to calcium, Sr is able to sustain
secretion of insulin in response to glucose in pancreatic islets but to a lesser degree [290].
The biological effects of Sr on bone metabolism are better defined and specifically
relevant to this discussion.

4.2.2

Incorporation and distribution of strontium in bone
Due to its physicochemical similarities to calcium, Sr is well known as a bone

seeking element.

A study by Raffalt et al., in which dogs were treated with various

concentrations of Sr malonate, demonstrated Sr uptake by bone to be dose-dependent, but
at high doses showed saturation tendencies [291]. Other researchers have shown similar
results in rats [287].

Boivon et al., using x-ray microanalysis, x-ray diffraction and

raman microspectrometric techniques, analysed bone mineral samples from the iliac crest
of monkeys treated for 13 weeks with Sr ranelate [292]. Not only did they demonstrate a
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similar dose-dependent effect, but also demonstrated heterogenous distribution with
higher concentrations of Sr found in newly formed bone [292], More recently, similar
results were obtained in a human trial, also showing cancellous bone to contain a higher
proportion of Sr than cortical bone [293], This is thought to be related to the higher
remodelling rate of cancellous bone, thus being proportionally richer in newly formed
tissue or the greater surface-to-volume ratio [293], Sr appears to be incorporated into
bone by 2 main mechanisms - sur&ce ionic exchange and heteroionic substitution [287],
In newly formed bone, ionic exchange predominates and Sr may be directly integrated
into the apatite crystals [294], Only a small amount of Sr atoms incorporate into the
apatite crystal lattice by ionic substitution, with a max of 1 strontium ion per 10 calcium
ions [295], Sr appears to stabilize the apatitic crystal structure and increased resistance to
acid degradation has been reported [290], Gender and skeletal site are also factors known
to influence Sr bone levels. Rats treated with Sr ranelate showed higher Sr bone content
in males than in females, an effect thought to be related to differences in GIT absorption
[287], Similarly, monkeys showed site-specific differences with higher levels present in
the iliac crest than in the lumbar vertebra or diaphysis of the femur [287],

4.2.3

Role of strontium in normal bone
Similar to Zn, Sr is known to have an anabolic effect on bone metabolism

effecting osteoblasts and osteoclasts [296], Figure 4.4 illustrates the effects Sr has on
bone cells. Osteoblastic production and activity is upregulated by the presence of Sr.
Canalis et al, demonstrated that the Sr salt SI2911 stimulated replication of rat calvarial
pre-osteoblasts, increasing their DNA and collagen synthesis.

This effect was Sr-

specific, as the equivalent calcium and sodium salts did not induce the same response
[296].
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Figure 4A: Illustration of the mechanism of action of strontium on bone cells [297]

Using Sr ranelate concentrations ranging from 0.01 - 2 mM, Brennan et al.,
indicated similar stimulatory effects on human osteoblast-like (HOB) cell replication and
also demonstrated enhanced cell differentiation as indicated by increased Runx2/cbfal
expression [298], Sr^^ concentrations as small as 0.1 mM have been shown to increase
the expression of ALP, bone sialoprotein (BSP) and osteocalcin (OCN) in murine
osteoblasts all indicating enhanced osteoblastic activity [299]. Data has signified that the
Sr induced stimulatory effect on pre-osteoblasts is in part mediated through the calcium
sensing receptor (CaSR) [300]. However, another cation-sensing receptor is also thought
to be involved as strontium similarly promotes replication in osteoblasts from CaSR
knockout mice [301].

Chondhary et al, indicated that induction of cyclooxgenase-2

(COX-2) enzyme expression and subsequent increase in prostaglandin E2 (PGE2)
production may also play a role in Sr induced osteoblastogenesis [302].
In contrast to its osteoblastic effects, Sr is known to inhibit osteoclast activity and
bone resorption in vitro.

Bonnelye et al, by quantification of TRAP activity,

demonstrated that Sr ranelate induced a significant dose-dependent inhibition of
osteoclast differentiation starting at 0.1 mM concentration [299]. Similarly, in a model of
differentiating osteoclasts, 0.5mM concentration of Sr ranelate decreased the number of
osteoclasts expressing 2 functional markers, carbonic anhydrase 11 and vitronectin
receptor [303]. Takahaski etal, discovered that a Sr ion concentration of ImM inhibited
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the formation of resorption pits by osteoclast-like cells and this appeared to involve a
decrease in mffled border formation by the osteoclasts [304], Other researchers having
shown similar inhibition of osteoclast activity relating such effects to the disruption of the
actin cytoskeleton organized in the sealing zone [299],

More recently, it has been

suggested that a potential effect of Sr is to stimulate an increase in osteoclast cell
apoptosis [305], As discussed in section 4.1.2, the RANKL/OPG ratio is essential in
controlling osteoclastogenesis and bone resorption. It has been suggested that, similar to
that of zinc, the observed Sr-induced effects on osteoclasts may be due to down
regulation of RANKL expression and upregulation of OPG expression [297, 306].
Many of these in vitro findings have been corroborated by in vivo research. After
feeding selected concentrations of Sr ranelate to adult mice, Delannoy et al., discovered
that Sr increased the trabecular bone volume by 25-59% and this was associated with a
27-62% increase in mineralized bone volume [307]. Ammann et al., demonstrated that
rats fed 225-800mg/kg/day Sr ranelate for 2 years displayed a dose-dependent increase in
bone strength and bone mass of the vertebral body and of the midshaft femur [308].
These results were linked to an improvement in the macro- and micro-architecture of the
bone, as assessed by an increase in trabecular and cortical bone volume and trabecular
number and thickness [308]. Similar results have been obtained in larger animals. Upon
feeding various concentrations of Sr ranelate to monkeys for 6 months, Buehler et al.,
demonstrated a significant decrease in indices of bone resorption (osteoclast surface and
number) and an increase in indices of bone formation (osteoblast surface) [309]. Thus
combined in vitro and in vivo research indicate that Sr has a stimulatory effect on bone
formation and an inhibitory effect on bone resorption, leading to beneficial effects on
bone mass and bone mineral in normal animals and indicating its potential in a fracture
healing role.

4.2.4

Role of strontium in osteoporotic bone
The dual mode of action displayed by Sr leading to increased bone mass and

quality suggested that Sr may have potential benefits in the treatment of osteopenic
disorders such as osteoporosis - disorders characterised by increased bone turnover and
bone loss [310]. Correspondingly, animal models of osteoporosis such as ovarectomized
rats have been adopted to evaluate the potential role of Sr treatment. The Sr salt SI2911,
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previously demonstrating bone anabolic effects in vitro, was administered to
ovarectomized rats at concentrations ranging from 77-308mg/kg/day for 60 days [311],
It was discovered that Sr treated groups displayed an increase in trabecular bone volume
by 30-36% and that bone ash and mineral content was restored to values equivalent to
sham operated rats [311]. Furthermore, for all examined strontium concentrations, no
deleterious effects on skeletal growth or mineralization were noted [311],

Similarly,

other researchers feeding Sr-containing diet to ovarectomized rats noted no changes in
bone resorption compared to a sham operated group, though significant changes were
noted for ovarectomized non-Sr fed animals [312],

The increasing body of evidence

implicating Sr in an anti-osteoporotic role has subsequently led to numerous large-scale
double-blinded placebo-controlled human clinical trials.

SOTI and STRi\TOS trials

were based on analysing the effect of various Sr ranelate concentrations on vertebral
fracture risk and bone mineral density (BMD) in osteoporotic postmenopausal women,
monitoring over 3 and 2 years respectively [313, 314], The SOTI study demonstrated
that Sr ranelate at a concentration of 2g/day decreased the risk of vertebral fracture by
41% after 3 years compared to the placebo group. Lumbar spine and femur BMD were
also significantly increased in Sr treated groups [313, 315],

The SRATOS study

similarly demonstrated a dose dependent increase m lumbar BMD, and the proportion of
patients experiencing an incident fracture during year 2 was decreased by 44% in the
strontium 2g/day group versus the placebo group [314].

The TROPOS trial also

illustrated a significant decrease in the risk of nonvertebral fractures in treated versus
placebo groups, indicating Sr ranelates effects are not just restricted to the vertebrae
[316], The PREVOS study was based on examining the efficacy of Sr ranelate in a
preventative rather than curative role. Early postmenopausal women were administered
Sr ranelate concentrations ranging 125-lOOOmg/day for 2 years.

The Ig/day group

showed significant increases in lumbar, femoral neck and total hip BMD versus a placebo
group which demonstrated decreases [314]. Overall, the results of these clinical trials
have supported other in vitro and in vivo findings, indicating the effectiveness of Sr in an
anti-osteoporotic role.
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4.2.5

Role of strontium in biomaterials
Similarly to Zn, the use of Sr in orthopaedic materials is largely centred around its

stimulatory effects on bone metabolism.

Its potential to promote healthy bone

regeneration and to improve osteointegration, even in those with pathological bone
disorders justifies its inclusion in many bone graft biomaterials [317], Furthermore, Sr is
known to confer radiopacity, an important property for any material in a fracture healing
capacity [318, 319], Secondary to its direct effects, Sr has also demonstrated the ability
to affect various material properties, thereby potentially enhancing in vitro and in vivo
compatibility. Landi et al., using Sr-substituted HA produced a porous structure with a
compressive strength of 4.52 ±1.4 MPa - within range of that of the human femur and
proximal tibia [320], Introduction of Sr into the apatitic structure is thouglit to cause
lattice distortions and crystal expansion, due to its larger atomic size than calcium.
Consequently, solubility and ion release is altered and bone-bonding may be enhanced as
shown by Ni et al. [321]. Sr has also been incorporated into ionomeric bone cements. In
an in \ivo model using male rats, Johal et al., demonstrated that the cement with the
highest

Sr

concentration

exhibited

the

greatest

amount

of

osteointegration,

osteoconduction and new bone growth [272]. Furthermore, Wren et al, illustrated Sr
cements to have compressive and biaxial flexural strengths of 75MPa and 34Mpa
respectively, indicating their potential in load bearing applications [322],

Wu et al.,

integrated Sr into a CaSi03 system leading to a decrease in dissolution kinetics while still
maintaining its bioactivity.

This Sr-doped material was also shown to stimulate the

proliferation of human bone derived cells indicating its potential to enhance bone
formation [323]. Induced attachment and differentiation of human osteoblasts has also
been demonstrated in Sr-hardystonite systems [324].
Sr has also been incorporated into bioactive glass systems.

Gentleman et ah,

incrementally substituted strontium for calcium in Si02-P205-Na20-Ca0 glasses,
illustrating enhanced osteoblastic activity and inhibited osteoclast differentiation and
activity in vitro [325]. It has been suggested that substituting Sr for calcium in bioactive
glasses expands the network slightly due to the atomic size difference, consequently
increasing ion dissolution rates and having pronounced effects on bone cells in vitro and
in vivo [326]. This again highlights the importance of controlling ion release in order to
deliver ion levels which are biocompatible but still maintain therapeutic efficacy. Boyd
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et al. have demonstrated Sr-doped silicate glass compositions to induce bone growth in
an ovarectomized rat femur healing model [327], The in situ release of Sr ions directly
from a synthetic bone substitute may also overcome the problems and limitations related
to oral administration of Sr. As discussed previously, accumulation of Sr is site-specific
and its bioavailability is dependent on the GIT absorption capacity, which is known to
decrease with age (section 4.2.1). Thus, for older osteoporotic individuals in particular,
local Sr release during fracture healing has the potential to enhance and prolong its
therapeutic action, promoting healthy bone regeneration.
With an understanding of the biological effects of Zn and Sr, their dual
incorporation into a bone graft can be envisaged to provide synergistic effects facilitating
localized treatment of diseased or damaged bone tissue, while simultaneously offering
protection against implant site infection.

/I
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5. In vitro material testing
5.1

Cell culture
Determination of biocompatibility and cytotoxicity has become the central

requirement for the medical application of materials and devices.

The ethical issues

regarding the use of animal models for the evaluation of biomaterials has led to the need
for effective and reproducible in vitro test systems.

The original concept of material

biocompatibility was based on a materials ability to be accepted by host tissue in an inert
fashion i.e. non-toxic and non-immunogenic [83], However biocompatibility has since
been redefined as “The ability of a material to perform with an appropriate host response
m a specific application” [83]. Such a definition allows biocompatibility to be perceived
as not only the absence of a toxic effect, but also the presence of a positive influence in
terms of biofunctionality. In relation to bioactive glasses in a bone graft capacity, their
ability to attract and regulate osteogenic cells is paramount. The objective of in vitro
biocompatibility tests is to simulate biological reactions to materials when they are placed
on or into tissues of the body.
Three primary cell culture assays are commonly used for the in vitro evaluation of
biomaterials - direct contact, agar diffusion and extract assays [328, 329]. The three
systems differ in the manner in which the test material is exposed to the cells. The direct
contact assay involves placement of the test material in contact with a monolayer of cells
to assess any cytotoxic effect. The advantage of this method is that it mimics clinical use
of the material in a fluid path, in which the material is placed directly in the culture
medium and extraction occurs is the presence of serum-containing culture media at
physiological temperatures [329]. However, there is a risk of physical trauma to the cells
from movement of the sample. In the agar diffusion assay, the material is separated from
the cells by interposition of an agar gel [328].

This method has the advantage of

cushioning the cells from any mechanical trauma caused by movement of the material,
while also providing a diffusion barrier to enhance the concentration gradient of
leachable toxicants [329].

The extract assay procedure involves using an appropriate

liquid in which the material has been stored for various time periods and has the added
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benefit of aiding in the identification of toxic leachates and allows for the prediction of
the temporal effect on a materials in vivo behaviour.
Cells used for these in \ntro assays are usually derived from established cell lines.
Cell lines maintain their genetic and morphological characteristics throughout a long life
span. Primary cells are seldom used, as they cannot be maintained indefinitely in cell
culture as after a few passages cells can lose their proliferative capacity which can
subsequently influence the experimental outcome [330]. Common cell lines used and
those advocated by ISO standards include fibroblast cells [328]. Fibroblast cells give rise
to connective tissue, are among first cells to populate a healing wound and are widely
distributed throughout the human body including in bone [331], making them particularly
suitable for testing bone substitute materials. L929 mouse fibroblast cells have been used
most extensively for biomaterial evaluation. These cells have the added advantage of
being easy to maintain in cell culture and are known to produce results which exhibit high
correlation with specific animal assays.
Determination of cell viability and proliferation has become a key technology to
assess the effect of test materials in a cell culture system [330]. A wide variety of assays
are available, many based on the determination of nucleic acids, metabolic activity,
protein content or membrane integrity [330].

A quantitative measure of material

cytotoxicity can be obtained using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT).

The mitochondrial enzyme, succinate-dehydrogenase, within viable

cells, is able to cleave MTT into a blue coloured product (formazan), which can be
spectrophotometrically measured and it is proposed that the amount of formazan
produced is proportional to the number of viable cells present [332].

5.2

Antibacterial testing
Use of implant materials is associated with an increased risk of bacterial infection,

often leading to implant failure and revision surgery, thus impacting greatly in terms of
morbidity, mortality and medical cost [278].

Common strategies to prevent such

infections have relied on improving operating standards and the establishment of
protocols regarding pen-operative systemic antibiotic prophylaxis [333].

Incomplete

success of such strategies has shifted focus to the development and use of inherently anti-
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bacterial materials. Common methodologies used to assess the antibacterial efficacy of
biomaterials are similar to those used in cell culture evaluation - namely agar disc
diffusion, direct exposure, and extract exposure assays. The agar disc diffusion method is
based on the placement of a disc of the test material on an agar surface previously
inoculated with the selected bacteria [282].

Antibacterial efficacy is determined by a

zone of growth inhibition around the disc, the diameter of which can be measured and
compared to control materials [334]. Numerous researchers have employed the direct
exposure method by incubating the test material in broth, which has been inoculated with
a known amount of the selected bacteria [335-337]. This procedure more closely mimics
in vivo conditions allowing for bacterial interaction with the materials surface, which can
lead to the formation of biofilms.

The extract procedure, similar to the cell culture

evaluation, allows for the identification of any antibacterial leachates from the material
and also allows for determination of the minimum inhibitory concentration - the lowest
concentration which produces an antibacterial effect [338],
After exposure to the test material, either directly or indirectly, numerous
procedures have been employed to evaluate the effect on the viability or growth of the
bacteria. One of the most commonly used methods is the viable counting method [339].
This method involves direct agar plating of the material-exposed bacterial suspensions
and growth is assessed in terms of colony forming units. The advantage of this method is
that it allows the differentiation between bactericidal and bacteristatic effects, however
the method can be very labour intensive. Turbidity or optical density measurements can
be employed to assess the effect on bacterial growth [340]

Bacteria scatter light in

proportion to their numbers, thus the optical density of a suspension of bacterial cells is
directly related to cell number [340], This method is simple, nondestructive and allows
for the temporal evaluation of bacterial growth. However, its sensitivity is limited to
about 10^ cells/ml for most bacteria and an extract procedure must be used due to optical
interference by test materials [339],
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6.

Work Programme Rationale

The objective of this research was to synthesize and evaluate synthetic bone grafts based
on phosphate free bioactive glasses comprising zinc (Zn), strontium (Sr) and the network
modifier sodium (Na).

In order to achieve this objective a rational and systematic

approach was adopted. The research has been carried out as follows:

1. Synthesis and Characterisation of glass compositions Eight compositions were synthesised, based on incremental additions of Na for Zn
in groups separated by variable Sr content. To evaluate the composition-stmcture
relationships of these materials the glass structure and resultant properties for
glass particles m the range 90-710pm were evaluated. Each glass was
characterised using DSC (Differential Scanning Calorimetry), XRD (X-ray
diffraction), and ^^Si MAS-NMR (Magic Angle Spinning - Nuclear Magnetic
Resonance Spectroscopy). In addition, experimental data was cross referenced
with theoretical structure as derived from the Network Connectivity (NC).

2. Sterilisation of glasses and re-characterisation As sterilisation is a pre-requisite for implantable materials, the experimental glass
compositions were sterilised in accordance with International Standards [341]. It
is known that some sterilisation procedures may induce changes in material
chemistry, thus all glasses were re-characterised using the same methods as 1
above. Data pertaining to glasses pre- and post-sterilisation was then compared,
in order to quantify and analyse any structural changes. Sterilised glass samples
were used in subsequent analysis.

3. Quantification of Therapeutic Ion release Based on the characterisation results from sections 1 and 2, the research project
quantified the Sr^^ and Zn^^ release from six glasses, BT110-BT115, using AAS
(Atomic Absorption Spectroscopy).

Therapeutic ion release profiles were

monitored as a function of incubation of the glasses under normal and extreme
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physiological conditions over a period of 1, 7 and 30 days to evaluate which
glasses exhibit the optimum ion release profiles in order to function effectively as
therapeutic bone grafts.

4. Evaluation of Cytocompatibility Based on the therapeutic ion release profiles from section 3, the three most
promising glass compositions were examined using cell culture testing and
compared to a state-of-the-art control (Novabone®). Extracts of each glass were
produced by exposing Im glass powder to a fixed volume of sterile tissue culture
water. Extracts were prepared based on 1, 7 and 30 day exposures. Cell viability
following exposure to each extract was examined using L929 mouse fibroblast
cells and the MTT assay technique. Concurrently, AAS was preformed on each
extract in order to quantify the entire ion release profile from each glass at each
timepoint, and allow for correlation with the cell viability results.

5. Evaluation of Antibacterial Efficacy Zinc-containing BTl 10 and BTl 11 were examined for antibacterial efficacy and
compared to a state-of-the-art control (Novabone®). Extracts of each glass were
produced at concentrations of 50mg/ml, lOOmg/ml and 200mg/ml in sterile ISB,
and exposed for 1 or 7 days.

The optical density of extracts incubated with

MRSA, MSSA, S. epidermis, E. feacalis or P. aeruginosa were monitored over
24hrs. Concurrently, the Zn^^ content of each extract was quantified using AAS
and the pH of each extract analysed, in order to possibly correlate with any
observed antibacterial effects.

Overall Hypothesis The inclusion of Sr, Zn and Na ions into phosphate-free bioactive glass
compositions will allow for enhanced therapeutic potential in a bone regenerative
capacity through controlled ion release at therapeutic levels, allowing for good in
vitro compatibility and antibacterial efficacy.
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Materials and Methods

7.1

Materials

7.1.1

Glass Synthesis

Eight Ca0-Sr0-Zn0-Na0-Si02 glass formulations were synthesized, as shown in Table
7.1.

Their compositions are based on incremental additions of Sr and Na across the

series.

Table 7.1: Glass compositions (mol. fraction)

Glass

Si02

ZnO

CaO

SrO

NaiO

0J2~~

0

0.28

0

Designation
BtT09
BTllO

0.40

0.20

0.10

0.20

0.10

BTlll

0.40

0.10

0.10

0.20

0.20

BT112

0.40

0

0.10

0.20

0.30

BT113

0.40

0.20

0

0.30

0.10

BT114

0.40

0.10

0

0.30

0.20

BT115

0.40

0

0

0.30

0.30

BT116

0.40

0

0

0.40

0.20

Glasses were prepared by weighing out the appropriate amounts of analytical grade
silicon dioxide, zinc oxide, calcium oxide, strontium carbonate and sodium carbonate
(Sigma Aldrich, Ireland) into a plastic container.

Each formulation was thoroughly

mixed in the closed container for 30 minutes. Compositions were then fired (1480°C for
1 hour) in platinum crucibles (Johnson Matthey, Ireland) and the glass melts shock
quenched into water (Figure 7.1). The resulting frit was dried (100°C, 1 day) ground
using a Gyro-mill and tungsten carbide grinding dish (Glen Creston Ltd, UK) and then
sieved to achieve a glass powder with a particle size in the range 90-71 Opm for all
subsequent analysis.
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Figure 7.1: Shock quenching of glass melts into water.

7.1.2

Novabone

I5,5cc of the commercially available glass bone graft Novabone (Lot No. 0403C1) was
purchased from the Musculoskeletal Transplant Foundation (New Jersey, US).
Novabones’ composition is stated in Table 7.2.

Table 7.2: Novabone composition (mole fraction)

Glass

SiOi

ZnO

CaO

SrO

NajO

P2O5

0.244

0.026

Designation
Novabone

0.461

7.2

Material Characterisation

7.2.1

Differential Scanning Calorimetry

0.269

The onset of the glass transition temperature (Tg), and crystallization peaks for each glass
were determined using a combined thermal gravimetric-differential scanning calorimetry
analyzer (TG-DSC) (LABSYStm, Setaram, UK). Between 60 and 70 mg of each glass
(90-710pm) was heated in a platinum crucible, in a nitrogen atmosphere, alongside an
empty reference crucible. A standard reference material was already preselected for a
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given temperature range. A heating rate of 10°C min'^ was used and sample
measurements were carried out every six seconds, up to 1000°C [342],

7.2.2 X-Ray Diffraction
X-ray diffraction (XRD) analysis was performed using a Philips Xpert MPD Pro 3040/60
X-ray Diffraction (XRD) Unit (Philips, Netherlands). Zero background nickel coated
sample holders were used for analysis of the 90-710pm glass particles with Cu ka
radiation (at 40kV and 35 mA). Diffractograms were collected in the range 5°<29<80°, at
a scan step size 0.0083° and a step time of 10 seconds. Any crystalline phases present
were identified using JCPDS (Joint Committee for Powder Diffraction Studies) standard
diffraction patterns using Xpert Highscore plus software (Panalytical, US) [342].

7.2.3

Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy
(MAS-NMR)

^^Si MAS NMR spectra were recorded at 7.05 T (tesla) on a Varian

1NOVA300 FT-

NMR spectrometer (Palo Alto, CA, USA), equipped with a CP-MAS probe. Powdered
glass samples were placed in a zirconia sample tube with a diameter of 7 mm. The sample
spinning speed at the magic angle to the external magnetic field was 6 kHz. ^^Si MAS
NMR spectra were taken at 59.59 MHz /4),

tts

pulse length (pulse angle, p with 5.0- 90-

second recycle delays, where the signals from about 895-1695 pulses were accumulated.
^^Si NMR chemical shifts are reported in ppm, with PDMS (polydimethyl silane) as the
external reference (-34 ppm vs. TMS 0 ppm). All NMR spectra were recorded in a room
for exclusive use of NMR, where the room temperature was kept at 300°K by means of
an air-conditioner [342].

7.2.4 Calculation of Network Connectivity
The network connectivity (NC) of the glasses was calculated with Equation 1 using the
molar compositions of the glass [200].
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NC =

No. BOs-No.NBOs
Total No. Bridging species

Equation 1

Where:
NC= Network Connectivity
BO = Bridging Oxygens
NBO = Non-Bridging Oxygens

The calculation for the network connectivity of BT109 is demonstrated below.

Table 4: Analysis of glass BT109 with the assumed role of eaeh glass constituent withm the
network.

Glass component

Mole Fraction in glass

Assumed role in glass
network

S1O2

0.40

Network Former

ZnO

0.32

Network Modifier

CaO

0

Network Modifier

SrO

0.28

Network Modifier

Na20

0

Network Modifier

NC = (40x4)-((32+28)x2)
40

NC = 160-120
40
NC = 1

7.2.5

Sterilisation

Each glass was sterilized using y-irradiation (Westport, Co. Mayo, Ireland), in
accordance with “ISO 11137; 2006; Sterilisation of healthcare products” [341].

The

radioisotope cobalt 60, produced by the bombardment of the naturally occuring cobalt 59
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with neutrons in a nuclear reactor, provided the energy source. Each particulate glass
was maintained in a sealed polypropylene test tube. The minimum and maximum doses
during sterilisation were monitored using a Red Perspex type 4034 dosiometer and
recorded as 30.5kGy and 30.8kGy, respectively.

7.2.6

Specific Surface Area Determination

The specific surface areas of the glasses, including the commercially available Novabone,
were determined using the advanced surface area and porosimetry, ASAP 2010 System
analyzer (Micrometries Instrument Corporation, Norcross, USA). 100-300mg of glass
was used in a nitrogen atmosphere to calculate the specific surface areas using the
Brunauer-Emmett-Teller (BET) method [237].

7.3 Quantification of Therapeutic Ion release
7.3.1

Evaluation of degradation products

In order to simulate nonnal and extreme pH environments, TRIS-HCL buffer and Citric
acid buffer solutions were prepared to have a pH of 7.4 ± 0.1 and pH 3.0 ± 0.2
respectively at a temperature of 37°C ± 1°C, according to ISO 10993-14 [343].

An

equivalent surface area of Im^ of each glass powder was immersed in 10ml of TRIS
buffer (n=3) and citric acid buffer (n=3) and maintained at 37°C in a shaking waterbath
(Haake SWB25, Fisher scientific, UK), agitated at 2 Hz. Specimens were stored for 1, 7
and 30 days. After each storage period, specimens were removed via filtration using a
buchner funnel and filter paper, and filtrates stored under standard laboratory conditions
before ionic content analysis.

73.2

Quantification of therapeutic ion release

The Zn^^ and Sr^^ content of each filtrate was analysed using a Perkin Elmer AA Analyst
100 (Figure 7.2), using flame atomic absorption spectroscopy in an acetylene-air flame.
Zn and Sr hollow cathode lamps were used at wavelengths 213.9nm and 460.7nm,
respectively. In order to eliminate interferences when measuring strontium levels, 0.5 g
KCL was added to each filtrate [237].
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Figure 7.2: Perkin Elmer AA Analyst 100

73.3

Statistical analysis

Each experiment was performed in triplicate and analysed using Graphpad prism 4
software (Graphpad software Inc.) Results are expressed as mean ± standard error of the
mean of triplicate determinations.

Analysis of the results was carried out using

Students’s /-test, with a significance level of p < 0.05 as previously used [344]

7.4 In vitro evaluation using cell culture techniques
7.4.1

Preparation of Extracts

An equivalent surface area of Im^ of y-sterilised glasses BTllO, BTlll, BT112 and
Novabone were immersed in 10ml of sterile tissue culture water (Sigma Aldrich, Ireland)
for 1, 7 and 30 days at 37°C in a biological incubator (Binder, Germany). After each
storage period, samples were filtered using a sterile 0.20pm filter (Sarstedt, Ireland), and
filtrates stored at 4°C prior to in vitro evaluation.

7.4.2

Quantification of entire ion release profiles

7.4.2.1 Atomic Absorption Spectroscopy
The Si"", Zt?\ Ca^*,

and Na^ ionic concentration of each glass extract was analysed

using a Varian SpectraAA 240. An acetylene-nitrous oxide flame was used for Si**^ Ca^^
and Sr^^ measurements and an acetylene-air flame for Na^ and Zn^^ measurements. Si,
Zn, Ca, Sr and Na hollow cathode lamps were used at wavelengths 251.6 nm, 213.9 nm.
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422.7 nm, 460.7 nm and 589.0 nm respectively. In order to eliminate interferences when
measuring Sr^^ and Ca^^ levels 0.5 g of KCl and LaCb respectively were added to each
filtrate.

7.4.2.2 Inductively Coupled Plasma-OES spectroscopy
The phosphorus (P) ionic concentration of Novabone extracts were analyzed using an
ICP-OES Agilent 7500A. Before measurements a calibration curve was obatined using
standards containing known amounts of P.

Each sample was nebulized and then

vapourized within argon plasma and the absorption wavelength used for detection was
880 nm.

7.4.3

Preparation of L929 cells

Culture media was made up consisting of 445ml of Ml 99 media (Sigma Aldrich,
Ireland), supplemented with 10% foetal bovine serum (50ml - Sigma Aldrich, Ireland)
and 1% L-glutamine (5ml - Sigma Aldrich, Ireland) [327]. A liquid nitrogen frozen vial
of L929 cells was rapidly defrosted, the Dimethyl sulfoxide (DMSO) cryoprotectant in
which cells were stored replaced with the mentioned culture media and cells grown in T75 flasks (Sarstedt, Ireland), in a cell culture incubator at 37°C and 5% C02/95% air
atmosphere.

When cells reached confluency, they were chemically detached using

trypsin (Sigma Aldrich, Ireland), centrifuged and re-suspended in lOmls culture media, of
which 0.1ml was added to T-75 culture flasks containing 14mls media. Flasks were then
incubated allowing cells to grow in a cell culture incubator at the above conditions, and
the process repeated. Cell passages 5-7 were used for the MTT assay.

7.4.4

Seeding of L929 cells and exposure to experimental extracts

To prepare the cells for seeding, media was removed from freshly confluent T-75 flasks
of L929 cells. Trypsin again was used to detach cells after which they were re-suspended
in 10ml culture media. Cell counts and viability were assessed using trypan blue staining
and hemaocyto meter cell counting. Cell controls (cells plus media) and experimental
wells of a 24 well plate were seeded with cell densities of 1 x 10‘*/ml [327]. Culture
media only was used as a negative control. The plates were then incubated for 24hr in a
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cell culture incubator at 37°C (5% C02/95% air atmosphere). After 24hr, lOOpl of sterile
tissue culture water was added to control wells. lOOpls of relevant experimental extracts
(section 7.4.1) were added to appropriate wells for testing (n=3). The plate was then
incubated again for 24hr in a cell culture incubator at 37°C (5% C02/95% air atmosphere)
[327].

7.4.5

MTT assay

After 24hr incubation, each well was exposed to MTT at an amount equal to 10% of the
culture media volume (lOOpl) [327]. Plates were then returned to the incubator for 3hrs.
After incubation, MTT solubilisation solution was added to each well at a volume equal
to the original culture media volume (1ml). Each well was titrated using a pipette, in
order to enhance dissolution of the crystals, after which the absorbance of each well was
spectrophotometrically measured (TriStar LB 941, Berthold Technologies, US) at a
wavelength of 570nm [327].

Cell control wells were assumed to have metabolic

activities of 100% [327] and the percentage metabolic activity of the cells exposed to
experimental extracts was calculated relative to this.

7.4.6

Statistical analysis

Each experiment was performed in triplicate and analysed using Graphpad Prism 4
software (Graphpad software Inc.) Results are expressed as mean ± standard error of the
mean of triplicate determinations.

Analysis of the results was carried out using

Students’s Mest, with a significance level of p < 0.05.

7.5

Evaluation of antibacterial efficacy

7.5.1

Preparation of extracts

Sterilised BTllO, BTlll and Novabone (90-710}im) were incubated in sterile Isosensitest broth (ISB, Oxoid) for 1 and 7 days at concentrations of 50mg/ml, lOOmg/ml
and 200mg/ml (n=3). After each storage period, samples were filtered using a sterile
045|im filter (Sarstedt, Ireland), and filtrates stored at 4°C prior to use.
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7.5.2

pH analysis of extracts and quantification of Zn^^ release

The pH of each glass ISB filtrate was analysed using a calibrated Metier Toledo pH
meter. The Zn^^ content of each glass ISB filtrate was analysed using Atomic Absorption
Spectroscopy (Varian SpectraAA 240). An acetylene-air flame was used and a hollow
cathode lamp of 213.9nm wavelength.

7.5.3

Analysis of bacterial growth using optical density

Clinical isolates (Waterford Regional Hospital, Ireland) of the following bacterial strains
were used in this study; MRSA, MSSA, S. epidetmis, E. faecalis and P. aeruginosa.
P.aemginosa was grown on nutrient agar and all other strains on BHI (Brain heart
infusion) agar at 37°C under aerobic conditions. Inoculum of each bacteria was produced
in sterile nngers and made equivalent to that of a 0.5 MacFarland standard using a
MacFarland densitometer [338],

200pl of each glass ISB filtrate (section 7.5.1) was

pipetted in duplicate into individual wells of a sterile 96 well microtitre plate Wells were
inoculated with 1 pi of relevant bactenal suspension [338]. Negative control wells (ISB
only) and positive control wells (ISB plus bacteria) were also included. The microtitre
plate was then incubated at 37°C for 24hr in a microtitre plate reader (Spectra Max Plus)
where optical density measurements of each well were recorded at a wavelength of
600nm every hour.

7.5.4 Statistical analysis
Each experiment was performed in triplicate and analysed using Graphpad prism 4
software (Graphpad software Inc.) Results are expressed as mean ± standard error of the
mean of triplicate determinations. Statistical analysis was carried out on 24 hour optical
density readings using one-way analysis of variance (ANOVA) with a bonferroni posthoc test, with a significance level of p < 0.05 [345].
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8.

Results & Discussion

Table 8.1 below restates the glass compositions studied.

Table 8.1: Glass compositions (mole fraction)

Group

Glass

SiOi

ZnO

CaO

SrO

NaiO

P2O5

ZnOiNaiO
Ratio

Designation
1

BTl 09

0.4

0.32

0

0.28

0

-

0

2

BTl 10

0.4

0.2

0.1

0.2

0.1

-

2

2

BTl 11

0.4

0.1

0.1

0.2

0.2

-

0.5

2

BTl 12

0.4

0

0.1

0.2

0.3

-

0

3

BTl 13

0.4

0.2

0

0.3

0.1

-

2

3

BTl 14

0.4

0.1

0

0.3

0.2

-

0.5

3

BTl 15

0.4

0

0

0.3

0.3

-

0

4

BTl 16

0.4

0

0

0.4

0.2

-

0

5

Novabone

0.461

-

0.269

-

0.244

0.026

-

The glasses studied can be divided into 5 groups 1.

BT 109 - containing no Na20 or CaO. This glass composition had previously

been examined [327] for use as a therapeutic bone graft. The cytocompatability of such
compositions has excellent potential but Na20, which would allow for better control of
degradation and ion release, is not included in its composition. This glass served as a
comparison for subsequent groups, in which Na20 was included.
2.

BTl 10, BTl 11 and BTl 12 - containing identical CaO and SrO content, and Na20

was incrementally substituted for ZnO across the series. The inclusion of calcium in
these glasses is justified, as this element is known to have a positive effect on bone
metabolism [220] and has been incorporated into other bone graft materials [327, 344]. It
was envisaged that the substitution of Na20 for ZnO across the series would impart
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degradability upon the network and allow for control of ion release. This glass group was
established to examine the effect of this substitution and calcium inclusion upon glass
structure and the resulting properties including ion release profiles and cytocompatability,
in order to assess their applicability as therapeutic bone grafts.
3.

BTl 13, BTl 14 and BTl 15 - contained no CaO and identical SrO; and identical to

group 2, Na20 was incrementally substituted for ZnO across the series. Because of the
known beneficial effects of Sr on bone [284], inclusion of the element at higher levels is
justified. This glass group was established to examine whether these higher levels of Sr
would

lead

to

cytocompatability.

more

favourable

glass

properties

including

ion

release and

Also, similarly to group 2, this group would examine whether the

substitution of Na20 for ZnO will allow for controlled ion release at therapeutic levels.
4.

BTl 16 - containing no ZnO or CaO and a higher mole fraction (0.4) of SrO.

Similar to group 3, this glass was established to examine the effect of higher levels of Sr
upon glass structure and resultant properties.
5.

Novabone - a commercially available glass bone graft. Novabones’ composition

is based on the original bioglass composition [346] which exhibits good in vitro and in
vivo compatibility.

Novabone served as a state-of-the art comparison for the glass

compositions examined here.
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8.1

Glass Characterisation - Pre- & Post-y Sterilisation

8.1.1

DiflFerential Scanning Calorimetry (DSC)

DSC, as described in section 7.2.1, was used to obtain the Tg onset values presented in
Table 8.2. The DSC curve obtained for BTl 13 is given as an example in Figure 8.1.

Table 8.2: Glass transition (Tg) onset temperature for each glass composition Pre- and Post-y sterilisation.

Group

Glass

Tg onset (°C)
Pre-sterilisation

Tg onset (°C)
Post-sterilisation

A Tg onset
CC)

1

BT 10'9

669

670

+1

2

BT 110

603

607

+5

2

BT 111

546

547

+1

2

BT 112

522

532

+10

3

BT 113

598

599

+1

3

BT 114

536

546

+10

3

BT 115

524

520

-4

4

BT 116
-------------------------------

BT113 pre-sterilisation

-----------------------

----------------- ------

BT113 post-sterilisation

Figure 8.1: DSC curve for BTl 13 pre- and post- y sterilisation
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Tg is a function of the composition of a glass. Glass modifier species act to disrupt the
glass network and, as a consequence, decrease Tg. The extent to which these modifier
species affect the network is dictated by the nature of the modifier [194]. It can be seen
from Table 8.2 that BT 109, a glass composition with no Na20, recorded the highest Tg
onset value. This result was expected as alkali earth oxides such as Na^O, due to their
monovalent nature lead to a more dismpted glass network [194] and subsequently lower
Tg values. Figure 8.2 illustrates that group 2 and 3 glasses, with identical ZnO;Na20
ratios show similar Tg onset values. This indicates that ,as Na20 is substituted for ZnO
across each series, the glass network becomes more disrupted and consequently Tg
decreases.

Tg Onset grp 2

—in—Tg Onset grp 3

Figure 8.2: Graph of Zn0:Na20 (pre-sterilisation) for group 2 and group 3 glass compared to their
respective Tg onset values.

No discemable glass transition was detected on the DSC trace recorded for BT116.
Further analysis using XRD (Section 8.1.2, Figure 8.5), confirmed the material to be
highly crystalline.

-94

Results & Discussion

Table 83: First crystallisation peak (Tpi) onset temperatures and Tpi onset -Tg onset for each glass
composition pre- and post- y sterilisation.

Grp
Glass

Tpi onset
(°C)
Pre
sterilisation

Tpi onset
(°C)
Post
sterilisation

Tpi onset - Tg
onset (”C)
Pre-sterilisation

Tpi onset-Tg
onset (”C)
Post-sterilisation

99

102

BT 109

76 f

BT no

752

750

149

143

BTlll

725

734

179

187

BT 112

600

608

78

76

BT 113

718

720

120

121

BT114

710

706

174

160

BT 115

560

564

36

44

BT 116

_

DSC was also used to obtain first crystallisation peak (Tpi) onset temperatures pre- and
post-y sterilisation (Table 8.3)

Glass stability is frequently characterised by the

difference in temperature between Tg onset and the onset of crystallisation (Tpi onset)
[194, 347], so correspondingly Tpionset-Tg onset values were calculated pre- and poststerilisation. It can be seen from Table 8.3 that the temperature at which crystallisation
occurs varies depending on glass composition, an effect also seen in other bioactive
glasses [348, 349].

Also glass stability (as defined here by the difference between

Tpionset and Tg onset) varies greatly between glass compositions. This glass stability
parameter, also referred to as the sintering window, can be used as an indicator of the
ability of glass compositions to undergo transformation into various products such as
porous blocks [349]. The technique of glass sintering can be used to allow significant
densification of a glass in order to produce such products [350].

However many

bioactive glasses are restricted by their tendency to crystallize at the temperatures
required to achieve significant densification [349]. The greater difference between Tg
onset and Tpionset seen here for example with glasses BTl 11 and BTl 14 may indicate a
greater stability of these glasses against crystallisation upon reheating, and they may thus
show greater versatility to form special products such as porous implants.
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From the results (Tables 8.2 and 8.3) we also gain valuable information about the effect
of y-sterilisation on these glass compositions.

When a glass is exposed to levels of

ionizing radiation required for sterilisation, changes in the physical properties of the glass
can take place. In silicate glass networks, y-irradiation has been known to disrupt the
continuity of Si-O-Si bonds [351], thereby modifying the structure and effecting
properties such a Tg and Tpi. The DSC results highlight that the 30kGy y-irradiation does
not appear to have altered the nature of the studied glasses with respect to the Tg onset
and Tpi onset values. The maximum deviation noted for Tg onset was for glasses BT 112
and BT 114, where ATg onset was +10°C, and for Tpi onset was for glass BTl 11 where
ATpi onset was +9°C. The associated error in measurement for the specific DSC used is
2% [342]. Thus, both ATg onset and ATpi onset are within the error of the machine,
highlighting the stability of the glass compositions with respect to the y-irradiation.

8.1.2

XRD

The XRD traces for glasses BT110-BT114 pre-sterilisation (Appendix A) demonstrated
amorphous humps only, indicating the amorphous nature of the materials.

The

diffractogram for BT 110 is shown below in Figure 8.3, and is representative of the
diffractograms collected for BTl 10-BTl 14.
Counts
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The diffractogram for glass BT 109 pre-sterilisation is presented in Figure 8.4.

Evidence of residual crystallinity was detected, though the phase proved difficult to
identify given the presence of only two peaks. Peaks at 31.284[°] and 50.161 [°] may
indicate the presence of Strontium Silicon (JCPDS ref code 01-076-2327) with a
tetragonal stmcture.
Counts

Figure 8.5: Diffractogram for BT 115 pre-y-sterilisation.
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The diffractogram for BT 115 (Figure 8.5) similarly indicated the presence of partial
crystallinity, peak positions indentifying the species as possibly Strontium (JCPDS ref
code 00-015-0305) with a cubic stmcture. The diffractogram for BT 116 pre-sterilisation
is presented in Figure 8.6.
r

T

V ffV VYTTT

»

T VV TT

VM V

T Vff V V

T

V

V If

Counts

Figure 8.6: Diffractogram for BT 116 pre-y-sterilisation.

The material is highly crystalline, with over 30 peaks identified, indicating the
predominate presence of Strontium Silicate (JCPDS ref code 01-076-1630) with a
monoclinic structure. It should also be noted that a hump characteristic of an amorphous
phase is also present.
The occurrence of crystallization in bioactive glasses has been known to lead to a change
in their level of bioactivity - it can decrease the formation kinetics of the apatite layer on
the material surface [214]. Li et al, showed that a bioactive glass of the Si-Na-Ca-P
system can be transformed into an inert glass-ceramic through controlled crystallisation
[352].

HCA layer formation only occurred if the glass-ceramic contained over 90%

glassy phase [353].

However, other researchers have demonstrated that a gradual

increase in crystallinity in the same glass system leads to a decrease in the rate of HCA
formation but does not fiilly inhibit its formation even at 100% crystallinity [353]. Thus
it appears that various crystal phases may affect the ability of glass to bond to bone
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through inhibition or slackening of HCA formation.

The effect of crystallization on

bioactive glass properties can be attributed to changes in corrosion behaviour and ion
release [354, 355], A more crystalline material, which contains less internal energy and
stronger atomic bonds than its glass counterpart, will be more stable and less reactive
[194],

Correspondingly, Elbatal et al, showed that crystalline phases in Si-Na-Ca-P

based glass-ceramics resulted in a slower rate of ion exchange between the material
surface and solution and this was a result of the corrosion behaviour of the formed
crystalline phases.

Similarly, El-Ghannam et al, demonstrated that ion release from

45S5 bioactive glass-ceramics with 45% and 85% crystallization was significantly lower
that its bioactive glass counterpart [356]. In bioactive glasses such as those examined
here, where controlled ion release at specific levels is essential for their functionality, it
could be envisaged that the formation of crystalline phases may lead to unfavourable ion
release profiles.

In particular, the diffractogram for BT116 (Figure 8.6) indicates the

material is highly crystalline, with the presence of Strontium silicate. Sr^^ release from
Strontium silicate powders was analysed by Zhang et al, and only at very high extract
concentrations (200mg/ml) did Sr"^ release levels border those known to offer therapeutic
efficacy [357]. Thus, due to the highly crystalline nature of BTl 16 the material may not
exhibit the appropriate ion, and specifically Sr^^, release profile necessary to function as
an effective therapeutic bone regenerating material. The partial crystallinity of glasses
BTl09 and BTl 15 may have little effect on their subsequent properties. El-Ghannam et
al, also demonstrated that the presence of low portions of crystallisation (8%) in
bioactive glass 45 S5 had no significant effect on ion release [356].
Diffractograms collected for all materials post-y-sterilisation remained unchanged
(Appendix B) with the exception of BT 113.

The diffractogram for BTl 13 post-y-

sterilisation is presented in Figure 8.7. Some partial crystallinity is evident, with peaks
possibly corresponding to those of Silicon oxide (JCPDS ref code 00-033-1161),
however identification of the crystal species proved difficult with the presence of such
few peaks.

As mentioned, when subjected to ionizing radiation, glasses may acquire

induced defects, resulting in structural modification and altered properties [358].
However, both thermal characterisation (section 8.1.1) and Si^^ MAS-NMR data (section
8.1.3) indicate that y-sterilisation had no significant effect on BTl 13.

Therefore, the

most likely explanation is that the crystalline phases were present in portions of the
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material poor to sterilisation, but not present and thus not detected in the specific sample
of the material used for XRD pre-sterilisation analysis.
Counts

Figure 8.7: Diffractogram for BT113 post-y-sterilisation.

8.1.3

Sterilisation

A darkening (brown colouration) of each glass composition occurred as a result of the
30kGy y-irradiation, though this colouration was not quantified.

Radiation has been

known to induce changes in the material properties of a glass, and the effect that radiation
has depends largely on the type of radiation, the type and composition of the glass and
the defects within it [358]. One of the most notable effects is visible colouration due to
high absorption in the visible region of the spectrum [359]. In multicomponent silicate
glasses non-bridging oxygen hole centres (NBOHC’s) are one of the most typical defects
caused by ionising radiation [359]. NBOHCs are formed through the following reactiony-ray

=Si-0'

=Si-0' + e'
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Where =Si-0' and =Si-0‘ represent the NBO and NBOHC respectively [360], The e'
represents the electrons released from the NBOs, which can move and recombine so that
the photoelectrons become trapped at various sites in the glass [361], Typical sites in
soda-lime silicate glasses include glass modifying cations such as Na^ and Ca^^ [362], In
fact, glasses with increased modifier content and thus higher numbers of NBOs are
expected to be more susceptible to induced defects [358], Also multivalent impurities
such as iron can strongly effect the formation and stability of these defects because they
function as electron and/or hole trapping sites [362], So the darkening of the glasses in
this work is most likely due to electron transitions causing high and broad absorbance in
the visible region of the spectrum [359], commonly referred to as colour centres [342],
Optical absorption spectroscopy can be used to investigate NBOHC production and
electron spin resonance (ESR) spectroscopy, a non-destructive technique used to study
species with one or more unpaired electrons, may be useful in the study and
quantification of the unpaired spins created in these glass compositions due to yirradiation [361 ] Of mention also is that a visible fading of the y-induced colour change
was noted with increased storage time of the examined glass compositions. This fading
can be attributed to the recombination of NBOHC’s with electrons over time resulting in
the fading of the induced colour [363].

8.1.4

^’SiMASNMR

^^Si MAS NMR was preformed on glass compositions BT110-BT114 in order to probe
the local environment of the Si isotope pre- and post- y irradiation. The ^Si MAS-NMR
spectra collected from each glass pre- and post- irradiation is illustrated in Figure 8.8.
Chemical shift data in the form of peak maxima, calculated theoretical NC and Q"
structure is presented in Table 8.4.
The dependence of the NMR signal of a nucleus on the magnetic field at the nucleus is
the basis of nuclear magnetic chemical shifts.

The probed nuclei resonate at slightly

different frequencies depending on their molecular environment. This is due to shielding
of the nucleus from the external field by its electronic shells. Thus variations in local
electron density reflect the distribution of other atoms about the nucleus and aid in
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determining the local structural environments present, and as such we gain insight into
the structure of a glass network.

Chemical Shift (ppm)
Figure 8.8: ^Si MAS NMR spectra for BTl 10-BTl 14, pre (black line) and post (red line) 30kGy y
irradiation.

The ^Si MAS-NMR spectra (Figure 8.8) for each glass recorded large broad peaks in the
range -60 ppm to -90 ppm. The appearance of broad peaks for glassy materials is not
unusual, and can be attributed to the real distribution of structural variables caused by
variations in the number of bridging oxygens (BO) and reflects a range of bond angles
and bone lengths [364]. This broadening is referred to as heterogeneous broadening and
reflects the disordered amorphous state [365]. The broad chemical shift data recorded
here is indicative of ^Si in a four co-ordinate state [366]. The peak maxima of a ^^Si
MAS-NMR spectra is largely dependent on the number of bridging and non-bridging
oxygens (BO and NBO, respectively) [367]. Increasing the number of NBOs moves the
peak in a positive direction, resulting from increased shielding of the nucleus [200].
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Increasing the number of BOs moves the peak in a negative direction resulting from
decreased shielding [200, 368],

Thus, it can be seen that different Q species have

resonances in different regions of the ^^Si MAS-NMR spectrum [369], though 2
resonances corresponding to different Q structures have been known to overlap and
merge into 1 peak [370], The peak maxima recorded for all glasses here ranged from
74.1 ppm to 78.6ppm, a chemical shift reported as being characteristic of a predominance
of Q* structural units in silicate glasses [371], However, the broadness of the recorded
peaks and the known precedence for peak merging in the literature appears to indicate
that there is an assortment of Q" structures present in these glass compositions [370],
Future investigation using specialised deconvolution software may aid in determining the
proportional contribution of each Q" species to the broad spectra [367] and allow for
further insight into the compositional effects on glass structure and connectivity.

Table 8.4: ^^Si MAS-NMR chemical shift data (peak maxima), associated Q" structures and network
Glass
Designation

BTllO

Pre-7irradiation
Chemical
Shift (ppm)
-74.1

Post- 7irradiation
Chemical
Shift (ppm)
-74.3

A Chemical
Shift (ppm)

Associated
Q" structure

-0.2

Q‘

NCZnO as
modifying
oxide
1

NCZnO as
intermediate
oxide
3.33

BTlll

-74.5

-74.6

-0.1

Q'

1

2.4

BT112

-78.6

-78.4

+0.2

Q’

1

1

BT113

-73.3

-74.5

-1.2

Q'

1

3.33

BT114

-75.4

-75.7

-0.3

Q'

1

2.4

The MAS-NMR data also provided information about the role that ZnO is playing in the
glass network. ZnO has been termed an intermediate oxide [372] as it can adopt either
tetrahedral or octahedral geometry, the first a characteristic of a network former and the
latter of a network modifier [373] There has been contrasting evidence in the literature
regarding the structural role of ZnO in alkali/alkaline earth silicate glasses. Previous
studies have suggested that ZnO acts as a network modifier in Ca-Sr-Zn-Si glasses [200],
while others have suggested that ZnO acts as a weak network former in soda-lime-silicate
glasses [374]. It is evident from the MAS-NMR data in Figure 8.8 that the addition of
ZnO to the examined glass compositions results in a shift in the peak maxima towards the
paramagnetic direction (low field).

This suggests that ZnO is depolymerising the
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network and playing a network modifying role, as a shift in this direction is known to be
associated with an increase in NBOs [200],
interpretation.

Caution is warranted however in this

Rather than assigning the downfield shift to a depolymerisation of the

glass, it could be assigned to the formation of Si-O-Zn structural units. It should be noted
that the chemical shift in a NMR spectra is not only determined by the connectivity of the
"^Si atom i.e. the number of BOs and NBOs. The chemical shift is also influenced by the
electronegativity of the structural species in wftich Si is located and by the nature of the
bond partner or cation which ultimately determines the electron density within the species
[204, 374]. Si-O-Zn bonds are known to be weaker than Si-O-Si bonds [373], Thus the
paramagnetic shift seen in the examined Zn containing glasses may be due to these
weaker bonds. In fact, models have shown that the substitution of Zn for Si in a Q" unit
causes the chemical shift to decrease (shift m the paramagnetic direction) approximately
10% [375]. Comparing the MAS-NMR data recorded here to network connectivity (NC)
may shed some more light on the role ZnO is playing in the glass network. The NC of
each glass composition was calculated using equation 1 from section 3.2.2. Based on
previous findings [200], the NCs were first calculated assuming ZnO was playing a
network modifying role and subsequently calculated assuming ZnO was playing an
intermediate role and correlated with peak ^^Si MAS-NMR data and associated Q"
structures. The results are presented in Table 8.4. The MAS-NMR data appears to be in
good agreement witli the hypothetically derived NC calculations which assume ZnO is
playing a network modifying role. Further evidence indicating ZnO in a modifying role
can be seen upon comparing the variation in chemical shift with respect to Na20 content,
as illustrated in Figure 8.9. As Na is substituted for Zn the chemical shift in the glass
series moves in a negative feshion from -74.1ppm for BTllO to -78.6ppm for BT112,
indicating a shift in the network towards a

predominant glass structure.

Thus, though it appears that ZnO is playing a network modifying role, if any ZnO is
playing a network forming role in the examined glasses this can not be confirmed based
on the MAS-NMR data presented. Further investigation using techniques such as Raman
Spectroscopy may aid to further elucidate the structural role that ZnO plays in these
glasses.
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Figure 8.9: Variation in chemical shift with respect to Na20 content

The MAS-NMR data also indicates that the local environment around the Si isotope
remained unchanged as a result of the y-irradiation. Small variations in peak maxima
chemical shift data were noted between glasses pre- and post-irradiation (Table 8.4), but
these variations can be attributed to the signal to noise ratio which can lead to small
differences in the recorded peak maxima.

8.1.5

Specific Surface Area determinations

The BET specific surface areas are presented in Table 8.5.

Table 8.5: BET specific surface areas of each glass composition
BET Surface Area

Designation (m^/g)
BTllO

15.32

BTlll

9.68

BT112

10.23

BT113

10.39

BT114

15.49

BT115

4.39

Novabone

1.77

Results & Discussion
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Specific surface areas were determined in order to equalise the surface area exposed to
the various solutions in subsequent experimentation and thus allow for comparison
between glass compositions.

The variation in specific surface area between glass

compositions can be explained by the large particle size range (90-710pm). This range
was decided upon as Novabone, the state-of-the-art comparison, is commercially
available and used within this range.

Results & Discussion
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QUANTIFICATION OF THERAPEUTIC ION RELEASE

Controlled release of therapeutic ions at beneficial levels is essential for the examined
materials to function effectively as bone grafts.

Classically, the HCA (Hydroxy-

carbonate apatite) formation of many bioactive glasses on exposure to physiological fluid
and the subsequent direct bond with bone was seen as the critical mechanism [212] for
bone regeneration.

However, mounting evidence has indicated the important role of the

ionic dissolution products in stimulating osteoblast growth and differentiation at the
genetic level [223, 376],

Unfortunately, the dissolution products of many bioactive

glasses offer little therapeutic potential for diseased bone. Incorporating elements such as
zinc and strontium into bioactive glass compositions may address this issue.

As

discussed in Chapter 4, these elements illicit beneficial and therapeutic effects on bone
formation. It is, however, essential that they are released at desirable dose levels, in
various physiological simulated conditions, in order to enhance therapeutic efficacy.
Therefore, Zn^^ and Sr^^ release was examined from glasses BTl 10-BTl 15 over 1, 7 and
30 days under 2 simulated physiological conditions; pH 7.4, representative of a normal
physiological environment [237] and pH 3.0, representative of extreme physiological
conditions and the acidic environment produced by osteoclasts [237].

8.2.1

Zinc release
20-1

(b)

15-

EQ.
^ 10
N

5-

Day 1
A

BT111

BT110

Day 7

■ BTl 13

A

Day 30
BTl 14

Figure 8.10:
release at normal pH 7.4 over 1,7 and 30 Days (cumulative) for
(a)Group 2 - BTl 10 and BT 111 & (b) Group 3 - BTl 13 and BTl 14
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The

release profiles at pH 7.4 for Zn containing glasses BTl 10, BTl 11, BTl 13 and

BT114 over 1, 7 and 30 days are shown in Figure 8.10. Glasses BTl 10 and BTl 13,
(comparable compositions from each group) showed a similar trend, with a statistically
higher release of Zn^^ at every time point when compared to the other glasses in their
respective group, except on day 1 when comparing BTl 13 and BTl 14. On comparing
BTl 10 and BTl 13, BTl 13 showed a statistically higher level of Zn^^ release at every
time point (Day 1, p=0.0353. Day 7, p=0.0029, and Day 30, p=0.0010).

Figure 8.11:
release at extreme pH 3 over 1,7 and 30 Days (cumulative) for
(a) Group 2-BTl 10 and BTl 11 & (b) Group 3-BTl 13 and BTl 14

The Zn^^ release profiles at pH 3.0 for Zn containing glasses BTl 10, BTl 11, BTl 13 and
BTl 14 over 1, 7 and 30 days are shown in Figure 8.11.

No statistically significant

difference in Zn^^ release was recorded at day 1 and 7, when comparing BTl 10 and
BTl 11. However, large error bars are associated with the mean Zn"^ concentration
recorded for BTl 10 at day 7. At day 30, Zn^^ release from BTl 10 was significantly
higher (p=0.0003) than BTl 11.

When comparing BTl 13 and BTl 14, statistical

significance was achieved at day 7 and day 30 (p<0.0001 and p=0.0059, respectively)
with BTl 13 releasing higher Zn^^ levels. Zn^^ release was significantly higher for all
glasses at all time points when immersed in the pH 3 compared to the pH 7.4 solution.
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Zinc containing glasses examined demonstrated Zn^^ release in the range of 3 ppm 19ppm under normal (7.4 pH) conditions and 124ppm - 750ppm under acidic (pH 3.0)
conditions. Ito et al, examined the effect of Zn^^ release from calcium phosphate on
MC3T3-E1 osteoblast cells and correlated an increase in cell growth rate to increased
Zn^^ release, recording a maximum at ~ 5ppm Zn^^ [270]. Zn^^ at a concentration of
6.54ppm increased bone protein content, calcium content and ALP activity in rat calvaria
in vitro [377]. Cerovic et al, demonstrated that levels as low as 0.065ppm increased
ALP activity in Saos-2 human osteoblast-like cells. Similarly, levels ranging from 6.54 x
lO ’® ppm up to 6.54ppm have demonstrated inhibition of osteoclast function from
isolated rat osteoclasts [264]. However, Aina et al, demonstrated that Zn^^ release from
bioactive glass at a concentration of 6.6ppm increased intracellular lactate dehydrogenase
(LDH) release from MG-63

human osteoblasts,

indicating cytotoxicity

[378].

Furthermore, similar Zn^^ levels were shown to induce indexes of oxidative stress, as
demonstrated by an increase in intracellular levels of malonyldialdehyde (MDA) [378].
Overall, Zn^^ levels previously reported to have clinically beneficial effects on bone
formation appear to range from 6.54 x 10'^^ ppm to 6.54ppm in vitro and in vivo [270,
379], with higher levels in vitro inducing cytotoxicity [378]. Similarly human Zn^^ blood
plasma levels have been shown to be approximately 6.4ppm [380], and Zn^^ release from
biomaterials in the range 3ppm-7ppm has shown antibacterial efficacy [282]. It can be
postulated that any glasses releasing Zn^^ levels within these ranges will have similar
beneficial effects. Thus all zinc-containing glasses, BTl 10, BTl 11, BTl 13 and BTl 14,
at pH 7.4 may have therapeutic potential, but the elevated Zn^^ levels released in the more
acidic pH3 environment may induce cytotoxicity. It warrants mentioning that the Zn^^
release recorded here for both pH environments is cumulative in nature. As such, the
levels recorded in the pH 3 solution, though previously showing cytotoxicity in static in
vitro experiments [378], may not induce the same response in a dynamic physiological
system. A build up of Zn^^ to these high levels may not occur in vivo, due to metabolism
of the ion and gradual transportation away from its release site through body fluid and the
vascular system [381]. Literature on the release of Zn^^ from biomaterials in vivo, in
particular bioactive glasses is sparse, so further investigation into whether the high Zn^^
levels seen in the pH 3 environment here would lead to in vivo cytotoxicity is warranted.
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Zn^ release from these glasses appears to be dependant on the Zn content - as Zn

compositional content increases so does Zn^^ release (Figure 8.12). This is an effect
which has similarly been shown in other Zn containing bioactive glasses [378, 381] and
may allow for talorability of the examined compositions, with respect to Zn^^ release.
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Figure 8.12; ZnO content for group 2 and group 3 glasses V Zn^"^ release at Day 30 pH 7.4.

An anomalous result occurred when comparing BT113 with BTllO (comparable in
respect of their ZnO:Na20 concentrations). At pH 7.4, BT113 exhibited a statistically
higher release ofZn^^ at each time point, as illustrated in figure 8.13, an effect not seen in
the pH 3 environment.

Figure 8.13: Zn^"^ release at pH 7.4 over 1,7 and 30 days for BTl 10 and BTl 13
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These glass compositions differ with regards to their CaO and SrO content (Table 8.1) BTl 10 contains (mol. fraction) 0.1 CaO and 0.2 SrO and BTl 13 contains no CaO and 0.3
SrO.

A possible reason for the higher Zn^^ release by BTl 13 maybe related to the

slightly larger ionic radius of the Sr^^ ion (1.16nm) compared to the Ca^^ ion (0.94nm)
[382].

The resulting lower field strength or charge to size ratio (Z/a^) of the Sr^^ ion

weakens the bonds to neighbouring oxygens thus slightly expands the glass network and
increases ion dissolution [194, 325]. The dissolution rate has been shown to increase,
correspondingly leading to higher ion release levels, in metasilicate glasses with
decreasing modifier field strength eg. Si02-Na20 demonstrates a greater dissolution rate
than Si02-CaO, with corresponding field strengths of 0.19 and 0.33 respectively [326].
The increased Na20 content (Table 8.1) of BTl 11 and BTl 14 may account for why the
same effect on Zn^^ release at the same pH was not seen upon comparing these 2
compositions.

It is reasonable to hypothesize that the increased presence of the Na^

modifier, which has a much lower field strength and correspondingly leads to a more
loosely cross-linked glass network, renders the effect of the Sr/Ca substitution negligible.

8.2.2

Strontium Release

Sr^^ release profiles at pH 7.4 for glasses BTl 10, BTl 11, BTl 12, BTl 13, BTl 14 and
BTl 15 over 1,7 and 30 days are shown in Figure 8.14.

Figure 8.14; Sr^'' release at normal pH 7.4 over 1, 7 and 30 Days (cumulative) for
(a)Group 2 - BTl 10, BT 111 and BTl 12 & (b) Group 3 - BTl 13, BTl 14 and BTl 15

-111

Results & Discussion

release showed a similar trend in both groups. As the Zn0:Na20 ratio decreased
across the senes (Table 8.1), Sr^" release increased.

This increase was statistically

significant at every time point when comparing all glasses in group 3, and similarly in
group 2, with the exception of day 1 when comparing BTl 10 and BTl 11.
Sr^^ release profiles at pH 3.0 for glasses BTl 10, BTl 11, BTl 12, BTl 13, BTl 14 and
BTl 15 over 1,7, and 30 days are shown in Figure 8.15.

Figure 8.15: Sr^^release at extreme pH 3 over 1,7 and 30 days (cumulative) for
(a) Group 2- BTl 10, BTl 11 and BTl 12 & (b) Group 3- BTl 13, BTl 14 and BTl 15.

There was a statistically significant difference between Sr^^ release from BTl 10 and
BTl 12 at day 1 and day 7 (p=0.0059 and p==0.0130, respectively), with BTl 12 showing
higher Sr^^ release. By day 30 there was no significant difference in Sr^^ release between
any of the glasses in group 2. BT 115 released a statistically higher amount of Sr^^ at day
1 when compared to BTl 13 (p=0.0488), but the same was not seen on day 7 and 30.
Similarly to group 2, group 3 by day 30 showed no significant difference in Sr^^ release
between glasses. Of interest is that BTl 12 and BTl 15, glasses with the highest Na20
content in their series, showed no significant difference in Sr^^ release over 1, 7 and 30
days. Sr^^ release, when comparing pH 3 and pH 7.4, was consistently higher at pH 3 for
glasses BTl 10, BTl 11 and BTl 13. Interestingly, BTl 12 showed statistically higher Sr^^
release at pH 7.4 on day 7 and day 30 (p=O.0413 and pFK).0171, respectively). BTl 14
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and BT115 showed no significant difference in

-

release between pH solutions at day

1 and day 7. By day 30, BT 115 showed a higher Sr^^ release at pH 7.4 (p==0.0109).
Strontium containing glasses demonstrated Sr^^ release in the range 7.5ppm to
3500ppm under pH 7.4 conditions and 88ppm - 1280ppm under acidic pH 3.0 conditions.
Brennan et al, reported that Sr^^ levels ranging between 8.7ppm - 87.6ppm induced
stimulation

of human osteoblast-like cell

replication

and

also enhanced cell

differentiation as indicated by increased Runx/cbfal expression [298]. Bonnelye et al,
demonstrated that levels as low as 8.7ppm promote differentiation of osteoblastic
precursors into mature osteoblasts and increase the expression of osteoblastic markers
such as ALP and OCN [299]. Sr^^ levels ranging from 8.7ppm - 2102ppm have been
shown to inhibit osteoclast differentiation in a dose-dependent manner, as indicated by
decreased TRAP activity [299], and similarly indicated a down regulation of osteoclast
resorption activity. The blood active Sr^^ concentration in postmenopausal osteoporotic
patients treated with Strontium Ranelate (Protelos®, Servier laboratories. Dun
Laoighaire, Ireland) has been measured at 10.5 ppm [299], However, some evidence has
also indicated that very high doses of Sr"^ may induce mineralization defects [383], It
can similarly be perceived that any glasses releasing Sr^^ within the above ranges will
show similar effects. Thus all glasses may have therapeutic potential with respect to the
Sr^" release profiles measured herein. The effect of Sr^^ on osteoclastic activity in vivo
appears to be dose-dependent [299]. The higher the Sr^^ level, the more pronounced the
inhibitory effect on osteoclast differentiation and resorption up to levels as high as
2102.8ppm [299]. The effect of Sr^^ on osteoblastic activity in vitro shows stimulatory
effects up to 87.6ppm [299], but at present no study has examined this osteoblastic effect
at much higher Sr^^ levels. Caution should be used in presuming that higher levels of
Sr^^ will cause similar stimulatory effects. So as to assess the bioactive glass with the
optimum Sr

release profile, relevant in vitro and subsequent in vivo studies with higher

Sr^^ levels are warranted.
Sr"^ release at pH 7.4 showed a similar trend in both groups. Unlike Zn^^ release, Sr^^
release appears related to the Zn0;Na20 compositional ratio.

As Zn0:Na20 ratio

decreased across the series, Sr^^ release increased (Figure 8.16). Na^ is known to impart
degradability on Si02 glassy networks by depolymerising Si-O-Si bridges [384].
Furthermore, an increase in ZnO addition to alkali silicate glasses has previously been
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shown to cause a global reduction in ion leaching [374, 385], This reduction has been
attributed to Zn adopting a network forming role, with evidence indicating that the Zn
tetrahedrals are charge compensated by alkali ions [372]. MAS-NMR (section 8.1.3) and
DSC (section 8.1.1) results presented here do not eliminate the possibility of Zn playing
such a network forming role in the examined glass compositions.

In fact, the large

increase in Sr^^ release seen in the Zn-free, high Na20 glass appears to support this
hypothesis.

However, further experimentation is needed to validate such a theory.

Overall, decreasing the ZnO content of these glass compositions, while simultaneously
increasing NaoO content appears to have the synergistic effect of increasing Sr^^ release.
Thus this substitution appears to induce increased degradability on the glass network and
may be a useful tool in controlling dissolution rate and specific ion release.

Zn0:Na20
Grp 2

-Tk-

Grp 3

Figure 8.16: Zn0:Na20 compositional ratio for Group 2 and Group 3 glasses V Sr^^ release at Day 30 pH
7.4.

Sustainability of ion release over time is important to prolong and enhance therapeutic
effect. For all glasses at pH 7.4, Sr^^ and Zn^^ ion release was sustained up to day 7. But
by day 30, for most glasses ion release levels had plateaued, showing no statistical
difference between day 7 levels. Saturation of silica at the surface and condensation of
surface silanol groups are generally considered to be responsible for this slow down in
ion release [213]. The pH of the immersion solution also played an important role on the
levels of Sr"^ and Zn^^ ion release from the glasses. Extremes of pH, such as very acidic
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conditions, can result in rapid dissolution of glasses [194], The introduction of network
modifying cations to a glass increases the polarizability of the oxygen ions and, therefore,
its vulnerability to acid attack [386],

This is greatest when the oxygen atoms are

associated with cations of low electrostatic field strength, eg. Na^, Ca^^ and Sr^^ and least
when the cations have a high electrostatic field strength e g. Si"^^ and Zn^^ [386]. This is
reflected in the results.

At pH 3.0 (Figure 8.15), glasses BT112 and BT115 which

contain a high percentage of Na20 and SrO and no ZnO, show high levels of Sr^^ release
at day 1 (mean 431 ppm and 677ppm, respectively). Zn^^ release for all glasses at every
timepoint was statistically higher at pH 3 than at pH 7.4. Whereas at pH 3 Sr^^ release
for the glasses with the highest NazO content, BT112 and BT115, showed either no
statistical difference or w'as significantly lower than its pH 7.4 counterpart. This result
may be related to a possible interaction of Sr^^ with the citric acid in the pH 3 buffer, as
citric acid has previously been shown to complex with metal ions such as calcium [387].
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8.3

IN VITRO EVALUATION USING CELL CULTURE

TECHNIQUES
The ion release data in section 8.2 indicated that the levels of therapeutic ions
being

released

from

glasses

BT110-BT115

may

allow

for

good

in

vitro

cytocompatability. In order to test this hypothesis. Group 2 glasses (BTl 10-BTl 12) were
selected for cell culture evaluation.

The therapeutic ion release profiles exhibited by

these glasses, according to the literature, indicated them to have the best overall potential
as functional therapeutic bone grafts [270, 299] An extract cell culture assay procedure
was utilised as it has previously been used to evaluate the cytocompatibility of other
bioactive glasses [388, 389]. Performed under aseptic conditions, using guidelines from
ISO 10993 [328] and using y-sterilised glass samples and sterile tissue culture water,
extracts (n=3) of BTl 10, BTl 11 and BTl 12 produced over 1, 7 and 30 days were
examined. Similar extracts of the commercially available Novabone were produced and
analysed in order to provide a state-of-the-art comparison. Concurrently with the cell
culture assays, AAS was preformed on each extract in order to quantify the entire ion
release profile from each glass at each time point. This quantitative analysis not only
allows for correlation with the cell culture results but also aids in understanding the
kinetics of the surface reactions and the potential of each composition in a regenerative
bone graft capacity relative to the levels of ions released.

83.1
83.1.1

Ionic Content of Extracts
Content
Si"*^ content of BTl 11, BTl 12 and Novabone extracts for Day 1, Day 7 and Day

30 are shown in Figure 8.17. No Si**^ content was detected for all BTl 10 extracts. In Day
1 extracts, BTl 12 contained statistically higher levels of Si"^^ compared to Novabone (3.5
± 0.5 ppm and 1.6 ± 0.3 ppm respectively). Both Day 7 and Day 30 extracts for BTl 11
contained significantly larger quantities of Si'*^ in comparison to BTl 12 and Novabone.
When Si"*^ content is assessed as a function of incubation time, glass extracts BTl 11,
BTl 12 and Novabone contain significantly higher levels of Si"^^ by Day 7, when
compared to their Day 1 counterpart (p=0.0014, p=0.0281 and p=0.0005, respectively).
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and by Day 30 when compared to Day 7 (p=0.0352, p=0.0066 and pFO.OOll,
respectively).
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Figure 8.17: Si ionic content of BTl 11, BTl 12 and Novabone for Day 1, Day 7 and Day 30 extracts.
Results represent mean ± SEM of tnplicate determinations (*p < 0.05).

Si"*' release from experimental glasses ranged from Ippm - 81 ppm, and from
Ippm - 48ppm for Novabone. Other researchers have demonstrated that Si'*^ release from
biomatenals ranging 0.1 - lOOppm stimulates the proliferation and differentiation of
osteoblast cells and meschemyl stem cells in vitro [223, 323, 357].

Similarly,

concentrations ranging 15-30 ppm have been shown to up-regulate and activate seven
families of genes known to favour the proliferation and differentiation of the mature
osteoblast phenotype [220]. Thus, based on the Si"^^ levels released from glasses BTl 11
and BTl 12, showing comparable or enhanced release in relation to Novabone; it can be
envisaged that similar effects on osteoblast cell activity will be induced, indicating their
potential in a bone graft application. An explanation for the higher Si"^^ release from
BTl 11 at Day 7 and Day 30 compared to the other compositions may be the effect of pH.
Upon immersion of a bioactive glass in water a rapid rise in pH can occur as a result of
ion exchange between network cations such as Na^ and protons from solution [207]. Na^
release data for BTl 11 at Day 7 and Day 30 (Figure 8.20) indicates much higher release
levels relative to the other experimental compositions. Correspondingly, pH levels in
BTl 11 exposed extracts may be much higher leading to increased Si'^^ release, as silica
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solubility is known to increase at pH levels above 9, where nucleophilic attack of Si04
units by OH‘ is promoted [212], However, further investigation evaluating pH changes is
warranted in order to validate such reasoning. BTlll, BT112 and Novabone also
increased in Si"^^ release with respect to incubation time. Si"^^ release and the formation
of surface silanol (Si-OH) groups are known to accelerate and enhance the precipitation
of biological apatite by acting as a nucleation site [390], Increased osteointegration of
biomaterials has subsequently been demonstrated in vivo by the incorporation of silicon
into their compositions [391, 392]. Thus the gradual release of soluble Si'^^ over time
seen by examined glass compositions here may lead to enhanced bone bonding and
osteointegration.
In order to gain further insight into the in vitro silicate network degradation of the
examined compositions, the kinetics of the silicate network dissolution can be examined
by curve fitting of the Si^" release profile in a non linear fashion [211]. The association
exponential function y=yma.x( 1-exp'‘“) provides the best-fit for the Si"^^ release data
(Figure 10.2), where y=Si'*^ concentration in ppm, ymax^Si'^^ concentration at infinite
times, k=rate constant and x=incubation time in days.

values for BTl 11, BTl 12 and

Novabone correspond to 0.9750, 0.9446 and 0.9786, respectively, indicating the good fit
of the applied function.

BT 111
A

BT112

▼

Novabone

Day
Figure 8.18: Fitting of the association exponential function y=ymax( 1 -exp'^^) to Si ionic content of BT 111,
BTl 12 and Novabone for Day 1, Day 7 and Day 30 extracts. Results represent mean ± SEM of triplicate
determinations.
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This exponential function is analogous to the homogenous model of glass network
degradation, suggesting that Si"*^ release from examined compositions here could be
predicted upon relation to such a model [210],

However, other researchers have

demonstrated the heterogenous model of glass dissolution more appropriate, which is
characterised by an initial phase, where Si'*^ release varies with the square root of time
and a subsequent phase where Si**^ release is linear with time [211],

Assessment of

whether such a biphasic model is valid for network dissolution here would be unreliable
as 81“*^ release was examined at only 3 time points. Furthermore, other researchers have
shown the transition between the models for other particulate bioactive glasses occurs 1560 minutes after immersion m solution [210, 211], In order to test the validity of the
heterogenous model on the network degradation of examined compositions here, the Si"*^
release at numerous time points, including minutes and hours after immersion should be
assessed.
No Si"^^ release was detected for BTl 10, which may be as a result of its lower Na
and increased Zn content compared to other examined glasses. Na is known to impart
degradability on Si02 glassy networks by depolymerising Si-O-Si bridges [384], and Zn
has been shown to retard degradation [276]. Thus the low Na/high Zn content of BTl 10
may lead to decreased degradation of the glass network, and consequently 81“*^ release at
levels too low to reach the minimum detection limit of the AA8.

8.3.1.2

Content
Ca^^ content of BTl 11, BTl 12 and Novabone extracts for Day 1, Day 7 and Day

30 are shown in Figure 8.19. No Ca^^ was detected for all BTl 10 extracts and for Day 1
and Day 7 BTl 11 extracts. At each time point Novabone released statistically higher
levels of Ca^^ than the other examined glasses. By Day 30, low concentrations of Ca^^
were detected for BT 111 (0.4ppm ± 0.1 ppm). When Ca^^ release is assessed as a
function of incubation time, both BTl 12 and Novabone show significantly higher levels
of Ca^^ at Day 30 wFien compared to their Day 1 counterpart (p=O.0051 and p<0.0001,
respectively).
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Figure 8.19: Ca ionic content of BT111, BT112 and Novabone for Day 1, Day 7 and Day 30 extracts.
Results represent mean ± SEM of triplicate determinations (*p < 0.05, **p<0.005).

release from experimental glasses ranged from 0.2ppm - 9.1 ppm and from
7.1 ppm - 17.2ppm for Novabone. The release of higher Ca^^ levels from Novabone is
not unexpected, as its initial Ca^^ content is much higher than that of the experimental
glass compositions (0.269 and 0.1 mole fraction, respectively).

Local release of

extracellular Ca^^ ions has been shown to induce osteoblast proliferation and stimulate
DNA synthesis in osteoblast cell lines in vitro [393]. Xynos et al., demonstrated that the
ionic dissolution products of Bioglass 45S5 in cell culture media, including Ca^^ at a
concentration of 88.35ppm, increased human osteoblast proliferation by 155% [376].
Other researchers have demonstrated that Ca

ranging from 60-90ppm stimulates the

mature osteoblastic phenotype and subsequent generation of extracellular matrix proteins
[220]. Induced cell proliferation has even been noted at Ca^^ concentrations as low as
13.1 ppm when present with other ions [394]. Thus, the lower levels of Ca^^ released by
experimental compositions here may, in isolation, have little stimulatory effect on bone
formation. However, it can be seen that BTl 12 and Novabone increased in Ca^^ release
over time and this may be a beneficial property. In addition to the induced biological
effects of Ca^^ ions, local release of Ca^^ from bioactive materials plays an important role
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in the precipitation of the calcium-phosphate surface layer and subsequent bonding of the
material to bone [217], The osteomtegration demonstrated in vivo by bioactive glass
compositions such as Novabone is related in part to the rate of release of soluble ions
including Ca^^ [395], Gradual release of the ion over time may thus be advantageous for
BTl 12 as it may aid in bone-bonding. No Ca^^ release was detected for BTl 10 and for
Day 1 and Day 7 BTl 11 extracts. Similarly to Si**^ release, this may be as a result of
their Zn:Na ratio.

8.3.1.3 Na^ Content
Na^ content of BTl 10, BTl 11, BTl 12 and Novabone extracts for Day 1, Day 7
and Day 30 are shown in Figure 8.20.
**
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Figure 8.20: Na ionic content of BTl 10, BTl 11, BTl 12 and Novabone for Day 1, Day 7 and Day 30
extracts. Results represent mean ± SEM of triplicate determinations (*p < 0.05, **p<0.005).

In Day 1 extracts, there was no significant difference in Na^ concentration
between each glass. However, by Day 7, BTl 11 released statistically higher amounts of
Na^ (317.7ppm ± 8ppm) than all other compositions. In Day 30 extracts, Novabone
released a significantly higher amount of Na^ than BTl 10 and BTl 12 (p=0.0101 and
p=0.0135, respectively) but not compared to BTl 11. When Na^ release was assessed as a
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function of incubation time, BTl 10 and BTl 12 extracts show no difference between each
incubation time. Day 7 release for BTl 11 was found to be significantly higher than Day 1
(p=0.0006), and Day 30 was found to be statistically higher than Day 1 for Novabone
(p=0.0398).
Na^ release from experimental glasses ranged from 101 ppm - 333ppm and from
191 ppm - 305ppm for Novabone.

Naturally occurring Na^ plasma levels are above

3200ppm [396], and Na* levels within animal cells are maintained at approximately
230ppm by the actions of an active Na^ pump [397], Thus, it can be inferred that the
small levels released here are of little physiological significance. One of the main roles of
Na" in bioactive glass compositions is not to induce biological effects itself, but to impart
degradability and control over the release of other constituent ions [237], This effect is
particularly evident upon examining Sr^^ and Ca^^ release from the experimental
compositions. As the Na20 concentration is increased (Table 8.1), the release of both Sr^"^
and Ca^^ increased (Figures 8.21 and 8.19). For BTl 10 and BTl 12 Na^ release was
independent of incubation time.

This result is not unexpected, as the first step upon

immersion of a bioactive glass in solution is the rapid exchange of Na^ for protons in
solution. Reasons for the increased Na^ release from BTl 11 at Day 7 and Day 30 are
currently unclear.

83.1.4 Sr

Content

Sr^^ content of BTl 10, BTl 11 and BTl 12 extracts for Day 1, Day 7 and Day 30
are shown in Figure 8.21.

In both Day 1 and Day 7 extracts, BTl 12 released

significantly higher concentrations of Sr^^ than BTl 10 and BTl 11. By Day 30, no
statistical difference was found, though a large error bar is associated with BTl 12. At
Day 30, BTl 11 released significantly higher levels of Sr^^ than BTl 10 {p=0.0034).
When Sr^^ release is assessed as a function of incubation time, BTl 12 extracts show no
difference between each time period. In contrast, both BTl 10 and BTl 11 extracts show a
significantly higher level of Sr^^ by Day 30 when compared to Day 1 (p^O.OOl and
p=0.0428, respectively).
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Figure 8.21: Sr ionic content of BTl 10, BTl 11 and BTl 12 for Day 1, Day 7 and Day 30 extracts. Results
represent mean ± SEM of triplicate determinations (*p < 0.05, **p<0.005).

release from experimental glasses in this study ranged from O.Sppm - SSppm*.
Sr^^ concentrations from 8.7ppm - 87.6 ppm have shown stimulatory effect on osteoblasts
[237] both in vitro and in vivo, again suggesting the potential of the examined glasses in a
bone grafting application. Relating results obtained here to those using the pH7.4 and
pH3 buffered solutions previously (section 8.2) prove useful in understanding the release
of this ion from examined glasses relative to the aqueous solution used. The levels of
Sr^^ released in tissue culture water here are much lower relative to those released in both
pH7.4 and pH3 solutions (Figures 8.14 and 8.15, respectively).

As mentioned, upon

immersion of a bioactive glass in a non-buffered solution, such as tissue culture water,
the pH will rise rapidly due to the exchange between network modifier cations and
protons in solution.

Researchers have previously shown a decrease in the release of

network modifiers, such as Ca^^, from bioactive glasses upon increasing solution pH
[212], a result thought to be related to the formation of less soluble salts at higher pH
values. Thus, a reasonable explanation for the difference in Sr^^ release levels between
the tissue culture water and the pH7.4 and pH3.0 solutions is the buffering capacity of the
latter.

8.3.1.5 Zn
.2+

Zn

Content
content of BTl 10 and BTl 11 extracts for Day 1, Day 7, and Day 30 are

shown in Figure 8.22.

At all time periods, BTl 10 released statistically higher
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concentrations of Zn^^ than BTl 11. It should be noted however that the overall level of
Zn^^ release was much lower than that of other examined ions (maximum of 1.36ppm for
BTl 10 at Day 30). When assessed as a function of incubation time, both BTl 10 and
BTl 11 extracts show statistically higher levels of Zn^"^ by Day 30, when compared to
Day 1 counterparts (p<0.001 and p=0.0006, respectively).
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Figure 8.22: Zn ionic content of BTl 10 and BTl 11 for Day 1, Day 7 and Day 30 extracts. Results
represent mean ± SEM of triplicate determinations (**p<0.005).

Zn^^ release from experimental glasses ranged from O.Sppm - 1.4ppm.

As

mentioned in section 8.2, Zn^^ levels ranging from 2.45-6.5 ppm have shown beneficial
effects on bone formation in vitro and in vivo. Thus the levels exhibited here may fall
short of those known to invoke therapeutic effects. However, Zn^^ release above 6.5 ppm
has shown cytotoxic responses [378], so it can be expected that the much lower levels
released here are tolerable in vitro.

The lower levels of Zn^' release from the

experimental compositions in relation to other ions is consistent with the findings of other
researchers, showing levels ranging from 0.7-3ppm for Zn-containing bioactive glasses
[277]. Similar to Sr^^, levels of Zn^^ released in tissue culture water are much lower
relative to those released in both pH7.4 and pH3 solutions (Figures 8.10 and 8.11,
respectively).
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83.1.6 P Content

The P ionic content of Novabone extracts for Day 1, Day 7 and Day 30 are shown
in Figure 8.23, and range from 0.11 ppm - 0.4ppm.
0.4-,
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Figure 8.23: P ionic content of Novabone Day 1, Day 7 and Day 30 extracts. Results represent mean ±
SEM of triplicate determinations (*p < 0.05, **p<0.005).

Both Day 1 and Day 30 extracts contained statistically higher levels of P than Day
7 extracts (p=0.0003 and p=0.034, respectively).

The role of phosphorus ions in

bioactive glass is not to induce cellular effects itself, but to promote HA nucleation on the
surface and stimulate bone bonding [398]. Though P release levels here are small, the
drop in release seen at Day 7 may reflect the formation of a Ca-P layer, though a similar
drop in Ca^^ release was not concurrently seen (Figure 8.19).
Overall, examination of ion release from the experimental glass compositions in
tissue culture water provides valuable information about the possible levels which may be
released in vivo and allows for correlation with the cell culture results in the subsequent
section. However, in order to fijlly evaluate the potential of these glass compositions in a
bone graft capacity, future in vitro assessment using media with added proteins and using
a differential immersion protocol is recommended.

The presence of proteins, more

accurately simulating the in vivo environment, is known to affect the dissolution of
bioactive glasses [211]. Sepulveda et al, demonstrated that in media with out protein
semm. Si dissolution was impeded by the formation of the silica-rich and HCA surface
reaction layers. However in media with proteins, the protective layer was still permeable
allowing continuous Si dissolution [211], Also, in \itro glass dissolution testing using

Results & Discussion
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the protocol used here may involve solution saturation due to the accumulation of
dissolution products [399], Saturation may be avoided in vivo by flow of physiological
fluids facilitating transport of ions away from the glass bed [400], Correspondingly, a
differential immersion protocol where the solution is continuously exchanged may be
more representative of the in vivo mechanism and kinetics of glass dissolution [399],
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83.2

Cell viability
The % cell viability of cells exposed to BTl 10, BTl 11, BTl 12 and Novabone

Day 1, Day 7 and Day 30 extracts are presented in Figure 8.24.
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Figure 8.24: % Cell viability of L929 cells in the presence of BTl 110, BTl 11, BTl 12 and Novabone Day
1, Day 7 and Day 30 extracts. Results represent mean ± SEM of triplicate determinations. (*:p < 0.05,
** :p < 0.005). Dotted line represents control cells with viabilities of 100%.

Upon comparing the cell viabilities after exposure to Day 1 extracts, BTl 12 and
Novabone both had viabilities statistically higher than BTl 11, but no significant
difference was found when they were compared to BTl 10 and to each other. BTl 10
showed no significant difference when compared to BTlll. On comparing Day 7
extracts, BTl 12 showed significantly higher cell viabilities than all other glass extracts.
BTl 12 also exhibited % cell viability (120.6 ± 10.1%) higher than the control used
(100%). On comparing Day 30 extracts, BTl 12 again showed significantly higher cell
viabilities than all other extracts. Similarly at Day 30, BTl 12 and BTlll show higher
than 100% viabilities (137.2 ± 4.9% and 111.8 ± 6.7%, respectively).
Subsequently, each glass composition was assessed as a function of incubation time. The
cell viability of the Day 30 BTl 10 extract (Figure 8.25) was significantly higher than
both Day 1 and Day 7 BTl 10 extracts (p=0.0054 and p=0.0245, respectively).
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Figure 8.25; % cell viability for BTl 10 exposed cells versus incubation time. Results represent mean ±
SEM of triplicate determmations. (*:p < 0.05, **;p < 0.005). Dotted line represents control cells with
viabilities of 100%.

Similarly, the Day 30 BTl 11 extract (Figure 8.26) exhibited significantly higher
viabilities than its Day 1 and Day 7 counterparts (p<0.0001 and p=0.0457, respectively).
Furthermore, the Day 7 BTl 11 extract was significantly higher than the Day 1 extract
(p=0.0024).
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Figure 8.26: % cell viability for BTl 11 exposed cells versus incubation time. Results represent mean ±
SEM of triplicate determinations. (*;p < 0.05, **:p < 0.005). Dotted line represents control cells with
viabilities of 100%.
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For BT112 (Figure 8.27), both Day 7 and Day 30 extract exposed cells exhibited
viabilities significantly higher than the Day 1 extract (p=0.0021 and p<0.0001,
respectively). However, no difference was found between Day 30 and Day 7.
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Figure 8.27: % cell viability for BTl 12 exposed cells versus incubation time. Results represent mean ±
SEM of triplicate determinations. (*;p < 0.05, ** :p < 0.005). Dotted line represents control cells with
viabilities of 100%.

For Novabone, no significant difference in metabolic activity was found between any of
the timepoints (Figure 8.28).
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Figure 8.28: % cell viability for Novabone exposed cells versus incubation time. Results represent mean ±
SEM of triplicate determinations. Dotted line represents control cells with viabilities of 100%.
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Overall, the results from the viability assay indicate that the experimental groups
show either no difference or significantly increased cell viabilities when compared to the
commercial control Novabone, demonstrating the equivalent or even enhanced in vitro
compatibility of these glass compositions in relation to a current state of the art material.
The only exception to this is for BTl 11 Day 1 exposed cells which exhibited significantly
reduced viabilities compared to the other examined compositions at the same incubation
time point (Figure 8.24). The reason for its reduced performance is currently unclear.
Zn^^ ranging from 8.2-9.8ppm [401] has been known to cause cytotoxicity in vitro with a
variety of cell lines. Similarly, Aina et al, demonstrated that Zn^^ release from bioactive
glasses ranging 1.8-6.2ppm induced in vitro cytotoxicity. However, the Zn^^ content of
the Day 1 BTl 11 extract was 0.1 ppm (Figure 8.22) well below known cytotoxic levels.
All experimental compositions increased cell viability with respect to time, showing
significantly higher values at Day 30 compared to Day 1 (Figures 8.25, 8.26 and 8.27).
This indicates that not only are the ionic products released over time tolerable in vitro but
they may lead to enhanced cytocompatibility. - an effect not see in Novabone (Figure
8.28). Experimental extract BTl 12 in particular showed enhanced performance at Day 7
and Day 30 illustrated by % cell viabilities higher than the control used (Figure 8.27).
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Figure 8.29: % cell viability for BT112 exposed cells versus ion release profile for Day 1, Day 7 and Day
30 extracts

130

Results & Discussion

This indicates that the ions present induced proliferation and growth of the cells.
When related to the ion release profiles (Figure 8.29) the only ion to significantly change
level between all timepoints is Si”* . (Day 1 - 3.5 ± 0.5 ppm. Day 7 - 17.33 ±2.67ppm and
Day 30 - 36.67 ± 2.33ppm). As mentioned, Si"*^ release from biomaterials ranging from
0.1 ppm - lOOppm has previously been shown to induce proliferation of various cell
types, suggesting that Si'^^ levels here are playing a role in the induced cell proliferation.
However, Novabone extracts show statistically similar Si"*^ levels to BTl 12 (Figure 8.17)
but with no corresponding proliferation or increase in cell viability (Figure 8.30).

Figure 830: % cell viability for Novabone exposed cells versus Si"*^ release for Day 1, Day 7 and Day 30
extracts

Previous studies have indicated that specific combinations and concentrations of
ions enhance cell proliferation of various cell types in comparison to exposure of
individual ions of equal concentration [323, 394]. In particular, stimulation of cells has
occurred in the presence of previously inactive levels of Ca^^ and Si**^ when Sr^^ is also
present [323].

Thus it is plausible to suggest that the enhanced cell proliferation of

BTl 12 exposed cells is due to a synergistic effect between certain concentrations of ions.
However, further investigation is required to identify the mechanisms of the specific
stimulatory effect of ion combinations.

Similarly, the alkaline pH levels caused by

bioactive glass dissolution may account for the induced proliferation observed.
Fibroblasts, such as the L929 cells used here, are known to express calcium-sensing
receptors (CaSR) [402, 403] and these receptors have been widely implicated in Sr^^
induced cell proliferation [300, 301]. Alkalinisation has recently been shown to increase
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the sensitivity of this receptor to its agonists such as Sr^^ [404],
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Thus, it is also

reasonable to hypothesise that increased alkalinity due to increased glass dissolution over
time enhances activation of this receptor by Sr^\ consequently stimulating cell
proliferation and accounting for the increased cell viabilities seen here (Figure 8.24).
However, further experimentation is needed in order to validate such a hypothesis.
Of note also is the presumption that enhanced cell viability evident by the induced
cell proliferation corresponds to a beneficial result. Genotoxic effects can cause DNA
damage, resulting in malfunctions within the regulation of the cell cycle and subsequent
uncontrolled proliferation of mutated cells [405]. Classic cytotoxicity tests, such as that
used in this study, do not differentiate between normal and aberrant cell growth. In order
to fully assess the materials exam.ined here and to support the findings that the levels of
ions released enhance biocompatibility, relevant genotoxicity testing is warranted.
Furthermore, to gain additional insight into the potential of these compositions in a
therapeutic bone graft role, in \itro assessment using tissue specific cells such as human
derived osteoblasts and osteoclasts is warranted. Analysis of the effects of the dissolution
products on osteoblast proliferation, differentiation and expression of genes involved in
bone metabolism will aid in understanding the potential of these materials in inducing
bone growth. Similarly, analysis of their effects on osteoclasts will aid in understanding
the potential of these materials to act in a therapeutic capacity, leading to healthy bone
growth in those suffering from metabolic bone diseases such as osteoporosis.
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8.4

EVALUATION OF ANTIBACTERIAL EFFICACY
The use of implants is associated with an increased risk of bacterial infection,

frequently leading to implant failure and revision surgery, thus impacting greatly in terms
of morbidity, mortality and medical costs [278], As previously discussed (section 4.1),
Zn^^ has been shown to impart antibacterial properties on various biomaterials.
Accordingly, group 2 zinc-containing glasses, BTllO and BTlll, were selected for
evaluation of their antibacterial efficacy, with Novabone, used as a state-of-the-art
comparison. Similar to the cell culture evaluation, an extract procedure was designed,
using concentrations of 50mg/ml, lOOmg/ml and 200mg/ml, as previous studies have
shown bioactive glasses to demonstrate antibacterial properties within this concentration
range [406].

As previous Zn^^ ion release results (section 8.2) from the examined

compositions demonstrated a plateau effect after 7 days, 1 day and 7 day extracts were
used to represent possible levels of Zn^^ released in vivo.

levels for all samples were

analysed, in order to correlate with any observed antibacterial effects. The antibacterial
properties demonstrated by other bioactive glasses have also been linked to increased pH
levels, therefore the pH of each extract was also analysed [238]. Staphylococcus aureus
and Staphylococcus epidermidis combined account for two out of three biomaterialassociated infections (BAI) [278]; therefore clinical isolates of Methicillin-sensitive
Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA)
and Staphylococcus epidermidis were chosen for investigation. Pseudomonas aeruginosa
was included as an example of an opportunistic gram-negative bacteria known to be the
third most prevalent bacteria in BAIs and to have high intrinsic antibiotic resistance
[339],

Enterococci are considered the next most clinically significant species,

consequently a clinical isolate oiEnterococci faecalis was also included [278].

8.4.1

content of extracts
Zn^^ content for all BTllO and BTlll Day 1 and Day 7 samples are shown in

Figure 8.31. When Day 1 Zn

levels were assessed as a function of composition, BTl 11

contained significantly higher levels than BTllO at 50mg/ml (p<0.001), no statistical
difference was found at lOOmg/ml and BTllO contained significantly higher levels at
200mg/ml (p<0.001).

When Day 7 extracts were similarly assessed as a function of

-133 -

Results & Discussion

composition, BTllO contained statistically higher Zn^^ levels than BTlll at 50mg/ml
lOOmg/ml and 200mg/ml concentrations (p<0.001, p<0.001 and p<0.01, respectively).
When Day 1 Zn^^ levels were assessed as a function of concentration, BTllO contained
significantly higher levels with increasing extract concentration (p<0.001).

However,

BTl 11 shows no statistical difference between different concentrations. When Day 7
Zn^^ levels are assessed as a function of concentration, BTllO exhibits no significant
difference, whereas BTl 11 200mg/ml extracts contained significantly higher levels than
50mg/ml and lOOmg/ml extracts (p<0.001 for both concentrations).
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Figure 8 Jl:
levels for BT110 and BTl 11 (a) Day 1 & (b) Day 7 extracts.
Results represent mean ± SEM of triplicate determinations (lines are used as a guide for the reader).

The gradual increase in the Zn^^ release level from BTl 10 observed for the Day 1
samples was not unexpected as the increase in glass concentration as such leads to the
availability of more Zn^^ for release.

However, the fact that the same concentration

dependence was not seen for the Day 7 extracts may indicate the longer immersion time
leads to saturation of the solution with respect to Zn^^. Zn^^ release by BTl 11 extracts
appears to be relatively independent of concentration.

8.4.2

pH of extracts
The pH for all BTl 10, BTl 11 and Novabone Day 1 and Day 7 extracts are shown

in Figure 8.32. For Day 1 extracts, BTl 11 exhibited significantly higher pH values than
BTllO and Novabone at all concentrations (p<0.001 for all comparisons).

Only at

200mg/ml did Novabone exhibit a statistically higher pH than the BTllO extract
(p<0.001). For Day 7 extracts, BTl 11 similarly exhibited a significantly higher pH than
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BTllO and Novabone at all concentrations (p<0.001 for all comparisons).

Also, the

200mg/ml Novabone extract exhibited a statistically higher pH than its BTllO
counterpart (p<0.001). When extracts were assessed as a function of concentration, no
significant difference was seen for Day 1 BTl 10 and BTl 11 samples. However, between
50mg/ml, lOOmg/ml and 200mg/ml, the pH of Novabone extracts increased significantly
(p<0.01 and p<0.001).

For Day 7 extracts, a statistical difference was seen between

50mg/ml and lOOmg/ml BTllO extracts (p<0.001).

BTl 11 50mg/ml extracts exhibit

significantly lower pH values than the lOOmg/ml and 200mg/ml extracts (p<0.001 for
both). Similarly to Day 1, Day 7 Novabone extracts significantly increased in pH with
respect to concentration. When identical concentrations from the 2 different incubation
times were compared. Day 7 BTllO and BTl 11 lOOmg/ml and 200mg/ml showed
significantly higher pH values than their Day 1 counterparts (p<0.001 for all
comparisons).

Novabone Day 7 50mg/ml, lOOmg/ml and 200mg/ml all showed

statistically higher pH values than their Day 1 equivalent (p<0.05, p<0.001 and p<0.01,
respectively).
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Figure 832: pH of BTl 10, BTl 11 & Novabone (a) Day 1 & (b) Day 7 extracts.
The dotted line represents the pH of ISB only. Results represent mean ± SEM of triplicate determinations
(lines are used as a guide for the reader).

As mentioned previously (section 3.2.2), one of the first reactions to take place
upon immersion of a bioactive glass in solution is the rapid exchange of Na^ from the
glass with H^ or HsO^ from solution, resulting in an increase in solution pH. The extent
of the rise in pH is affected by various parameters, including composition and particle
size. BTl 11 demonstrated a significantly higher pH at both incubation time points. This
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may be related to its Na20 content, 0.2 mol. fraction (Table 8.1), as a glass with a higher
Na20 content has the ability to generate a higher pH in solution [384].
Novabone contains 0.244 mol. fraction Na20.

However,

The lack of a similar rise in pH for

Novabone is possibly related to its higher proportion of network formers (total of 0.483
mol fraction, compared to 0.4 for BTl 11), which would affect the network connectivity,
rate of dissolution and the subsequent rise in pH. A possible difference due to particle
size must also be considered. The particle size range used here for all compositions has a
wide range, 90-710pm. As such, a variation in particle size may account for the higher
pH values demonstrated by BTl 11 extracts. However, the surface area analysis data
(section 8.1.5) provides information of the surface area exposed per gram of material.
BTl 11 demonstrated a lower surface area per g (9.68 m^/g) than BTl 10 (15.32 m^/g).
Thus, the possibility that the higher pH values demonstrated by the BTl 11 extracts here
are due to the presence of smaller particles appears to be inconsistent with the surface
area data.

All extracts, with the exception of BTl 10 and BTl 11 50mg/ml extracts,

significantly increased in pH with a longer incubation period. This was not unexpected,
as a longer immersion time allows for further surface reactions, leading to increased
alkaline and alkaline-earth oxide release and subsequently a higher pH.

8.4.3

Optical density results

8.4.3.1 MRSA
The optical density (OD) results for all BTl 10, BTl 11 and Novabone Day 1 and
Day 7 extracts incubated with MRSA are shown in Figure 8.33. ISB only with MRSA is
included as a control.
No antibacterial effect was seen with all BTl 10 extracts, as indicated by a lack of
statistical difference between the OD of these extracts and MRSA only at the 24 hr
timepoints. BTl 11 Day 1 200mg/ml and all Day 7 extracts exhibited a prolonged lag
phase, however, only the Day 7 200mg/ml extract demonstrated a significantly lower OD
after 24hrs, compared to the MRSA alone (p<0.001). The lag phase of bacterial growth
represents the time during which the bacteria adapt to their new environment and its
length depends on a wide variety of environmental factors, including temperature, pH and
available nutrients [407].

The prolonged lag phase demonstrated by BTl 11 extracts
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appears to indicate sub-optimal growing conditions, and may be related to the alkaline pH
of the extracts, which ranged from 9.1 - 9.88 (Figure 8.32).

Time (hrs)
BT110

—^Novabone

Time (hrs)
MRSA

BT110 —^ BT111Novabone

MRSA

Figure 833: Optical density v. incubation time for MRSA inoculated samples (a) 1 Day 50mg/ml (b) 1 Day lOOmg/ml (c) 1 Day
200mg/ml (d) 7 Day 50mg/ml (e) 7 Day lOOmg/ml (f) 7 Day 200mg/n:il.
Results represent mean ± SEM of triplicate determinations.
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Staphylococcus aureus is known to be capable of growing in pH ranging from 4.0-10.0,
but can demonstrate stunted growth at the extremes of this range, as its optimum pH for
growth is between 6.0-7.0 [408]. Other researchers have previously demonstrated that
50mg/ml and lOOmg/ml samples of bioactive glass 45S5 raised the pH to above 9.8 and
correspondingly demonstrated a 98% bactericidal effect on S. aureus [240]. Coleman et
al, determined that Zn^^ release from Tobermorites inhibited the growth of S. aureus
strains [409] and Fox et al, correlated Zn^^ release from zeolites to inhibted growth of
MRSA and MSSA [345]. However, DNA fragments conferring resistance to Zn^^ ions
have been isolated from S. aureus strains [410].

The reason why the BTlll Day 7

200mg/ml samples demonstrated significantly lower growth after 24hrs does not appear
to be related solely to pH or Zn^^ levels alone (Figure 8.34). There was no statistical
difference between BTlll Day 7 lOOmg/ml and 200mg/ml pH values (Figure 8.32) yet
the lOOmg/ml extract does not exhibit a similar effect on the 24 hr OD (Figure 8.33).
Similarly, all Day 7 BTl 10 extracts demonstrate higher Zn^^ levels (Figure 8.31) but with
no apparent antibacterial effect.

However, it could be hypothesised that it is a

combination of high pH and Zn^^ that exerts an antibacterial effect as suggested in Figure
8.34. Other researchers have linked the antibacterial effects of some bioactive glasses to
a combination of pH and specific ion concentration [411]. However, further investigation
would be needed in order to validate such a hypothesis.
Novabone demonstrated no antibacterial effects against MRSA.

In fact,

Novabone day 1 and day 7 lOOmg/ml and 200mg/ml extracts demonstrated significantly
higher 24 hr OD readings compared to the MRSA only sample (Figure 8.33). Previous
studies have demonstrated than in some specific cases certain bioactive glasses have
transiently promoted bacterial growth but a mechanism or reason for such an effect was
not speculated [339,412]. Both BTl 10 and BTl 11 Day 1 lOOmg/ml and Day 1 & Day 7
200mg/ml extracts demonstrated significantly lower optical densities than Novabone
(p<0.001 for all comparisons), illustrating a more favourable response than the current
state-of-the-art material
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■o

X

BT111 7rt

BT111 pH

Figure 834:24 hr optical density readings for all MRSA BTl 11 Day 7 extracts v. Zn^^ content and pH
(lines are used as a guide for the reader)

8.43.2 MSSA
The optical density results for all BTl 10, BTl 11 and Novabone Day 1 and Day 7
extracts incubated with MSSA are shown in Figure 8.35. ISB only with MSSA was
included as a control.
BTl 10 Day 1 200mg/nil and all Day 7 extracts exhibited a prolonged lag phase,
however only Day 7 50mg/nil and lOOmg/ml showed significantly lower 24 hr optical
densities versus the MSSA only extract (p<0.001 for both).

Similarly BTl 11 Day 1

200mg/ml and all Day 7 extracts exhibited a prolonged lag phase, however only Day 7
50mg/ml and 200mg/ml showed significantly lower 24 hr optical densities versus the
MSSA only extract (p<0.001 for both).

All Novabone extracts demonstrated no

antibacterial effect. Similar to the MRSA results, Novabone exhibited statistically higher
optical densities versus the MSSA only extracts for the Day 1 50mg/ml, lOOmg/ml and
200mg/ml extracts (p<0.001). BTl 10 extracts appear to have a better antibacterial effect
against the Methicillin-sensitive strain of S. aureus (MSSA) than the methicillin-resistant
S. aureus (MRSA) (Figures 8.35 and 8.33, respectively), which may indicate the MSSA
strain is more susceptible to the higher Zn^^ levels released by BTl 10 extracts (Figure
8.31). BTl 11 extracts exhibited a very similar response to that observed against MRSA,
though MSSA growth was repressed at a lower concentration for the 7 day samples. In
order to assess whether the observed antibacterial effects are related to the Zn^^ or pH
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levels of the extracts, 24 hour OD readings for all 7 day extracts were plotted against pH
and Zn^^ levels, as in Figure 8.36.

Time (hrs)
BT110

-^Novabone

MSSA

Time (hrs)
BT110

BT111

Novabone

Time (hrs)
MSSA

BT110

BT111

Novabone

MSSA

igure 8J5; Optical density v. incubation time for MSSA inoculated samples (a) 1 Day 50mg/ml (b) 1 Day lOOmg/ml (c) 1 Day

200mg/ml (d) 7 Day 50mg/ml (e) 7 Day lOOmg/ml (f) 7 Day 200mglhil. Results represent mean ± SEM of triplicate
determinations.
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-^BT110Zn^^ -•-BT110 pH

bT

111 Zn 2+

BT111 pH

—Novabone pH
Figure 836; 24 hr optical density readings for all MSSA BTl 10, BTl 11 and Novabone Day 7 extracts v.
Zn^^ content and pH (lines are used as a guide for the reado-)

The 7 day 200mg/ml BTl 11 extracts which exhibited the best antibacterial effect
and lowest OD, also demonstrated the highest pH (9.75 ± 0.03) with a combined high
level of Zn^^ (45ppm ± 5ppm). This again may suggest that a S5mergistic effect between
pH and Zn^^ level is contributing to the demonstrated antibacterial effect.

However,

using the same rationale does not elucidate the antibacterial effects exhibited by BTl 10
extracts, which may indicate that other ions released are playing a role in the antibacterial
activity. Novabone again demonstrated higher OD values than MSSA only (Figure 8.35)
which similarly as suggested for MRSA may be due to the extracts promoting bacterial
growth.

8.4.33 S, epidermidis
The optical density results for all BTl 10, BTl 11 and Novabone Day 1 and Day 7
extracts incubated with S. epidermidis are shown in Figure 8.37.

epidermidis was included as a control.

ISB only with S.

-141 -

Results & Discussion

BT110 —^ BT111

BT110 ^ BT111

Novabone —^ S. epidermidis

Novabone —^ S. epidermidis

Figure 8 J7: Optical density V incubation time for S.epidermidis inoculated samples (a) 1 Day 50mg/ml (b) 1 Day lOOmg/ml (c)
1 Day 200mg/ml (d) 7 Day 50mg/ml (e) 7 Day lOOmg/ml (f) 7 Day 2(X)mg/ml. Results represent mean ± SEM of triplicate
determinations.

BTllO extracts demonstrated an antibacterial effect at all concentrations and at
both incubation time points.

Both the Day 1 and Day 7 50mg/ml extracts exhibited
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delayed growth. However, there appears to be no bacterial growth in all other extracts as
demonstrated by the lack of change in the OD readings over time and the significantly
lower 24hr OD values, compared to the S. epidermidis alone (p<0.001 for all
comparisons).

All BTlll extracts exhibited complete inhibition of S. epidermidis

bacterial growth, demonstrated also by the lack in OD change with respect to time.
However, whether this effect is merely bacteriostatic or possibly bactericidal in nature
can not be elucidated using this model. Novabone demonstrated an extended lag phase
for all extracts, except Day 1 50mg/ml.

However, only at Day 7 lOOmg/ml and

200mg/ml was there a significant difference between the 24hr OD readings versus S.

epidermidis only (p<0.05 and 0<0.001, respectively). Hu et al, demonstrated that 10lOOmg/ml of the bioactive glass 45S5 exhibited bactericidal effects on S. epidermidis, an
effect which was more pronounced as the pH increased from 8.7 to 9.8 [240].

A

bioactive glass with a higher compositional % of Si02 exhibited a similar bactericidal
effect on S. epidermidis, an effect also linked to an increase in pH [406].

Other

researchers have demonstrated that increasing Zn^^ levels can lead to the inhibition of S.

epidermidis growth [413].

Optical Density (600nm) @ 24hrs

BT110Zn 2+

♦-BTHOpH

-^BTmZn^^

BT111 pH

—Novabone pH
Figure 838:24 hr optical density readings for all S.epidemiidis BT110, BTl 11 and Novabone Day 7
extracts V Zn^^ content and pH (lines are used as a guide for the reader)

Figure 8.38 assesses the relation between extract pH, Zn^^ level and OD readings
after 24 hrs for all Day 7 samples. There is no statistical difference between the pH
values of the lOOmg/ml and 200mg/ml BTl 10 and Novabone extracts (Figure 8.32) yet
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exposure to BTllO results in much lower OD values.

However, the OD value for

Novabone does show a significant decrease vsdien the pH of the extract is close to pH 9.
The pH of all BTlll extracts ranged from 9.13-9.88 (Figure 8.32) and no change in OD
was detected (Figure 8.37). Therefore, it appears that pH is certainly playing a role in the
antibacterial effect of the examined compositions against S. epidermidis but it appears to
not be the only fector. Similar to that suggested previously, it may be a combination of
high pH and Zn^ level, as demonstrated in Figure 8.38, that leads to the enhanced
antibacterial properties exhibited by the experimental compositions here.

8.43.4 P. aeruginosa
The optical density results for all BTl 10, BTl 11 and Novabone Day 1 and Day 7
extracts incubated with P. aeruginosa are shown in Figure 8.39.

ISB only with P.

aeruginosa was included as a control.
BTllO extracts demonstrated antibacterial effects against P. aeruginosa at all
examined concentrations and both incubation time points, showing significantly lower
24hr OD values compared to the P. aeruginosa only control (p<0.001 for all
comparisons). All BTlll extracts demonstrated similar antibacterial effects with 24hr
OD values also statistically lower than the control (p<0.001 for all comparisons). The
most pronounced antibacterial effect was seen for BTlll Day 7 200mg/ml extracts,
which exhibited no bacterial growth as indicated by the unchanged OD over the 24hrs.
Novabone also demonstrated antibacterial effects at all concentrations (p<0.001 for all
comparisons with the control), with the exception of Day 7 lOOmg/ml extract, an
anomalous result.

Bellantone et al, determined bioactive glass 45S5 to have no

antibacterial effect against P. aeruginosa using the same particle range as used here (90710pm) but at lower concentrations (0.05-lmg/ml) [339].

Other researcher have

demonstrated an inhibitory effect on P. aeruginosa growth with Si-Na-Ca-P based
bioactive glasses at concentrations above 50mg/nil [414]. Furthermore, Mortazavi etal.,
showed that the bioactive glass 58S (containing weight % 57.72 Si02 and 35.09 CaO)
inhibited the growth of P. aeruginosa at concentrations of lOOmg/ml. They speculated
that this effect was due to the high pH (>pH 9) and possibly related to the high level of
Ca^^ release [415].
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BT110

BT111

Novabone —^ P. aeruginosa

BTIIO^^ BT111 —^Novabone —^P.aeruginosa

Time (hrs)
*- BT110 —^ BT111 —^ Novabone —^ P. aeruginosa

BT110 —^ BT111 —^ No^bone —^ P.aeruginosa

Figure 839; Optical density v. incubation time for P. aerugirwsa inoculated samples (a) 1 Day 50mg/ml (b) 1 Day lOOmg/ml (c)
1 Day 200mgAnl (d) 7 Day SOmgAnl (e) 7 Day lOOmg/ml (f) 7 Day 200mg/ml. Results represent mean ± SEM of triplicate
determinations.
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Coleman et al, determined that Zn^^ ion release from zn-containing tobermorites
induced an antibacterial effect against P. aerugninosa cultures [409].

Similarly, zinc

salts have been shown to perturb the growth of P. aeruginosa in broth [416].

■o

z

Novabone pH
Figure 8.40:24 hr optical density readings for all P.aeruginosa BTl 10, BTl 11 and Novabone Day 7
extracts v. Zn^^ content and pH (lines are used as a guide for the reader)

In order to assess whether Zn^^ or pH level correlated with the observed
antibacterial effect, 24hr OD values for all day 7 samples were plotted against Zn^^
release and pH as in figure 8.40. The antibacterial effect can not be correlated directly to
either Zn^^ or pH level alone, but it could again be hypothesized that a synergistic effect
between a high pH and high Zn^^ levels, as with BTl 11 200mg/ml in figure 8.40, leading
to the observed antibacterial effects.

8.4.3.5 E. faecalis
The optical density results for all BTl 10, BTl 11 and Novabone Day 1 and Day 7
extracts incubated with E. faecalis are shown in Figure 8.41. ISB only with E. faecalis is
included as a control. BTl 10 demonstrated antibacterial effects against E. faecalis for
Day 1 50+200mg/ml extracts and Day 7 50+100mg/ml, as indicated by the statistically
lower 24 hr OD values verses E. faecalis alone (p<0.01, p<0.001, p<0.001 and p<0.01,
respectively).

Results & Discussion
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Figure 841: Optical daisity v. incubation time for E. faecalis inoculated samples (a) 1 Day 50mg/ml (b) 1 Day lOOmg/ml (c) 1
Day 200mg/ml (d) 7 Day 50mg/ml (e) 7 Day lOOmg/ml
7 Day 200mg/ml. Results represent mean ± SEM of triplicate
determinations.

BTl 11 extracts appeared to show no antibacterial effect at any concentration or
incubation time, as no significant difference was observed when compared to the 24hr
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ODs of E. faecalis alone.

Novabone demonstrated varying results between

concentrations and incubation times.

Both the 1 day and 7 day 50mg/ml extracts

exhibited significantly lower ODs than the E. faecalis alone (p <0.001). There was no
difference for the 1 day lOOmg & 200mg/ml extracts whereas the equivalent 7 day
extracts exhibited statistically higher OD then the E. faecalis.
E. faecalis is a bacterium which is fi'equently associated with persistent
endodontic infections [417]. Zehnder et ah, previously demonstrated mild antimicrobial
effects with bioactive glass S53P4 against E. faecalis [418].

Other researchers have

demonstrated a bactericidal effect against £■. faecalis using bioactive glass 45 S5, an effect
which they suggested was due to an increase in pH, however they exposed a very high
surface area (71m^/g) [419]. Researchers have shown that Enterococci can withstand
harsh enviroiunental conditions including extreme alkaline pH [420]; in &ct various
Enterococcae species are known to exhibit optimal growth at pH > 9 [420,421 ]. In order
to assess whether pH correlated with the results seen in Figure 8.41, 24hr OD values for
all day 7 samples were plotted as a function of pH as illustrated in Figure 8.42.

BT110

BT111

Novabone

Figure 8.42:24 hr (^tical density readings for all E. faecalis inoculated Day 7 ©(tracts v. pH (lines are
used as a guide for the reader)

An increase in pH does appear to induce growth of E. faecalis, the extent of
which appears composition dependent and may be related to the release of other ions.
Various bacterial isolates of E. faecalis have been shown to be susceptible to high levels
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in the form of zinc chloride [422], The higher Zn^^ levels of the BTl 10 extracts

(figure 8.31) may thus account for their overall lower OD readings.

8.4.4

Summary of results

Table 8.6 provides a summary of all of the above results, in order to compare the
effects of the experimental compositions and Novabone on all of the examined bacteria.
The best antibacterial effects for experimental compositions were noted against S.
epidermidis and P. aeruginosa, and overall both BTl 10 and BTl 11 demonstrated better
antibacterial efficacy than the state-of-the-art comparison Novabone.

Table 8.6: Summar>' of the results of all BTl 10, BTl 11 and Novabone extracts against all examined
Glass

Day

Cone.
(mg/ml)

MRSA

MSSA

S.epidetmidis

P.aeruginosa

E.faecalis

BT110

1 day

50
100
200
50
100
200
50
100
200
50
100
200
50
100
200
50
100
200

+
+
+
+
+

+
+
+
+/+/-

+/+/-

+/+/+/+/-

+/+
+/+/-

+
+

+
+

-

+/+/-

-

+/-

+/+
+

+

+

+

-

+/-

+
+
+

+/+

+/+
++
++
+
++
++

+/++
++
++
+
+
+

7 day

BT111

1 day

7 day

Novabone

1 day

7 day

+
+
+
+
+/+/-

+/+/+/-

+/+/+/+/+
+/-

+
+
+
+
+/+
+
+/++
++

The results of the assessment of the antibacterial efficacy of the experimental
glass compositions have demonstrated these glasses to have good antibacterial potential.
Many researchers have correlated the antibacterial efficacy of various bioactive glasses
and biomaterials to a local pH increase and/or Zn^^ release [238, 409, 414],

No

consistent correlation was found during the above research, though the data does suggest
a possible synergistic effect between pH and Zn^ level. In order to further understand
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the antibacterial effects demonstrated by the experimental compositions, analysis of all
ions released is recommended. Though little literature exists, other ions including Si"^^
and Na^ have been linked to the antibacterial properties of other bioactive glasses [411,
418]. In order to further assess their antibacterial properties and supplement this study,
the following future work is also recommended. An extract protocol was used for this
study which aids in understanding the effect of the released ions on the various bacterial
species.

However, direct use of the bioactive glass particles in the antibacterial

assessment is warranted as researchers have shown the presence of the particles to
enhance their antibacterial properties [240], The use of optical density as a measure of
bacterial growth would not be appropriate for such analysis due to the light scattering
properties of the particulate glass [339]. Thus, using a viable count procedure would be
recommended. Furthermore, using such a protocol may aid in differentiating between
bacteristatic and bactericidal effects.

Conclusions

9.
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Conclusions

Based on the results of this research the following points can be concluded:

1. It can be concluded from data pertaining to glasses pre- and post- 30kGy y
sterilisation that sterilisation by this method does not structurally effect the
examined glass compositions.

2. Based on the correlation between the experimental data and the theoretical
calculations, it can be assumed that ZnO largely plays a network modifying role
in the Ca-Sr-Na-Zn-Si glass network.

3. The Zn^^ release results indicated that, at pH 7.4, all examined Zn-containing
glass compositions may have potential as therapeutic bone grafts, but at pH 3 high
Zn^^ levels may produce cytotoxic effects.

4. Sr

release results indicated that all examined glass compositions may have

therapeutic potential in both a physiological pH 7.4 and a more acidic pH 3.0.

5. Ion release results indicated that decreasing the Zn0:Na20 compositional ratio of
the examined glasses increased release of Sr^^ ions, whereas Zn^^ release was
dependant on Zn content.

6. In vitro evaluation results indicated glasses BT110-BT112 demonstrated
equivalent or enhanced cytocompatibility versus the state-of-the-art comparison
Novabone.

7. Glasses BTllO & BTlll demonstrated good antibacterial properties against
bacteria which commonly infect orthopaedic implant sites, both exhibiting
superior antibacterial efficacy than Novabone.

Future Work
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10. Future Work
This research to date has established the excellent potential of the examined glass
compositions to function as therapeutic bone grafts. In order to further evaluate their
biocompatibility and therapeutic efficacy the following future work is recommended:

1. In vitro evaluation using an osteoblast cell line, a dynamic test protocol and a
direct contact assay inclusive of proteins in order to better simulate in vivo
conditions.

2. Evaluation of genotoxicity according to ISO 10993-3 protocols as international
standards stipulate that any implantable material in contact with tissue for more
than 30 days must undergo such testing.

3. In vitro evaluation of genetic up and down regulation of osteoblasts and
osteoclasts exposed to the ionic dissolution products of the experimental glass
compositions in order to assess the ability of the experimental compositions to
genetically steer the tissue towards regeneration and repair.

4. In vivo animal trial involving implantation of experimental glass compositions
into a critical size defect using a normal and osteoporotic model.

5. Anti-bacterial assessment of experimental compositions using a direct contact
method and bacterial biofilms in order to further assess their antibacterial efficacy
in commonly found in vivo conditions.

6. Creation and assessment of corresponding glass-ceramic materials in order to
assess the ability of the experimental glass compositions to be adapted for loadbearing applications.
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